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ABSTRACT
Epstein-Barr virs (EBV) is a ubiquitous human herpesvirus which causes acute
infectious mononucleosis and is etiologically associated with malignant lymphoproliferative
disorders including Burkitt's lymphoma, nasopharyngeal carcinoma, B-cell lymphomas in
imunocompromied hosts, Hodgki' s disease, T cell lymphomas, and smooth muse tuors in
allograft recipients. The medical signficance of EBV is underscored by its potent growth
transformg effects m human B-Iymphocytes in-vitro and the potentially oncogenc
consence of infection in-vivo. The majority of EBV-associated malignancies occu in the
settg of chronic inection and strong virs-specific humoral imunity, suggestig that cellular
imunty is primarily responsible for preventing the outgrowth of EBV-transformed B cells in-
vivo. Similarly, primary EBV inection in adolescents and adults stimulates an intense
cytotoxic- Iymphocyte (CTL) response which coincides with a marked reduction in the num
of infected B cells in the peripheral blood. Evidence of previous EBV inection can be confed
by the presence of EBV-specific, HLA-restricted memory T cells in the peripheral blood which
inibit the outgrowth of newly EBV-transformed B cells and effciently lyse established
autologous B-Iymphoblastoid cell lies.
Worldwide, EBV is responsible for substantial morbidity, comparable to measles
mumps and hepatitis virus, for which vaccines exists. Accordingly, the potential public health
impact of an EBV vaccine has reinorced ou efforts to identify the imunodomiant virus-
encoded T-cell epitopes which stimulate naive CTL effectors durg acute inection and
maintain memory CTL surveilance durg convalescence. The EBV-encoded antigens against
which the memory CTL respons is directed have be partially defined, and include most of
the EBV latent proteins (EBNA- , 3a, 3b, 3c, LP, and LMP- , 2a, 2b) consistently expressed by
in-vitro EBV-transformed B lymphocytes (type-II latency). Importantly, all EBV-associated
malignancies express EBNA- , and as yet 11 EBNA-1-specific memory CTL have bee
convincingly demonstrated. Additionally, many EBV-specific CTL lies and clones have bee
described which do not recogne any of the known latent proteins or other EBV protein antigens
tested thus far. Thus while much is known about CTL-mediated imunty against EBV, our
knowledge of EBV-derived CT epitopes remains incomplete. In contrast to the EBV-specific
memory CTL response, very little is known about the source of viral epitopes recogned durg
the primary CTL response to EBV. In this regard, acute inectious mononucleosis represents an
ideal model system to study virs-specific, cell-mediated imunity. Acute 1M is a self-limited
illness characterized by the appearance of "atypical" lymphocytes (CD3+ /CDS+ /HLADR+
includig both virs-specifc and alloreactive CTL, which undoubtedly contrbute to virus
eliination and provide CTL precursors for lie-long imunity to EBV.
Like other herpesvirs, EBV can undergo either lytic or latent cycle replication. During
primary EBV infection many lytic cycle genes are expressed which are likely responsible for
stimulating the intense cellular imune response associated with acute infectious
mononucleosis. Dug convalescence a mior population of circulating B cells remain latently
inected, harbor multiple EBV episomes, and express only EBNA-1 and possibly LMP-2a (type-
I latency). Thus, latency tye-I inected B cells in-vivo express a much more restricted spectr
of latent protein and are therefore not subject to elimation by the same virus-specifc CTL as
are tye-II EBV latently inected cells. Accordingly, many mechansms have been proposed to
explain EBV persistence including; restricted expression of EBV latent genes, reduced levels 
cellular adhesion molecules, downeguation of:MC class-I molecules, absence of EBNA-1 T-
cell-epitopes, and most recently, EBNA-1-mediated inibition of antigen processing. While
these mechanisms may contribute to ineffective T cell surveilance against latency type-I EBV-
infected cells, B cells expressing the full spectr of latent proteins (type-II) also exist
traniently in vivo and maitai detectable humoral and CTL responses to most latent proteins.
Ou first goal was to identify the vis-encoded imunodomit antigens recogned
by in-vivo activated :MC class-I restricted CTL isolated from college students experiencing
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primary EBV infection, manifested as acute 1M. Following a prodromal period of several
weeks, newly EBV infected patients present with sign and symptoms of acute 1M, including
elevated num of activated CD8+ T cells in their peripheral blood, many of which, like
memory CTL, are EBV-specific and HLA-restricted. In order to address the issue of EBV
persistence and the imune control of EBV-induced lymphoproliferation, we also studied the
long-term EBV -specific memory CTL response in these same individual.
Blood from acute 1M patients and healthy EBV seropositive donors served as a source of
peripheral blood lymphocytes to generate bul CT cultues and autologous target cells. The
inectig strain of EBV was determined for each patient by DNA-PCR amplification of virus
from saliva. Lymphocytes were isolated from whole blood by Ficoll-Paque density
centrifgation and T- and B-cell enriched populations were obtained by AET-sheep red cell
rosette selection. Autologous B cell blasts served as a sour of target cell and recombinant
vaccinia virs constrcts were us to introduce individual EBV latent genes into target cells.
Expression of individual EBV genes in target cell was confed by both western blot and
imunofluorescence. Primary CTL responss to EBV were evaluated in standard 51Cr release
assays using freshly isolated, T-cell enriched PBL from acute 1M patients as effector cells.
EBV-specific memory CTL responss were evaluated with bul CTL cutue generated by in-
vitro restimulation with autologous B-LCLs. FACS analyses were routinely performed m bulk
cutues of effector CTL populations in order to more clearly characterize their phenotype.
Lastly, monoconal antibody blockig studies and cold target competition assays were
performed in order to accurately identif the viral antigen and MHC components responsible for
target cell recognition.
Ou results based upon evaluation of 35 acute 1M patients and 32 convalescent patients
demonstrate that the virus-specific primary CTL respons is broadly directed against the full
spectrm of latent protein, including EBNA1 and the viral coat glycoprotein gp350, while the
memory CTL respons, which essentially lacks EBNA1 reactivity, is directed primarily
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agaist the EBNA 3 family of proteins (3A, 3B, 3C). Importantly, the imunodomiant
response by both primary and memory CTL was directed against the EBNA3 protein.
CTL from 7 of the 35 acute 1M patients evaluated recognzed EBNA1 expressing targets,
and in 4 of these 7 patients, EBNA1 was an imunodomiant antigen. Similarly, CTL from 7 of
35 acute 1M patients recognized gp350 tranfected targets, while 11 gp350-specific memory CTL
responses were observed.
Whle the phenotype of in-vivo primed CTL effectors were CD8+ /HLA-DR+ /CDllb+
the major subpopulation of memory CTL were CD8+ /HLA-DR+ /CDllb-. The CDllb "memory
marker" reached peaked levels on the first sample day for all patients and gradually declined
to baselie levels over a period of several month. In contrast, the CDllb marker was quickly
shed from in vitro propogated CTL, over a period of 5-10 days.
Target cell lysis by in-vivo activated CTL was alost completely blocked by antibody
directed agait class-I molecules (BBM.1), whereas the effect of blockig target cell lysis 
anti-CD8 mAb varied between 40-75%. These findings are consistent with an absolute need for
class-I restricted antigen presentation, and imply that CD8 was variably requied, likely for
the lower affinity TCR/ Ag combinations. Cell lysis mediated by in-vitro-restimulated
memory CTL was also largely inibited by anti-class-I mAb, while anti-CD8 mA was only
mild/moderately effective in blockig target cell lysis, in keeping with the concept that
memory CTL bear higher avidity TCR which can recognze antigen independent of CD8.
Our detection of only one EBNA1-specific memory CTL response among the 32 patients
tested support the theory that latently infected B cells in-vivo, expressing only EBNA1
escape CT recogition and thus might serve as a reservoir for viral persistence and/or
reactivation. The rare abilty to detect an EBNA1-specific memory CTL responses remains a
relatively unexplained phenomenon and may involve a num of tolerizing mechansms
including the induction of anergy by presentation of EBNA-1 in the absence of costimulation
clonal deletion of low affinity T cell, the absence of dominant T cell epitopes within EBNA1 or
a result of the recently described inibiting properties of EBNA-1 m antigen processing and
presentatio
Alternatively, the absence of detectable EBNA1-specific memory CTL may be the
result of inufficient or inappropriate restiulation of memory CTL ri. We addressed this
possibilty by attemptig to selectively restimulate and expand EBNA1-specific CTL from
acute 1M patients by using EBNA1 expressing B cells blasts as a stiulus. Effector cells
generated in this maner kiled target cells in an :MC class-I restricted maner but were
specific for an unspecified vaccina antigen. Interestingly, the phenotype of the effector cells
was predominantly CD3+/CD4-/CD8- /yo T cells.
In sumar, ou findings suggest that a multitude of previously unecogned, EBV-
specific CTL are present in the peripheral blood durg acute 1M, and include EBNA-1-specific
CTL. The importance of accurately defining the in-vivo imune response to EBV is underscored
by the ever-growing list of EBV associated malgnancies. In addition to providing insights into
the oncogenesis and potential treatment of NPC, a newly described lik between precuor
lesions and EBV inection raises the possibilty that heightened imunty to EBV or EBV-
infected cells may prevent the development of NPC. An obvious expectation would include
extension of such knowledge to other EBV associated malignancies such as B and T cell
lymphomas, Hodgki' s lymphomas, and smooth muscle tuors. First however, existing gaps in
knowledge regarding the imune respons to EBV and EBV-associated malignancies must be
closed. Details about the viral gene products which are involved in stimulating a broadly
protective, virus-specific imune response in a large num of individuals is fudamental to
the design of an effective EBV vaccine. Since the presence of activated CD8+ T cells correlates
with the rapid decline of EBV infected B cells in the peripheral blood, a concise description of
the EBV-specific CTL response in the settig of acute inection wil be necessary for the rational
design of an effective acute 1M vaccine. Increased understandig of viral escape mechanms 
also liely to contribute to therapeutic modalities to treat autoimune disorders.
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CHAPTER I
INTRODUCTION
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History of Epstein-Barr Virus
Discove & Classification of EBV. Diseases caused by virs infections have plagued
man for centues and represent some of the most formidable scourges of human includig such
virlent illesses as rabies, AIDS, poliomyelitis, small pox and yellow fever. While attempts
by ma to prevent disease though virs eradication have clearly succeeded as evidenced 
the virtual eliination of small pox (Bloch, 1993), today, viral inections remain a foreruer
as the caus of human ailents. Quite possibly the most intriguing aspect of viral ilnesses
involves the heterogeneity of disease manifestations caused not only by disparate vises but
also by a single strain of virs infecting different individuals. Variables such as genetic
makeup, previous vir exposure, underlyig illness, route of inection, age and so on, all
contribute to the clinical picture and course of iless. Typicaly, diseases caused by vires are
first recogned by the presentation of patients with a characteristic set of sign and symptoms
whose onst closely correlates with exposure to the suspected soure of the infectious agent.
While this scenario holds tre for many acute viral infections such as smallpox and rabies
(Baer, 1994), it differs markedly from the insidious onst of illess which follows exposure to
HIV. Accordingly, the search for virses which caus human disease is frequently plagued
with inconsistencies in clincal presentation and exposure history.
In the century preceeding the discovery of EBV, various clincians had speculated m an
infectious etiology to explain a coon clinical syndrome initially termed "glandular fever
(Pfeiffer and Kiderh, 1889), characterized by fever, tonsilar adenopathy, splenomegaly and
mononuclear leukocytosis (Sprut and Evans, 1920). Three years later Downey described the
now classic atypical lymphocytes which provided a more accurate marker for recogning
glandular fever, later renamed "inectious mononucleosis" (1M) (Downey and McKilay, 1923).
Alost a decade later, Paul and Bruell described high titers of spontaneously occug
heterophile antibodies in the sera of patients with infectious mononucleosis (Paul and Bunell
1932). Initial attempts to isolate the etiologic agent were unuccesfu as were attempts to
transmit the disease to human (Evans, 1950). A systematic analysis to identify the etiologic
agent did not occur until the late 1950's when British surgeon Den Burkitt suggested a causal
relationship between a com tuor of children in equatorial Africa and an infectious agent
(Burkitt, 1958)(Burkitt, 1962)(Burkitt, 1962). This idea immediately attracted the attention of
an English pathologist named Anthony Epstein who began searching for an oncogenc virs in
Burkitt' s lymphoma cells grwn in vitro (Epstein and Barr, 1964). In 1964 Epstein's lab
analyzed tuor biopsies by thin-section electron microscopy and discovered a new, large
icosahedral herpesvirus which could be directly reactivated from in vitro grwn Burkitt
lymphoma cells. The initial findings were reported in Lancet and the vir was later named
after Epstein and his graduate student YVOIme Barr (Epstein et aI., 1964). Shortly thereafter
two independent groups (Henle et aI., 1967)(Pope et al., 1968) reported on the abilty of EBV to
transform primary human B lymphocytes into permanently growig lymphoblastoid cell lines
providing the first concrete evidence to support a causal role for EBV in the establishment of a
human cancer. It was during this same period of tie that a techcian in the Henle laboratory
whose blood was being us as a negative control in se antibody tests contracted infectious
mononucleosis and simultaneously developed a high titer of EBV specific antibodies (Henle et
aI., 1968), thus providing the first convicig evidence that EBV was the caus of infectious
mononucleosis-glandular fever. Several large-scale sero-epidemiologic prospective studies
susequently showed conclusively that EBV was the causative agent of inectious mononucleosis
(Evans et aI., 1968) (Niederman et aI., 1968). Exposur to the vi is exceedingly common as
sera from 90% of American adults contain EBV-specific antibodies, indicating a high
prevalence of subcliical inections.
Further evidence for the causal role of EBV in human cancers came from early studies
involving non-human primates, which when inected with EBV rapidly developed malignant
lymphomas (Shope et aI., 1973). Fortuitously, these cotton top tamarin lymphomas such as the
B95-8 line grow readily in vitro, and unke most human cell lines, are permssive for virus
replicati (Miler et aI., 1972) thus providing a contiued source of EBV for research purposes.
EBV is a membe of the gama herpesvirs family and is the prototype for the
lymphocryptovir geus (Roizman, 1993). In vitro, all gama herpesviruses replicate in
lymphoid cell and some are capable of lytic replication in epithelial and fibroblastic cells.
The host range of the lymphocrytovirs genera is restricted to primate B lymphocytes which
are also the site of latent vi infection in vivo. Infection of primate B lymphocytes with
lymphocrytovirses typically results in a latent infection characterized by persistence of the
viral genome along with expression of a restricted set of latent gene product which contrbute
to the transformation process and help drive cell prolieration (Kieff and Liebowitz, 1990).
Viru & Geome cture. Herpesviruses are highly disseminated among most animal
species and nearly 100 have be partially characterized, eight of which have be isolated
from humans (HSV-1, HSV-2, HCMV, VZV, EBV, HHV6, HHV7, and HHV8) (Roizman, 1993).
The most recently characterized, HHV8, is associated with karposi's sarcoma and abdominal
lymphomas. Membership in the Herpesviridae family is based upon virion architecture. EBV
consists of a toroid-shaped protein core wrapped with linear double-stranded DNA, an
icosahedral nucleocaspid contaig 162 capsomeres, an amorphous protein teguent
surundig the capsid, and an outer envelope contaig glycoprotein spikes (Liebowitz and
Kieff, 1993).
Similar to HSV-1, the major EBV capsid proteins range in size from 28-160 KDa
(Dolynuk et aI., 1976) , however, unlike most other herpesviruses, the outer viral envelope of
EBV consists of predominantly a single glycoprotein known as gp350/220 (Dolyniuk et aI.,
1976)(Thorley-Lawson and Edson, 1979).
The EBV genome was first characterized in 1970 and consists of a linear, 172-kilobase-
pai, double-stranded DNA molecule composed of 60 mole % guane and cytosine (Pritchett et
aI., 1975). In the late 1970' , DNA from the entire B95-8 EBV genome was cloned into bacterial
plasmids (Dambaugh et aI., 1980), and was the first herpesvirs genome to be completely
sequenced (Baer et aI., 1984). The characteristic featues of the EBV geome include a single
overall format and gene arrangement, tandemly reiterated 0.5 Kbp terminal direct repeats
(TR), and tandemly reiterated 3 Kbp internal direct repeats (IR) which divide the genome into
long and short, predomiantly unque regions (UL and US). These characteristic DNA repeat
elements (IR) serve as important, unque landmarks m the EBV geome which allow one to
distinguish between EBV strains (Bornkam et aI., 1980). Whle various EBV isolates differ in
their tandem repeat frequency, individual EBV isolates tend to contai a constant num 
internal repeats even through virs replication and serial passage to new B cells (Dambaugh et
aI., 1980). In contrast, the terminal repeats are covalently linked durg episome formation
and only remai constant durg latent replication from ori-p. Dug lytic replication the
termal repeats are randomly cleaved and thus do not remai constant durg serial passage.
This principle is extremely useful in determining whether or not latently inected cells, such as
Burkitt' s lymphoma, arise from a single progenitor (monoclonal) or multiple progenitor cell, as
in polyclonal posttransplant lymphomas (Brown et aI., 1988). The following is a schematic
depiction of the linear EBV genome showing the location of EBV genes expressed durg viral
latency.
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Overall, there is general conservation of the genetic organization between herpesvirus
saimiri (HVS) and Epstein-Barr virus, although the homology to HVS is disrupted by unque
EBV DNA segments which fuction in latent B cell infection (Nicholas et aI., 1992). Antigenic
cross-reactivity between EBV and other herpesviruses is rare, even among the protein encoded
by the more consrved genes. In fact, the EBV genes expressed in latent inection as well 
several lytic cycle genes have 11 detectable homolgy to other herpesvirus genes and many
believe they may have arisen in part from cellular DNA (Heller et aI., 1982) (Heller et aI.,
1985). In particular, an irregular repeat motif GGGG present in the latent cycle EBV
nuclear antigen 1 (EBNA1) is also interspersed in human cell DNA (Heller et aI.
1982)(Hennessy et aI., 1983). Other examples of EBV lytic cycle genes with significant
homology to the human genome but little homology to other herperviruses include BZLF1
BHRF1, and BCRFl. BZLF1 is an imediate early gene closely related to the fos and 
transcriptional activators (Packham et aI., 1990). BHRF1 is an EBV early gene with
significant homology to the human bcl-2 gene (Cleary et aI., 1986) thought to be involved in
preventing B cells and other cells from undergoing apoptosis. Lastly, BCRF1 is an EBV late
gene with nearly identical primary amo acid seuence homology and biological activity 
human IL-lO (Hsu et al., 1990).
e & Strain Variations. Two types of EBV, formerly designated EBV type-A and - B
now referred to as EBV-1 and EBV-2 so as to parallel the HSV-1 and HSV-2 nomenclatue
(Liebowitz and Kieff, 1993) have been identified in most human populations (Bomkam et aI.
1980)(Dambaugh et aI., 1980)(Sample et aI., 1990)(Zimber et aI., 1986). Unlike HSV-1 and
HSV- , however, there is extensive homology and restriction endonuclease site conservation
thoughout most of the EBV-1 and EBV-2 genomes (Dambaugh et aI., 1984). The major
identiied differences between the EBV-1 and EBV-2 genomes exist in the latent inection cycle
nuclear antigen genes EBNA- , EBNA-LP (Dambaugh et aI., 1984), EBNA-
, -
, and -
(Rowe et aI., 1989) and in the small, non-polyadenylated RNAs EBERs 1 & 2 (Arrand et aI.
1989). As expected, the differences between EBV-1 and EBV-2 EBNA genes are reflected in
type-specific and tye-ommon EBNA epitopes (Hennessy and Kieff, 1985). Similarly, the
imune recogntion of BLCLs by EBV type-specific CTL is dependent upo the infecting EBV
strain (Moss et aI., 1988)(Misko et aI., 1991)(Moss et aI., 1992). The prevalence and geographic
distribution of the two EBV strains has be determed by serologic reactivities to EBNA-
Results indicate that African-derived EBV genomes are alost as frequently type-2 as type-
(1:2), which contrasts with American and European EBV genomes which are 10 ties more
liely to be type-1 than type-2. Similar serologic findings extend to the EBNA-
, -
, and -
3C genes (Rowe et aI., 1989). Sera from type-1 EBV-inected patients preferentially react with
type-1 EBNA-
, -
3B, and - , whereas sera from individuals infected with type-2 EBV react
preferentially with type-2 EBNA-3 gene products. With respect to homology, the EBNA gene
products share between 50-85% primary amo acid sequence identity, specifically, the type-
EBNA-2, -
, -
3B, and -3C differ in predicted primary amo acid seuence from their type-
counterpart by 47%, 16%, 20% and 28% respectively (Sample et aI., 1990). There also exists
limited genomic divergence between various type-1 EBV isolates. In one study 2% nucleotide
sequence and 5% amo acid seence divergence was observed between two EBV-1 latent
membrane protein-1 (LMP-1) genes (Hatfull et aI., 1988). Importantly, the EBV type
associated with various malignancies appears to correlate well with the degree of imune
dysfuction. For example, type-1 EBV is present in virtually all EBV-associated Hodgkin'
disease tuors (Gledhil et aI., 1991), except those in AIDS patients (Boyle et aI., 1991), in
essentially all nasopharyngeal carcinomas (Chen et aI., 1992), and two thirds of African
Burkitt' s lymphomas. In contrast, type-2 EBV is present in approximately one half of EBV-
associated lymphomas in AIDS patients, and virtually all EBV-associated T cell lymphomas
(Borisch et aI., 1993).
t Ran e & Virus Re tor. The host range of Epstein-Barr virs is restricted to
human and certai sub-human primates including squirrel monkeys and cotton top marosets
(Miler et aI., 1972). In general, the host range of lymphocryptovirses is restricted to
imature B lymphocytes which selectively express a cell surface protein which also serves as
a virs receptor. In vitro, B cell infectivity with EBV correlates with the imature stages of
development, when the highest density of a 140 kDa glycoprotein (CR2, now renamed CD21)
receptor is present, makig it a likely candidate for the vi receptor ijondal et aI.,
1976)(Aman et aI., 1984) (Fingeroth et aI., 1984) (Frade et aI., 1985). The identity of the EBV
receptor was confed in several studies showing that 1) purified CD21 binds to EBV
(Nemerow et aI., 1986), 2) vir infection is blocked by antibody directed against the CD21
glycoprotein (Nemerow et aI., 1987), and 3) expression of CD21 m heterologous cells confers
bindig to EBV (Ahearn et aI., 1988). CD21 is also the receptor for the C3d component of
complement. For review see (Cooper et aI., 1988).
The initial stage of inection involves the interaction of the major EBV outer envelope
glycoprotein gp350/220, with the B cell surface molecule CD21 (Taner et aI., 1987). Currently,
gp350 is believed to bind exclusively to the CD21 molecule as it does not bind to any other B cell
surface molecules. Comparon of the primary amo acid seences of gp350 and C3d has
revealed a shared nonapeptide (EDPGFFNVE) which likely explains their coon binding
properties with CD21 (Lambris et aI., 1985).
In human, the majority of primary EBV infections are believed to origiate in
oropharygeal lymphocytes (Anagnostopoulos et aI., 1995), and oropharyngeal epithelial cells
(Sixbey et aI., 1983)(Li et aI., 1992). In fact, double-label in-situ hybridization studies
performed by Anagnostopoulos suggest that EBV infection is restricted to B- and T-Iymphoid
cell, as they found no evidence of EBV inected oropharyngeal epithelial cells in 9 of 9 acute
1M patients examed. Accordingly, while the identity of the virs receptor m B cells is
clearly the type-2 complement receptor (CR2/CD21) (Fingeroth et aI., 1984), the EBV receptor
on epithelial cells, if one exits, remains unown. In general, EBV binds much less efficiently
to epithelial cells than B cells, and most anti-CD21 antibodies do not bind to epithelial cells.
These findings have led some to suggest the presence of a 200 kDa CD21 homologue m normal
epithelial cells (Sixbey et aI., 1987). More recently, northern blot hybridization has bee 
to demonstrate the presence of small amounts of CD21 mRNA which is indistiguishable in size
from that expressed in B cells. Additionally, clonig and sequencig of the epithelial cell
derived RNA has shown it to be identical to the B cell derived CD21 (Birchenbach et aI.
1991).
A large body of evidence suggests the presence of CD21, or related strctures, are also
present on cells of the T lieage (Tsoukas and Lambris, 1993), and T lymphocytes are known to be
EBV-inected during acute 1M (Anagnostopoulos et al., 1995). Both thymocytes and peripheral
T cells express CD21 or CD21-like molecules, however, their reactivity with anti-CD21
antibodies differs from that of B cells, suggesting there may be structural differences between T-
and B-cell CD21 molecules. Low levels of the CD21 receptor are also expressed on established T
cell lines such as MOLT- , and T cell lies (MT-2) transformed with the human T cell leukemia
virus 1 (HTLV1) (Koizumi et aI., 1992).
ges of Infe ion. In general, the herpesviruses undero lytic replication in one cell
type while simultaneously establishing latent inection in another, indicatig that cell
specific factors determine the overall balance of virs/cell interactions. In keeping with the
replication of human herpesvirses in epithelial cells, large amounts of EBV have bee
reported to be present in sqous epithelial cells recovered from the oropharynx of persons
with acute inectious mononucleosis (Lemon et aI., 1977). In fact, the oropharygeal epithelium
is believed to be permissive for viral replication and was once considered to be the site of
primary EBV inection (Sixbey et aI., 1984). Recent data convincingly demonstrate that
lymphocytes, and not epithelial cells, are the primary cell infected durg acute 1M
(Anagnostopoulos et aI., 1995). These EBV infected lymphocytes are present in the crypt
epithelium of palantine tonsils and are the likely mean of EBV transfer to uninected
individuals. Dug primary EBV inection, persistent active replication enues which then
contiues at some level for many years, usually accompaned by prolonged oropharyngeal virus
excretion (Miler et aI., 1973). Early in the cour of primary infection, EBV inects small
resting B lymphocytes which traffic through the orophary dose to the epithelial basement
membrane. The virs rarely undergoe lytic replication in B cells, but instead establishes a
latent type of inection whereby the genome is maintained as an episome and gene expression is
restricted to the EBNAs, LMs and EBERs, thereby dissemiating the viral genome through
cellular proliferation. The same process can also occur in reverse, as shown in studies involving
the analysis of EBV strains in donor recipient pairs, prior to, and following bone marow
transplantation. In one case, a boe marow recipient's strain of EBV disappeared from the
orophary following radiation induced imune ablation and was subsequently replaced with
the EBV strain of the marrow donor (Gratama et aI., 1988)(Gratama et aI., 1990). This finding
also lends credence to the theory that B cells, and not epithelial cells, are the reservoir for
EBV persistence (Miyashita et aI., 1995). The following diagram depicts the pathway leading
from primary oropharyngeal infection with EBV through the establishment of latency in B
cells. In this model, cell-mediated imunty (CD8+ CTL) limits the proliferation of latency
tye-II EBV-inected B cells (imunoblastic phenotye) in the peripheral blood, which only
rarely enter lytic cycle replication and give rise to progeny virions. EBV-infected cells with a
latency type-I phenotye (EBNA-1 expression in quiescent B cells) serve as an immunologically
protected reservoir for EBV persistence.
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EBV Adso tion netration Uncoati EBV inection is initiated by interaction of
the virus with the CD21 molecule on epithelial or B cells. Virus binding as well as the initial
phase of penetration are mediated through the major viral coat glycoprotein gp350/220 (Wells
et aI., 1982) (Taner et aI., 1987). As mentioned earlier, the only B-Iymphocyte surface
molecue known to bind gp350/220 is CD21 (Nemerow et aI., 1987) and EBV infection can be
blocked by monoconal antibody directed to either CD21 or gp350 (Hoffman et aI., 1980).
Further evidence supportg the essential role of gp350/CD21 interaction durg EBV
adsorption is the demonstration that soluble gp350 can block virs inection by saturation of
available CD21 binding sites (Taner et aI., 1988). Virus adsorption m the surface of B cell
results in capping of CD21, followed by endocytosis of EBV into smooth membrane vesicles
(Nemerow and Cooper, 1984). A second EBV envelope glycoprotein (gp85) then mediates fuion
of the virs with the vesicle membrane, causing release of the nucleocapsid into the B cell
cytoplasm (Miler and Hutt-Fletcher, 1988).
Dissolution of the viral nucleocapsid and tranport of the genome to the cell nucleus are
less well understood. Once inide the nucleus, the linear EBV geome circularizes (Adams and
Lindahl, 1975) (Lindahl et aI., 1976), which precedes, or at least coincides with the earliest
gene expression (Alfieri et aI., 1991), directed from the first latent infection promoter Wp. The
EBV genome is replicated by cellular DNA polymerases durg the cell cycle S phase (Adams,
1987), and persist as multiple, extrachromosomal double stranded EBV episomes, which are
organed into nucleosomes similar to chomosomal DNA (Dyson and Farrell, 1985).
Virus E sion in La ent Infe ion. The hallmark of B lymphocyte infection with
EBV is the establishment of latency, which is characterized by three distinct processes,
including (i) viral persistence, (ii) restricted virs expression which alters cell growth and
proliferation, and (iii) retained potential for reactivation to lytic replication. Intracellular
persistence of the entire viral genome is achieved through circularization of the linear EBV
genome present in viral particles, and maintaience of multiple copies of this covalently closed
episomal DNA (Adams, 1987). The episomes are replicated semi-conservatively durg cell
cycle S-phase by cellular DNA polymerases, and equal partitioning of episomes to daughter
cells is mediated by interactions between the latent origi of plasmid replication (OriP) and
EBV nuclear protein 1 (EBNA1) (Yates et aI., 1984). The 172 Kbp EBV genome encodes
approximately 100 genes, ten of which are expressed durg latency and are thought to be
involved in establishig and maintaining the "immortalized" state, includig six EBV nuclear
proteins (EBNAs 1, , 3A, 3B, 3C, LP), two latent membrane proteins (LMP-1 and 2), and two
small untranslated, non-polyadenylated RNAs (EBERs 1, 2) (Liebowitz and Kieff, 1993).
Latency can be disrupted though a variety of cellular activators, resultig in expression of
BZLFl, a key mediator which induces the switch from viral latency to lytic replication
(Flemington and Speck, 1990) (Packham et aI., 1990).
Unlike the short term proliferation induced by crosslig surface Ig m B cells,
proliferation of B lymphocytes driven by EBV transformation is indefinite. In spite of this
difference in proliferation potential, the phenotye of antigen driven B lymphocytes is similar
to that induced by EBV, which tranform B cells though autocrie growth mechanms that
promote or at least maintain a differentiated B cell phenotype. Ths is in marked contrast to
the poorly differentiated phenotype characteristic of most Burkitt lymphomas carrying the c-
myc translocation, many of which express the germinal center B cell marker CDlO but do not
express activation (CD21, CD23, CD80) or adhesion molecules (LFA- , LFA- , ICAM-1).
While only about 10% of the genes encoded by EBV are expressed in latently infected B
cells, the trancribed regions encompas a major porton of the viral genome. Trancription of
the EBNA and LM genes is mediated by cell derived RNA polymerase while the EBERs
are primarily trancribed by RNA polymerase II (Arrand and Rymo, 1982) (Howe and Shu
1989). By far, the most abundantly transcribed EBV genes in latently infected cells are the
EBERs (107 copies/cell), distantly followed by LMP1, which in tu is significantly more
abundant than the EBNAs and LMP2. The majority of the genome 3' of the Wp promoter is
transcribed, however, the selection of specific promoters and alternate splicing ultimately
determine the levels of latent gene expression (Sample and Kieff, 1990). The following
diagram depicts the extensive transcription and long-range splicing of the EBV genome which
occurs in latently infected B lymphocytes.
(Adapted from E. Kieft
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Transcription of EBV Episome in Latently Infected B Lymphocytes
Following circularization of the liear EBV genome within the cell nucleus, rightward
transcription of the EBNAs is initiated from the Wp promoter within IR1, a copy of which is
encoded in each 3kb long internal repeat (Sample et aI., 1986). The EBNA mRAs are
assembled by alternative splicing and 3' processsing of a coon precr encoded by over 100
kb of the genome (Bodescot and Perricaudet, 1986) (Sample and Kieff, 1990). EBNA LP and
EBNA 2 are the first EBV protein expressed during latent inection of B cells, and reach their
steady state levels within 24-32 hrs (Alfieri et aI., 1991). EBNA 2 is essential to the
imortalization process as virses with deletions encompassing EBNA 2, such as P3J-HR-1 and
Daudi, are imortalization incompetent (Bornkam et aI., 1982) (Jones et aI., 1984). Infection
of primary B cells with the EBNA 2 mutant HR-1, not only results in failure of EBNA 2
expression, but also in failure to express EBNA genes not deleted in HR-1 such as EBNA 1 and
EBNA 3 genes (Rooney et aI., 1989). Thus, EBNA 2 is requied for expression of other EBV
latent genes, and has bee shown to transactivate cellular genes including CD23 (Wang et aI.,
1987), CD21 (Wang et al., 1990), c1gr (Knutson, 1990), and EBV genes including LM 1 and 
2 (Abbot et al., 1990)(Rooney et aI., 1992).
EBNA 2 also likely plays a role in promoter switching durg the initial stages of
latent B cell infection. Promoter usage in some cells has be shown to move upstream from the
dominant latency promoter Wp to an alternative latency promoter Cp (Woisetschlaeger et aI.
1990)(Woisetschlaeger et aI., 1991). All resultig Wp or Cp initiated transcripts have the
same repeatig exons (W1 and W2) in their leader sequences. A potential splice donor site near
the 5' end of the EBNA 2 exon which preceeds the EBNA 2 intiation codon is activated in some
trancripts, resulting in alternate splicing to a far downtream acceptor in U3. The U3 exon is
then alternately spliced to anyone of four acceptor sites in the ORFs that encode EBNAs 3A
, 3C and 1 (Bodescot and Perricaudet, 1987). LM1 and LM 2 are trancribed in opposite
directions under the control of closely positioned promoters sharing the same EBNA2 response
element. By 32 hr post-infection, all of the EBNA proteins and LM1 can be detected using
appropriate antisera (Alfieri et aI., 1991). While less is known about onset of expression of
LMP 2A and LMP 2B due to lack of good quality antisera, their regulation appears to be similar
to that of the other EBNAs, as both of the LMP 2 promoters are EBNA2 responsive.
Concomitant with LM1 expression is a further increase in the level of CD23 and the
onset of cell DNA synthesis. Expression of the EBNA proteins reaches a steady state level
within 48 hours of primary B cell infection (Allday et aI., 1989) (Moss et aI. , 1981).
In contrast to EBV tranformed lymphocytes grown in-vitro many EBV-carrying tuors
grown in-vivo, do not express the full spectr of latent proteins (Rowe et aI., 1986) (Rowe et
al., 1987), uness they are derived from an imunocompromised host (Young et al., 1989). In the
case of endemic Burkitt' s lymphoma (BL), most latent cycle genes are not expressed, while
EBNA-1 is expressed from an alternative promoter, Fp or more correctly Qp (Schafer, 1995 
ViroI.), located downstream of the EBNA2 gene (Sample et al., 1991). Presumably, the Cp and
Wp promoters are suppressed in BL, and the Qp promoter is inactive in B-LCLs. This specific
downegulation of other latent proteins demonstrates the significance of tissue-specific
regulation of latent genes in vivo, as EBNA1 does not induce adhesion molecues required for
cytotoxic T-cell (CTL) mediated kiling (Rowe et aI., 1986), thus contrbutig to the lack of
recognition of BL cell by class-I-restricted CTLs (Rooney et al., 1985).
ans rmation an ate Pro . All latently infected B cells harbor one, or usually
more, complete EBV episomes and when grwn in vitro express a restricted set of latent genes
comprised of six nuclear antigens ( EBNA 1, 2, 3A, 3B, 3C and LP), two latent membrane proteins
(LM 1 and 2) and two untranslated, nonpolyadenylated RNAs (EBER-1 and EBER-2). While
all of the EBNA genes are expressed in latently inected B lymphocytes transformed in vitro,
considerable variation in EBNA gene expression exists among various EBV-infected cells
growing in-vivo (Miyashita et aI., 1995) (Gregory et aI., 1990) (Rowe et aI., 1987). The family
of EBV-encoded nuclear antigens (EBNA) was origially named as such based up the ability
of antisera from persons previously inected with EBV to recogne these proteins in the nuclei
of infected cells.
Sl nuclease protection and DNA seuencig were us to identify the first EBNA
protein (EBNA1) which encodes an irregular glycine-alanine repeat whose length varies
according to the strain of EBV (Hennessy et al., 1983). Based upon the predicted primary amino
acid sequence, EBNA 1 consists of 641 amino acids, is highly charged and has an apparent M.
of 76 KDa (Hearing et aI., 1984). While most of the EBNA proteins bind DNA cellulose and are
therefore presumed to have DNA binding capabilty, only EBNA-1 has sequence-specific DNA
binding propertes, and binds to thee cognate sites (TAGGA TAGCA T ATGCT ACCCAGATCCAG)
located m the EBV genome (Rawlis et aI., 1985) (Jones et aI., 1989). The EBNA1 cognate
sequence having highest bindig affinity consists of 20 tandem 30 bp repeats (region 1), while
the site having the second highest affinity consists of two cognate seuences in dyad symmetry
and two in tandem (region 2). Together, the site of dyad symetry and the 20 tandem direct 30
bp repeats constitute the origi of plasmid replication (OriP) (Reisman et aI., 1985), which 
required for efficient episome persistence and replication in latently inected cells (Wysokenski
and Yates, 1989)(Lupton and Levine, 1985)(Yates et aI., 1984). Region 2 contai four EBNA1
bindig sites, is located near the initiation site of latent cycle DNA replication, and is
absolutely requied for episome replication and maitenance (Gah and Schild kraut, 1989).
Likewise, region 1 is absolutely required for the maitenance of plasmids contaig region 2 in
cells expressing EBNA1, and region 1 contai the termination site for replication. Lastly,
durg metaphase, EBNA1 is diffusely associated with all chomosomes in latently infected
cell nuclei, and it is through this combined interaction of EBNA1 with both OriP and
chomosomal protein which assures equal partitionig of EBV episomes to progeny cells
(Harris et aI., 1985). EBNA-1 also transactivates the EBNA-2 protein, which in tu,
activates production of two latent membrane protein (LMP-1 and -2), as well as several B-cell
encoded products CD21, CD23 and c-fgr.
EBNA 2 is essential to the process of B lymphocyte immortalization as vires having
deletions encompassing EBNA 2, such as P3-HR-1 and Daudi, are unable to tranform primary B
lymphocytes into permanently growig B-Iymphoblastiod cell lies (B-LCLs) (Miler et aI.
1974) (Bornam et aI., 1982) (Jones et aI., 1984). Inection of primary B cells with the EBNA 2
mutant P3HR-1, not only results in failure of EBNA 2 expression, but also in failure to express
EBNA genes not deleted in P3HR-1 such as EBNA 1 and EBNA 3 genes (Rooney et aI., 1989).
Restoration of the deleted DNA in defective P3HR-1 EBV produces progeny vir with the
abilty to transform primary human B lymphocytes (Skare et aI., 1985) (Cohen et aI. , 1989).
Two major tyes of EBV exist, types 1 and 2, and variations in the EBNA2 protein
impart the most signicant biologic difference between these two EBV tyes. In general, type 1
EBV (B95-8) transforms normal human B lymphocytes much more efficiently than type 2 EBV
(P3J-HR-1 and its nondeleted parental strai Jijoye) (Rickison et aI., 1987). Confirmation of
the critical role played by EBNA2 in the transformation process was made by inserting cloned
type 1 EBNA2 DNA into the P3HR-1 deletion site, which conveyed to it a highly effcient
transformation phenotye identical to that of type 1 EBV (Cohen et aI., 1989).
The predicted primary amino acid sequence of tye 1 EBNA2 consists of 491 amo acids
(90 KDa), while that of tye 2 EBNA2 consists of 443 amo acids (78 KDa) (Hennessy and
Kieff, 1985) (Mueller-Lantzsch et aI., 1985). Overall, EBNA2 is an acidic molecule with
several domai, one of which, located in the carboxy termus, is reponsible for nuclear
localization (Cohen et aI., 1991).
The first biochemical evidence for a role of EBNA2 in B cell growth-transformation
came from the demonstration that EBNA2 specifically transactivates expression of the B
lymphocyte activation marker CD23 (Wang et aI., 1987), which is abundantly expressed m
EBV-tranformed and antigen-primed B lymphocytes (Hurley and Thorley-Lawson, 1989).
EBNA2 also upregulates expression of the cellular genes CD21 (Wang et aI., 1990) and c-fgr
(Knutson, 1990), and the EBV iatent genes LM1 (Abbot et aI., 1990) and LM2 (Zimber-Strobl
et al., 1991). Thus, most of EBNA 2's role in B lymphocyte tranormation comes from it's ability
to transactivate cellular and EBV genes.
EBNA 3 consists of a family of three high molecular weight gene products (EBNA 3A
, 3C) rangig in size from 145-165 kDa (Hennessyet aI., 1985) (Hennessyet aI., 1986) (Petti
and Kieff, 1988) (Petti et aI., 1988) (Sample et aI., 1990). The EBNA 3 genes are located in
tandem on the EBV genome and their mRNAs are the least abundant, with only several copies
of each being present in latently infected cells (Kallin et aI., 1986). Despite the low levels of
EBNA 3 mRNA in latently infected cells, all of the EBNA 3 proteins accumulate in large
intranuclear clumps which almost completely fil the nucleus, sparing only the nucleolus (Petti
et aI., 1990). Much lie EBNA 2, the EBNA 3 genes are polymorphic and differ according to the
EBV type, 1 or 2. The sizes of the tye 1 EBNA3s based upo predicted primary amo acid
seuence are 3A=944, 3B=938, 3C=992 and share 84%, 80% and 72% amo acid identity,
repectively, with their corresponding type 2 proteins (Rowe et aI., 1989) (Sample et aI., 1990).
Unlike the difference in transformation phenotype imparted by the EBNA 2 type (lor 2), the
type specificity of the EBNA 3 genes (lor 2) does not affect the abilty of the virs to initiate
growth transformation, episome maitainence or lytic replication (Tomkon and Kieff, 1992).
Systematic analysis of the transformation capabilty of EBV recombinants having specific
mutations in each of the EBNA 3 genes demonstrated that whie EBNA 3B is dispensable for B-
lymphocyte growth transformation, mutations in either EBNA 3A or 3C renders the virs
transformation incompetent (Tomkison et aI., 1993).
EBNA LP or leader protein is actually a set of highly polymorphic proteins encoded
primarly by repeating exon (W1 and W2) from IR1 within the leader of the EBNA mRNAs.
Translation is dependent up a splice between exons downtream of either the Wp or 
promoters and the first W1 exon. As the num of IR1 repeats varies among different EBV
isolates, so does the size of EBNA LP, rangig from 22-70 kDa (Dillner et aI., 1986). EBNA LP
has a somewhat unusual nuclear location, being partially spread diffusely through the nucleus
and also concentrated in several small nuclear granules. While the fuction of EBNA LP
remais unclear, some have speculated that it may playa role in RNA processing or associate
with soe nuclear regulatory protein (Jiang et aI., 1991), alternatively, it may fuction by
upregulatig expression of autocrine factors critical to B-LCL growth (Manick et aI., 1991).
Strictly speakig, EBNA-LP is not required for transformation but it appears to augment growth
transformation of primary B cells.
The seond most abundant EBV mRNA species present in latently infected B
lymphocytes (60 copies/cell) is highly stable and encodes a 63 kDa integral membrane protein
LMP-1 (Fennewald et al., 1984) (Hennessy et al., 1985). While the LMP-1 promoter contain an
EBNA2 repons element which fuctions to upregulate LM-1 expression (Abbot et aI., 1990),
LMP-1 is expressed in the absence of EBNA2 during lytic cycle activation in BL cells (Contreras-
Salazar et aI., 1990), and in NPC tumors (Brooks et aI., 1992).
Based upo predicted primary amo acid sequence, LM-1 was correctly asumed to
represent an integral membrane protein compose of a hydrophilc 20 amo acid cytoplasmic
amo termus, six highly hydrophobic, 20-amino-acid, tranmembrane segments, and a
highly acidic 180 amino acid cytoplasmic carboxy terminus. The plasma membrane location of
LMP-1 was determed by measurement of LM-1 content in various membrane fractions as
detected with a mA (S12) raised against a LMP- galactosidase fuion protein (Man et aI.
1985). Additionally, protease digestion of live cells and imunofluorescence revealed that
30% of LMP is located in the plasma membrane, and with the exception of a small outer reverse
turn loop, the vast majority of LMP-1 is not exposed on the outer surface of the cell (Liebowitz et
aI., 1986).
In vitro, LMP-1 is essential for EBV-induced transformation of B cells into BLCLs (Kaye
et aI., 1993) (Kaye et aI., 1995), and induces many of the activation markers associated with
EBV inection of B lymphocytes (Rowe et aI., 1994). Shortly after being translated, LMP-1 is
phosphorylated and beomes tightly bo to vimentin, in association with the cytoskeleton
(Liebowitz et aI. , 1987). The majority of LMP-1 is associated into discrete patches within the
plasma membrane, which are often further assembled into a single caplike strcture, a
behavior characteristic of many activated receptors (Schechter et aI., 1979). The process of
LMP-1 cap formation does not requie any additional EBV proteins, as LMP-1 contiues to form
patches when introduced by single gene transfer into the EBV-negative B-Iymphoma cell line
(Loukes) (Wang et aI., 1988). This characteristic plasma membrane patching of LMP-
prompted an exploration of its role in B-Iymphocyte growth transformation. Transfer of the
LMP-1 gene into continuous rodent fibroblast lines (NIH-3T3 and Rat-1), demonstrated multiple
tranorming effects, including altered cell morphology and reduced se requiements (Wang
et al., 1985). In Rat-1 cell, LMP-1 expression induces a loss of contact inibition and anchorage-
independent growth in soft agar. Simar effects on cell growth by LMP-1 occur in NIH-3T3 cell
(Wang et aI., 1988). Importantly, Rat-1 cells, which are not normally tuorigenic in nude mice
beome unormy tuorigenc when expressing LMP-1 (Wang et aI., 1985). The cytoskeletal
association of LMP-1 appears to be integral to its activity, as a partially deleted form of the
molecue (D1LMP) localizes to cytoplasmic membranes, does not form aggregates associated
with the cytoskeleton and has little effect m B lymphocyte growth (Wang et aI., 1988)
(Moorthy and Thorley-Lawson, 1993). In many respects, the effects of LM-1 m B lymphocyte
growth resemble those mediated by activation of the CD40 receptor in the presence of IL-
(Banchereau et aI., 1994).
Expression of LMP-1 in EBV-negative Burkitt's lymphoma lies induces many of the
changes typically associated with EBV infection or antigen activation of primary B
lymphocytes (Wang et aI., 1990) (Wang et aI. , 1988) (Liebowitz et aI., 1992). LMP-expressing
cells exhibit increased vilous projections and grw in tight clumps due to increased expression
of the homotyic cellular adhesion molecues LFA-1 and ICAM-1 (Wang et aI., 1988). This
effect is advantageous to the virs as in-vitro grwn BLCLs proliferate in discrete cell clumps
which serves to enhance the effective concentration of secreted autocrine growth factors.
Importantly, LM-1 induction of the adhesion molecules LFA- , LFA-3 and ICAM-1 promotes
interaction between B and T lymphocytes via the LFA-3/CD-2 and LFA-1/ICAM-1 adhesion
pathways. These heterotypic ahesions are important as the in-vivo elimination of EBV-
tranformed B lymphocytes is dependent on conjugate formation with cytotoxic T cells. Indeed,
the levels of LFA-3 and ICAM-1 on infected cells influences their susceptibilty to CT lysis by
modifing the affinity of effector-target conjugate formation (Makgoba et aI., 1988). LMP-
also induces cell surface expression of a num of B-cell activation molecules, including CD23,
CD39, CD40, CD44 (Wang et aI., 1990). More recently, LMP-1 has be shown to protect EBV
inected B cells from programed cell death (apoptosis), mediated in part though induction of
the cellular oncogene bcl-2 (Gregory et aI., 1991) (Henderson et aI., 1991).
LMP-2 is an integral membrane protein contaig twelve hydrophobic tranmembrane
domains which co-localizes with LMP-1 in the plasma membrane of EBV inected lymphocytes
(Longnecker and Kieff, 1990). Amg the transformation associated EBV proteins, EBNA1
LMP-1 and LMP-2 are present most consistently in NPC tuor biopsies and EBV related
malgnancies (Young et aI., 1989) (Brooks et aI., 1992) (Buson et aI., 1992). Since both LMP-
and LM-2 contai T cell epitopes (Murray et aI., 1992), their persistent expression in-vivo
argues for an important role in the persistence of EBV in the human host. The LMP-2 gene is
simultaneously transcribed from two promoters, resultig in trancripts (LMP-2A and 2B) which
are spliced into nearly identical mRAs differing only in their 5' exons (Sample et aI., 1989).
The LMP-2A and -2B mRAs encode for nearly identical protein which share similar
tranmembrane domai and a 27 amo acid carboxy terminal domai (Kieff and Liebowitz,
1990). LMP- , however, lacks the entire 119 residue amo terminal cytoplasmic domai of
LMP-2A.
Functionally, LM-2 is a substrate for B lymphocyte src family tyrosine kinases,
particularly lyn and fyn and associates with a 70 kDa tyrosine phosphorylated cellular
protein (Lngnecker et aI., 1991) (Burlhardt et aI., 1992). While LMP-2 appears to play an
important role during EBV infection in-vivo, its role in-vitro remais in question. Epstein-Barr
virs recombinants carrying LMP-2A mutations, which do not express LMP-2A protein, are fully
capable of initiating and maintaing B-Iymphocyte growth transformation in-vitro
(Lngnecker et aI., 1992). Surprisingly, expression of EBNA- , EBNA-2 and LMP-1 are
unaffected by the LMP-2A mutation. Importantly, BLCLs derived from the LMP-2A mutants
are identical to wildtype EBV-transformed BLCLs with regard to growth characteristics,
permisivity to lytic infection and virus replication. Thus, an important role for LM-2 in-vivo
is further supported by the expression of LMP-2 in latently infected B lymphocytes and NPC
cells in-vivo, despite CT activity against this protein. Recently, LMP-2 has be shown to
block the effects of surface Ig cross-likig m Ca++ mobilzation and m lytic reactivation of
EBV in latently inected B lymphocytes (Miler et aI., 1995). LMP-2 appears to act as a
constitutive domiant negative modulator of surface Ig receptor sigaling though its effects cr
the Lyn and Syk protein tyrosine kiases, or regulators of these kiases. The effect of LMP-2 cr
preventing reactivation in-vivo likely contributes to imune escape and prevents destrction of
the latent reservoir of EBV.
The most abundant EBV RNAs in latently infected B-cells are the EBV -encoded, small
nonpolyadenylated RNAs named EBER-1 and -2 (Howe and Shu, 1989). Unlike the other EBV
genes expressed durg latent infection, the EBERs are also transcribed durg lytic infection.
The majority of EBERs are localized within the cell nucleus where they are complexed with
the cellular protein La (Howe and Steitz, 1986). Functionally, the EBERs have long bee
suspected of being involved in RNA splicing due to the long-range transcription and extensive
splicing characteristic of latent infection, and because of the base complementarity of EBER-
to known splice sites (Glickman et aI., 1988). Realistically, this theory is incompatible with
more recent evidence demonstratig that EBER expression durg primary inection is delayed
until after the splicing which is requied for EBNA and IM gene expression (Alfieri et aI.
1991). Similarly, speculation of possible interferon effects of the EBERs are likely unounded
(Swaminathan et aI., 1992).
The constrction of EBV recombinants carrying EBER mutations has now helped 
establish that both EBERs are dispensable for the in-vitro growth transformation of B-
lymphocytes (Swaminathan et aI., 1991). These EBER deletion mutats tranform B-cells into
BLCLs which are phenotypically identical to wildtype BLCLs in growth characteristics and
abilty to undergo lytic virus replication.
EBV DNA Persisten e in Latenc . Durig convalescence, low levels of virs are thought
to be maintained by sporadic replication in the epithelial and/ or B-cells ling the oropharynx
and latent virs persists in 1 in 105-6 small restig B lymphocytes (Tosato and Blaese, 1985).
Latently infected B cells typicaly contain between one and ten complete EBV episomes per cell
(Adams and Lindah, 1975) (Heller et aI., 1981) and all EBV latently-infected cells express a
mium of the EBNA1 protein, which is requied for episome maintenance and also likely
requied for episome amplification. However, while most EBV DNA persists in latently
infected cells in an episomal form, the EBV genome is also known to integrate into chomosomal
DNA (Matsuo et al., 1984) (Hurley et aI., 1991). Evidence thus far indicates that integration is
neither site specific nor a regular feature of EBV-mediated growth transformation. Since LMP-
2 is the only EBV latent gene disrupted by linearization of the genome, the integrated form of
EBV stil retais it potential to tranform B cell into permanently growig BLCLs. Clearly,
the integrated form of EBV is limited in its abilty to infect new cells, as episomal DNA is
likely necessary for lytic cycle EBV replication, and lytic replication has not be reported in
cells contaiing only the integrated form of EBV.
While BLCLs grown in-vitro express a restricted set of EBV latent genes (EBNAs- , 2
3B, 3C and LP, LM-1 and 2, and EBER-1 and 2), EBV-infected restig B cells growig in-
vivo express an even more restricted porton of the viral genome, limited to EBNA-
(Miyashita et aI., 1995) (Chen et aI. , 1995), and probably LMP-2a (Qu and Rowe, 1992) (Tierney
et aI., 1994). Following acute infection, EBV resides in small resting B cells which express a
mial number of B-cell activation markers or adhesion molecules and, largely for th reason
escape imune surveilance of the normal host. Thus, EBV transformed cells should be
considered oncogenically tranformed as they wil proliferate indefinately when cultued in
vitro (Pope et aI., 1969)(Henle et aI. 1967)(Miler et aI., 1969) and give rise to
lymphoproliferative disorders including lymphoma in individuals with congenital (severe
combined imunodeficiency; ataxia telangiectasia) or acquired (allograft recipients and AIDS)
imunodeficiencies (Purtio et al., 1975)(Crawford et al., 1980) (Ziegler et aI., 1982).
tic In Virus Re lication. The vast majority of latently inected B cells do not
undergo lytic cycle replication, but can be induced to do so by activation with either phorbol
esters, calcium ionophores or by crosslikig cell surface Ig (Luka et al., 1979) (Takada and Ono
1989) (Sinclair et aI. 1991). Following induction, cells undergo cytopathic changes
characteristic of lytic herpesvirus inection, including chromatin margiation, viral DNA
synthesis, nucleocapsid assembly at the nucleus periphery, virs buddig though nuclear
membrane, and inbition of host cell protein synthesis (Takagi et aI., 1991).
In lytic EBV infection, imediate-early genes are defined as genes that are transcribed
in newly infected cell in the absence of new viral protein synthesis. The key immediate-early
trans-activators of EBV lytic cycle genes are the 1kb ZLF1 mRA and the 2.8kb RLF1 RNA
(Jenson and Miler, 1988) (Flemigton and Speck, 1990). Transient expression of the ZLF1 ORF
under the control of a heterologous promoter trans-activates two major EBV early gene
promoters, HLF1 and DR, and the pattern of EBV early gene expression induced by ZLF1 is very
similar to TPA-induced early lytic replication (Takada et aI., 1986).
The induction of EBV lytic cycle replication results in increased episome copy num
and suggests that circular episomal DNA replication is a precr to subseuent DNA
replication (Shaw, 1985). Unexpectedly, the EBV DNA polymerase is not requied for viral
DNA replication associated with episome establishment (Sixbey and Pagano, 1985).
The EBV genes expressed durg the late stages of lytic inection are mostly structural
viral proteins which permit virs development and egress. The viral glycoprotein are all late
genes which have be extensively studied due to their potential importance in antibody-
mediated imunty to EBV. The known glycoprotein genes are LLF1 gp350/220, BDLF3 gp150,
ALF4 gp110, XLF2 gp85 and ILF2. ALF4 encodes encodes a late 3.0 kb mRA with a translated
product of a 93 kDa protein, and when glycosylated is 110 kDa (Gong and Kieff, 1990).
Two EBV glycoproteins formg important parts of the vir coat are gp350/220 and
gp85 (Dolyniuk et aI., 1976) (Beisel et aI., 1985) (Heineman et aI., 1988). Gp85 is a relatively
mior virs component which is functionally involved in the fuion between vir and cell
membranes (Miler and Hutt-Fletcher, 1982). Gp350/220 is the major virs coat glycoprotein
and mediates virus binding to the B lymphocyte receptor CD21 (Fingeroth et aI., 1984)
(Nemerow et aI., 1987) (Taner et aI., 1987). The fiding that gp350/220 is the most abundant
viral protein in lytic ally infected cell membrane has led to the hypothesis that high levels of
gp350 may saturate CD21 so that newly released vir is not readsorbed to lytic ally infected
cells.
Several potential strategies for inibiting EBV replication are currently being
developed, and most are based upo the unque interaction of EBV with B lymphocytes.
Potential strategies include: 1) the dependence m gp350/220 interaction with CD21 for virs
adsorption and penetration (Taner et aI. 1988), 2) preventig persistent infection by
attemptig to specifically block the interaction of EBNA1 with the ori-p site in EBV DNA
and 3) preventig the ZLF1 trans-activation of lytic vir replication by blockig recogntion
and interaction with cellular transcription factors.
Experimental Models of EBV Infection
A monumenta breakthrough in ou abilty to study EBV inection came with the
discovery that EBV can infect primary human B lymphocytes in vitro and tranform them into
permanently growing lymphoblastoid cell lines (Henle et aI. , 1967) (Pope et aI., 1968). EBV-
transformed B-cells wil proliferate indefinitely in the absence of imune-mediated growth-
regulation and not surrisingly, can be grwn in nude mou brai or in the peritoneum of SCID
mice (Mosier et aI. , 1988) (Rowe et aI., 1991) (Pisa et aI., 1992). Latently inected B
lymphoblastiod cells grown in vitro appear to phenotypically resemble the EBV tuors formed
in SCID mice. In fact, EBV gene expression in SCID mice tuors is similar to BLCLs grwn in
vitro, albeit, EBNA2 expression is somewhat lower. Histologically, peripheral blood
lymphocyte (PBL)-derived hu-SCID tuors resemble the EBV+ large cell lymphomas that
develop in imunosuppres patients and, like the human tuors, are often located in
multiple sites as individual monoclonal or oligoclonal foci (Rowe et aI., 1991). These tuors
develop with remarkable efficiency in the hu-SCID model and strongly suggest that
lymphomagenesis involves the direct outgrowth of EBV -transformed B cell without the need
for secondary genetic changes. It is therefore reasonable to assume that selection on the basis 
cell growth rate alone is sufficient to explai the monoclonal /oligoclonal nature of these tuor
foci. These fidigs are potentially very important as EBV+ large cell lymphomas in
imunosuppressed individuals are likely to arise in a similar maner.
The contribution of individual EBV latent genes in maintaining growth transformation
has be assayed by gene transfer into a variety of cell includig primary or early passage
contiuous rodent fibroblasts and human B-Iymphoma cell lies (Kieff and Liebowitz, 1990).
EBNA- , EBNA-LP and EBNA-3A have 11 apparent direct effect m primary or contiuous
rodent fibroblast growth alone or in cotransfection with other known oncogenes and have 
effect m human B-Iymphoma cell growth (Wang et aI., 1987). EBNA-2 however, is directly
involved in B-Iymphocyte transformation, as two EBV strai (P3HR-1 and Daudi) deleted for
EBNA-2 are unable to initiate growth transformation (Bomkam et aI., 1982) (Cohen et aI.
1991). In spite of their inabilty to tranform B cells (Miler et aI. , 1974), P3HR-1 and Daudi
can stil infect, replicate, and persist in a latent state in EBV-negative Burkitt's lymphoma
cell. Constrction of recombinant vir with the EBNA-2 mutat P3HR-1 and other defective
EBV genomes, followed by selection of transformation competent EBV demonstrates the
fudamental role played by EBNA-2 in that all transforming recombinants have 
reconstituted EBNA-2 gene (Cohen et aI., 1989). Additionally, gene transfer of EBNA-2 into
Rat-1 cells has the effect of reducig se requirements over that of Rat-1 control cells.
Surprisingly, EBNA-2 has 11 tranformg or imortalizing activity in primary rodent
fibroblast cells alone or in combination with myc or ras (Kieff and Liebowitz, 1990). In gene
transfer experiments LMP-1 has been shown to impart potent tranformg effects in contiuous
rodent fibroblast lines (Wang et aI., 1985). In Rat-1 and NIH-3T3 cells, LMP-1 alters cell
morphology and allows cell growth in medium contaig markedly reduced amounts of seru.
LMP-1 also causes loss of contact inibition and loss of anchorage dependence in Rat-1 cells,
enabling high efficiency clonig in soft agar. Additionally, Rat-1 cell expressing LMP-1 are
tuorigenic in nude mice, whereas control Rat-1 cell are non-tuorigenic.
Initial attempts to develop a primate model for EBV infection were thwarted by the
finding that old world primates are unormly infected with and imune to a
lymphocryptovirs closely related to EBV. However, new world primates are not uniformly
inected with EBV related viruses and primary infection with EBV frequently results in death
from acute lymphoprolierative disease (Shope et al. , 1973). This form of inection provides an
important model and studies of EBV-induced lymphomagenesis in cottontop tamarins have
revealed that the tuors can be either monoclonal or oligoclonal large cell lymphomas closely
resemblig the EBV genome-positive B-celllymphomas in human alograft recipients (Young et
aI., 1989). These tamarin tuors express at mium, EBNA 1, EBNA 2, EBNA LP and LMP-
as determed by imunohistochemistry and imunoblottg. Demonstration of EBNA 2 and
LMP-1 expression in these tuors is particularly signficant as it strengtens their resemblance
to posttranplant lymphomas in humans. Furthermore, since EBNA-2 and LMP-1 are known to
be required for EBV-induced B-cell growth transformation in vitro, their expression in these
lymphomas constitutes some of the best evidence for a direct oncogenic role for EBV in vivo.
Clinical Manifestations & Immunobiology of EBV Infection
The propagation of EBV in man is dependent up viral replication in the oropharynx
and spread of virs to uninfected persons via contact with virs contaminated saliva (Gerber et
aI., 1972). In developing countries, primary infection with EBV tyically occurs during the first
several years of lie, and is often sub-clincal. By contrast, in the western world where primary
infection with EBV is often delayed until the seond decade, up to 50% of infections result in a
self-limted constellation of signs and symptoms consistent with acute inectious mononucleosis,
including fever, sore throat, lymphadenopathy, malaise, headache, atypical lymphocytosis
and splenomegaly (Henle and Henle, 1979). During the early stages of primary infection, large
numbers of EBV inected B cell can be found in both peripheral blood and tissue, with as many
as 10% of peripheral B cells being infected (Miler, 1990). Primary inection involves lytic
replication in epithelial cells and latent infection of B cells which stimulate a profound
cellular imune response, first by natural kiler (NK) cells and closely followed by EBV-
specific cytotoxic T cells and imunoglobuli secreting B lymphocytes (Tosato and Blaese, 1985)
(Tomkison et aI., 1987) (Tomkison et al., 1989) (Moss et aI., 1992).
A hallark of primary EBV infection is the appearance of "atypical lymphocytes" in
the peripheral blood, which account for 60-70% of the total white cell counts averagig 12 000-
000/mm . The atyical lymphocytes are primarily activated T lymphocytes and NK cells,
which secrete large amounts of inflamatory cytokies, believed to be the principle mediators
of clical symptoms during acute inectious mononucleosis (Niedobitek et aI., 1992). A result of
this intense imune respons to the vir is a marked reduction in the num of latently
infected B cells in the peripheral blood, which drop to around 1 in 105-6 B cells durg the
subseuent month and remai at such levels indefinitely (Tosato and Blaese, 1985). This
miute fraction of latently infected B cells serves as a reservoir for viral persistence or
reactivation, and when grwn in-vitro, these latently infected B cells can be propagated as B
lymphoblastoid cell lines (BLCL). One pre-requisite to the efficient in-vitro expanion of
latently infected B cells into BLCLs is the removal of EBV -specific CD8+ cytotoxic- T -cells or
their inibition by cyclosporin A (Bejarano et aI., 1985). The virus-specific cellular imune
response is long-lived in that EBV-specific CTL persist in the peripheral blood for life, likely
a result of contiued re-stimulation by EBV-antigen-bearing B-cells. These EBV-specific CTL
bear unique receptors which recognze virus derived peptides in the context of self :MC c1ass-
molecules (Zinkernagel and Doherty, 1980). Prior to recogntion by virus-specific CTL
endogenously synthesized viral proteins are first processed by cellular proteases to yield
peptide fragments which bind self :MC class I molecues in the endoplasmic reticulum.
Subsequently, the peptide-MHC complex is transported to the cell surface for presentation 
virs specific T cells. In the process of lysing EBV infected B cells, non-specific CTL binding to
target cells is initiated by the interaction of cell surface adhesion molecues, including LFA-
and ICAM-1 (Rodrigues et aI., 1992) (Ybarrondo et aI., 1994) (Teunsen et aI., 1994) which are
upreguated by LMP-l. Additional contrbutions to effector-target cell binding oc between
the CD8 molecule on T cells and MHC class-I molecules on target cell.
ogy. Inormation on the geographic distribution of EBV and incidence of 1M
in different environmental and sociologic conditions has evolved though sero-epidemiologic
studies of EBV antibody. EBV is a widely dissemiated, relatively labile herpesvirus which
is spread by intiate contact between susceptible persons and asymptomatic EBV shedders. For
now known reasons, the majority of primary EBV infections thoughout the world are
subclinical and inapparent. Inectious mff is an easily recogned adult illness in societies
with advanced hygiene standards, whereas the disease is a rarity in crowded, developing
regions with lower standards of hygiene. For example, by 18 month of age, 82% of children in
Ghana and Accra have experienced primary EBV inection as determined by EBV serology
(Biggar et aI., 1978). Many ascribe this fiding to the intense personal contact and primitive
personal hygiene as providing the opportuty for early acquisition and spread of EBV.
Antibodies to EBV have been demonstrated in all population groups and worldwide, about 90-
95% of adults are EBV-seropositive. The two strains of EBV (type-1 and 2), which differ in
genomic seuence and abilty to tranform human B lymphocytes (Bornam et aI., 1980)
(Dambaugh et aI., 1980) (Sample et aI., 1990) are widely distributed geographically, while
type-1 EBV is ten times more prevalent than type-2 in western countries, the ratio of type-1 to
1 '
type-2 EBV in African countres is only 2:1, and some individuals are co-infected with both
types.
The incidence of clinically apparent infectious mononucleosis (1M) is greatest when
primary exposure to EBV is delayed until the seond decade of life. In the United States and
Great Britian EBV seroconversion oc before age 5 in about 50% of the population, with a
seond wave occug in the middle of the seond decade. The overall incidence of 1M in the
u.s. is about 50 cases/105/yr, with the 15-24 year old age grup having the highest incidence
(Evans, 1969). No obvious yearly cycles or seasonal changes in incidence are known, as 
with influenza.
Low titers of virs are present in throat washings of patients with 1M and persist in the
oropharyx for up to 18 month after clinical recovery. Interestigly, only 6% of 1M patients
recall previous contact with others having 1M. Likewise, the abilty to recover vir from
throat washigs is, not surprisingly; related to degree of imune compromie, with higher
titers being present in more critically il patients.
Fre uenc of EBV in throat ashi s in relation to de ee of imune com romie
Patient P ulati Fre uenc of EBV sheddin
EBV seronegative individuals
Healthy EBV seropositive adults
Solid tumor patients
HIV-1 infected individuals
12-25%
27%
50%
Renal transplant patients
Inectious mononucleosis patients
Leukemia or lymphoma patients
56-70%
50-100%
74-92%
With regard to the impact of EBV m public health, in one study (Evans, 1960)
infectious mononucleosis accounted for 5% of all student hospitalizations at the University of
Wisconsin, with an incidence of 450 cases/UP students/year. Across the countr approximately
12-15% of susceptible college students undero EBV seroconversion yearly (Evans et aI., 1968),
with hospital admision rates as high as 1449 cases/UP patients/year reported for Priceton
University. Similar rates oc in the ared forces, and inectious mono ran fourth as the
cause of days lost to iless among ary personnel.
Diagnosis. Distinction from other com viral infections depends m the complete
triad of clinical, hematologic, and serologic determinations. In addition to the classic
symptoms of fever, cervical lymphadenopathy, and pharyngitis, certai laboratory findings
are necessar to conf the diagnosis of 1M. While heterophile antibodies and atypical
lymphoctosis are present in 70-95% of new 1M cases, EBV -specific antibodies can be
demonstrated in virtually 100% of new cases (Lai, 1977). The IgM heterophile antibodies are
present only during the initial stages of infection, in contrast to the IgG antibody against EBV
structural proteins, which persist for the life of an individual (Henle and Henle, 1981).
Serologic Diagnosis of Epstein-Barr Virus Infection
Clinical Heterophile Anti-VCA Anti- VCA Anti-EA- Anti-EBNA
Dial7osis Antibodv
No EBV
Exposure
Acute EBV
Infection
Previous
+/-
Infection
Histo athologic Chan es. Primary EBV inection in adults typically causs a self-
limited, usually begn illness characterized by sore throat, fever and lymphadenopathy
lastig 2-3 weeks. During the acute phase, lymph nodes thoughout the body are enlarged and
contai increased numbers of large, moderately active lymphoid follcles. Germal centers are
also enlarged with increased numbers of blast cells, lymphocytes and histiocytes.
Splenomegaly occurs in about one half of 1M cases and autopsy studies have revealed
that the organ is usually 2-3 times its normal weight. Histologically, the splenic capsule and
trabeculae are edematous appearing and filed with lymphoid cells.
Not surprisingly, biopsies have demonstrated intense lymphocytetonsilar
proliferation with numerus mitoses. Additionally, boe marow biopsies are usually not
strikigly abnormal and hepatic histology is typically only mildly changed.
Acute Infectious Mononucleosis
linic l Manifestations. Primary infection with EBV induces a self-limited ilness
lasting 2-3 weeks, which may present with a relatively broad spectrum of symptoms, several of
which are almost always present with inectious mononucleosis (Schooley, 1995). The classical
symptoms consists of pharyngitis, fever, and cervical lymphadenopathy (Hoagland, 1960).
Onet may be abrupt, but more often is preceeded by several days of prodromal symptoms,
including anorexia, chils, sweats, headaches, myalgias, malaise and abdominal fullness. The
most frequent complait is sore thoat, usually described as very severe.
Fre of Symptoms socia Acute Inectious Mononucleosis
tom % Patients ith tom Ran
Sore throat 70-
Malaise 43-
Headache 37-
Anorexia 10-
Myalgias 12-
Chils
Nausea
Abdomial Pain
Cough
Emesis
Arthralgias
Adapted from Schooley, R. , (1995) Harrisons Principles of Internal Medicine.
The clinical manifestations of primary EBV inection are closely correlated with
patient's age. While EBV infection in infants and children is often asymptomatic , adolescents
and adults frequently experience symptoms of 1M.
Some of the more common sign of acute 1M are listed in the table below. Fevers to 38-
390C oc in over 90% of patients and typically resolve within 10-14 days. The tonsils are
usually enlarged and the pharynx is erythematous with an exudate present in about 1/3 of
cases. Symmetric, mildly-tender posterior cervical adenopathy is present in 80-90% of patients
and splenomegaly can be appreciated in about 1/2 of patients if carefully sought.
Fre enc of Si s Associated with Ac te Inectiou Mononucleosis
% Patien s with Ran
Lymphadenopathy
Pharyngitis
Fever
93-100
69-
63-100
50-Splenomegaly
Adapted from Schooley, R.T., (1995) Harrisons Principles of Internal Medicine.
ral Imune ponse t EBV Infe n. Primary EBV inection induces circulating
antibodies directed againt viral antigens as well as unelated antigens found m sheep and
horse red cells. The latter antibodies, naed heterophile antibodies, are a heterogeneous
group of mostly IgM antibodies with either Forssman or Paul-Bruell specificity, which do not
cross-react with EBV antigens (Paul and Bunell, 1932) (Paul and Bunell, 1982). Serologically,
the EBV-specific response represents a crucial component in the differentiation of primary EBV
inection from other diseases presentig with lymphocytosis, fever, lymphadenopathy, and
malaise. Diagnosis of EBV infection is based up the transient se levels of IgM against
viral capsid antigens (VCA), as well as IgG against viral capsid antigens, early antigens (EA)
and EBNA protein (Henle et aI., 1974) (Henle and Henle, 1981) (Okano et aI., 1988). The
transient IgM respons to VCA reaches high titers early and disappears within weeks. IgM
VCA antibodies are not demonstrable in the general population, and thus their presence is
virtually diagnostic of acute EBV infection. IgG antibody titers to VCA reach peak levels two
weeks later and thereafter persist at lower levels thoughout life. Interestingly, IgG directed
against early lytic cycle proteins (EA-D) tends to appear with the peak IgM response, and
reaches maxial levels after the IgM respone, significantly before the appearance of IgG to the
structural proteins. Lastly, signficant IgG anti-EBNA titers usualy do not develop until well
after primary infection. The following diagram depicts the onset and tie cour of peak anti-
EBV Ig titers in relation to the correspondig clinical presentation durg primary EBV
infection.
Antibody Responses to EBV Anti ens Durine Acute Infectious Mononucleosis.
Heterophile
Antibody
Ti ter
2560
640
0'" anti-EA
0'"
VCA 160an 1-J:gM 
640
anti-VCA 160
J:gG
0'" anti-EBNA
160
160
160 Onset of
symtoms
J:ncuba t ion monthsAcute J:M Convalescence
Later Life
l1 Densely hatched areas represent ranges of antibody measured in normal hosts.
EZ Finely hatched areas represent ranges of antibody measured in immunocompromised hosts.(Adapted from Henle, W: Human Pathology 5: 551-565, 1974)
Gp350/220 is the most abundant viral protein in lytically infected cell plasma
membranes and accordingly, most of the human EBV neutralizing IgG antibody response is
directed against gp350/220 (Thorley-Lawson and Poodry, 1982) (North et aI., 1982). These
neutralizing antibodies reach maximal levels 6-7 weeks after the onst of illness and stable
titers persist for life. Gp350-specific antibodies also mediate complement fixation and
antibody-dependent cellular cytotoxicity (Khyatti et aI., 1991). Fortuitously, the gp350
molecule is highly conserved between EBV strains 1 and 2 (Lees et aI., 1993), and thus
gp350/220 is considered to be an esssential component of any prospective EBV vaccine. In fact,
imunzation with purified gp350/220 or inection with vaccina expressing 
gp350/220 protects
cottontop tamarins against a lethal
, lymphomagenic EBV challenge (Morgan et a!., 1988)
(Morgan et al. , 1988).
Indu tion of EBV-Specif CTL. The atypical lymphocytes which appear in the
peripheral blood of acute 1M patients between 1-3 weeks after onset of symptoms are primarily
activated (HLA-DR+) CD8+ T-cells and also include CD16+ NK cells (Giuliano 
et a!., 1974)
(Johnen et a!., 1978) (Haynes et a!.
, 1979) (Tomkon et a!.
, 1987). In 1975, several grups
independently showed that when the high NK 
activity present in acute 1M peripheral blood
was removed from in-vitro T cell suspenions
, there remained in-vivo activated T cells which
specifically lyse EBV infected B cells independent of HLA restriction (Royston et a!.
, 1975)
(Svedmyr and Jondal
, 1975). Importantly, the development of CD8+ T cell-mediated imunty
agaist latently infected lymphocytes correlates closely with the 
declie of EBV-infected B
cells from 1 in 10 durg acute 1M to 1 in 105 106 durg convalescence (Thorley-Lawson et aI.
1977) (Robinon et al.
, 1980) (Tosato and Blaese
, 1985) (Miyashita et a!.
, 1995). Ths latter
finding is strengtened by 
in-vitro studies showing that EBV imune individuals posses virus-
specific T cells which prevent the 
in-vitro outgrowth of EBV tranormed BLCLs (Rickison et
a!., 1977) (Rickison et a!.
, 1979) (Rickion et a!.
, 1980). Initial efforts to demonstrate HLA
class-I restriction of the EBV-specific T cells were hampered by the lack 
of a homogeneous
population of effector cells us in 51Cr release assays (Lipinsky et a!.
, 1979) (Seeley et aI.
1981). Subsequently, EBV-specific T cell 
lies and clones were generated in-vitro by stimulation
with autologous BLCLs in the presence of rIL-
, which lysed only EBV genome carrying cells in
a HLA class-I-restricted maner (Sugamura and Hinuma
, 1980) (Misko et a!.
, 1980) (Rickison
et a!. , 1980) (Moss et a!.
, 1981) (Rickison et a!. , 1981) (Wallace et a!., 1982). The succe of
expanding EBV-specific
, HLA class-I restricted T cells in-vitro is heavily dependent 
repeated, selective stimulation of memory CT at an appropriate responder to stimulator cell
ratio of 40:1 (Wallace et aI., 1982) (Allen et aI., 1982). Similarly, the in-vivo activated, non-
HLA-restricted T cells originally described to be present durg acute 1M were subsequently
shown to contain both EBV-specific, MHC class-I restricted CTL and a large non-HLA restricted
population referred to as alloreactive CTL (Strang and Rickion, 1987) (Strang and Rickison
1987) (Tomkon et aI., 1989). Limiting dilution assays and regression plots have since
estiated the precursor frequency of EBV-specific, memory cytotoxic-T-cells in the peripheral
blood to be unusualy high, at around 1/550 to 1/25 000 PBMC during convalescence (Rickion et
aI., 1981) (Bourgault et aI., 1991) (Carmichael et aI., 1993).
Monoclonal antibody blockig studies have since confed the HLA-restricted nature
of target cell lysis by EBV-specific CTL (Wallace et aI., 1981). Specifically, antibodies
directed against various :MC class-I alleles (W6/32, BB7. 7) or 2-microglobul (BBM1) 
target cells block 75-85% of the CTL mediated lysis, while antibodies directed agaist coon
leukocyte antigens (HLe1, AC2) or HLA-DRw (TDR31.1) have 11 such effect. Additionally,
antibody directed agaist CD8 (Leu 2a) on the EBV-specific effector CTL blocks the majority of
target cell lysis (Wallace et aI., 1982), while anti-CD4 antibody (Lu 3a) has 11 such effect.
CTL mediated lyis of EBV-infected target cells can also be largely abrogated by antibody
directed against the CD3 component of the T cell receptor (Tsoukas et aI., 1982). Convincing
evidence supportg the strict EBV antigen-specificity and HLA-restriction of EBV -specific
CD8+ CTL comes from work demonstratig that only EBV-containing, HLA-compatible cells
can serve as "cold target competitors" to inibit lysis of 51Cr-Iabeled autologous BLCLs
(Tanaka et aI., 1982). Interestingly, this same type of experimentation has led to the
description of HLA-type-specific recogntion (Gaston et aI., 1983), whereby serologically
indistinguishable HLA-A2 antigens encode differentially recogned T cell-restricting
elements. Surprisingly, the serologically distinct HLA antigens HLA-A2 and HLA-Bw57 are
capable of serving as cross-reacting restriction elements to a single CTL clone.
In contrast to the well characterized fuction of CD8+ CTL in eliminating EBV infected
cells, a similar role for CD4+ T cell-mediated lysis of EBV-infected B cells durg acute
infectious mononucleosis has not been established (Enssle and Fleischer, 1990).
The activated NK cells observed in the peripheral blood of acute 1M patients are also
seen with other viral infections and were first described in 1967 (Holm, 1967). NK cells are
considered to playa primary role in the imune surveilance against virally or neoplastically
modified cells, as they requie 11 in-vitro stimulation or previous antigen exposure.
Additionally, the cytotoxic activity of NK cells is known to be both spontaeous and IFN
inducible (Landazuri et aI., 1981). Interestingly, NK cells alone are not sufficient to counteract
the establishment of EBV-transformed B cell lines in-vitro, however, they do contrbute to
improved BLCL regression in the presence of EBV-specific CTL (Masucci et aI., 1983). This
effect by NK cells may be due to either direct cytotoxicity or IFN production, as EBV and EBV-
infected cells induce y-IFN production by NK cells (Andersson et al., 1984), and a-IFN is known
to inibit EBV-induced B-cell proliferation in-vitro (Thorley-Lawson, 1981).
A concise sumary of the major early advances in the study of host imune responss to
EBV has be published (Sullvan, 1983), and provided the foundation for formulatig the
following integrated concept of human imunity to EBV.
Immune Response to EBV Infection
Adapted from Sullivan J.L (1983) In: Human Immunity to Viruses
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More recently, efforts to identify the EBV-encoded CT epitopes have be hampered
by a lack of appropriate target cells in which to screen individual EBV latent genes. The same
is not tre for the study of other human viruses, as the majority of cuent research aimed at
identifying T-cell epitopes encoded by virses which inect human contiues to rely m EBV
tranformed BLCLs as a source of autologous target cell. The expression of EBV latent proteins
in these cells preclude their use as targets in studies aimg to identify EBV CTL epitopes, the
single exception being their us in studies characterizing EBV -type-specific T-cell epitopes
(Moss et aI., 1988) (Murray et aI., 1990). A major advance in ou abilty to bypass this long-
standing hurdle came with the development of EBV negative target cells consistig of
autologous human B cell blasts activated by ligation of cell surface IgM in the presence of IL-
and IL-4 (Khana et aI., 1991). The constrction of vaccinia vi recombinants encodg single
EBV latent genes, us in conjuncton with B cell blast targets, has allowed a relatively
detailed analysis of EBV target antigens recogned by EBV-specific memory CTL (Khana et
aI. , 1992) (Murray et aI., 1992) (Masucci et aI., 1993). Results indicate that memory CT from
most EBV imune individuals recognze several of the eight known EBV latent proteins, with
individual differences being largely accounted for by variation in each persons genetic makeup
of HLA class-I alleles. Worthy of mention is the repeated absence of EBNA-1-specific memory
CTL in published studies. A more detailed description of identifed EBV CT epitopes is
included herein under the heading of "latent protein recognzed by CD8+ CTL"
ptosis of EBV - ecific CTL in Acute 1M. The in-vitro expanion of previously in-
vivo activated EBV-specific HLA-restricted CTL directly from the blood of inectious mmo
patients was first described in 1987 (Strang and Rickison, 1987). These in-vivo activated CTL
display several unusual features which differ significantly from the more familiar in-vitro
activated memory CTL. Most significant is the need for imediate addition of IL-2 to the
media used to expand in-vivo activated CTL. Unlike the procedure of stimulating memory CTL
in-vitro, witholding IL-2 durg initiation of an in-vivo stimulated cutue results in
apoptosis of the entire cultu within 48 hours. Ths fiding is in marked contrast to the in-
vitro expanion of memory CTL, in which the early addition of IL-2 to the growth media results
in the expanion of a population of cells which display non-specific anomalous T-cell
cytotoxicity (Wallace et aI., 1982). Several more recent studies have demonstrated that
addition of exogenous IL-2 to growth media prevents the in-vitro apoptosis of primed CD45RO+
T cells from acute infectious mononucleosis patients (Uehara et aI., 1992) (Akbar et aI., 1993).
These same activated, CD45RO+ T cell destied for apoptotic death can be identified using a
mA (IMN3.1) which recognes a molecule intensely expressed m acute 1M T cells, and only
dimly expressed on CD45RO+ memory T cells from normal individuals (Uehara et aI., 1993). In
keeping with the fuction of the proto-oncogene bcl- in blockig apoptosis (Korsmeyer, 1992),
the absence of bcl- expression in activated CD45RO+ T cells from acute 1M patients support
their increased susceptibilty to programed cell death (Tamar et aI., 1993). This latter
finding also contrasts with the CD45RO+ memory T cells and naive CD45RA + T cells from
normal individuals which express much higher levels of bcl- The significance of this
activation-driven depletion of mature T cells may partially explain our observed differences in
priar vs memory T cell responses (described in the results section). One grp has suggested
that the low bcl-2 levels found in activated CD45RO+ T cells can be reconciled with studies
demonstratig that T cell memory responses in-vivo are dependent m restimulation with the
origial priming antigen (Gray and Matzinger, 1991), which increases bcl- expression (Akbar
et aI., 1993). Thus, the familar activation driven transition of naive CD45RA + cells into
activated CD45RO+ T cell (Clement, 1992), is accompaned by reduced bcl- expression
necessitating contiued antigen stimulation for survival.
Lymphoproliferative Diseases
The principle biologic fuction of EBV that accounts for its role in the pathogenesis of
lymphoproliferative diseases lies in the abilty of the vir to induce unliited proliferation
of B lymphocytes, otherwise known as imortalzation. Specific cell tyes susceptible to this
EBV induced transformation include mainly well-differentiated, IgM+, resting B-Iymphocytes
which have undergone VDJ rearrangement and heavy-chain class switchig (Brown et aI.,
1985). The efficiency of the imortalization process by EBV is quite high, and the percentage
of cells susceptible to transformation has bee estimated at 10% of all B cells (Sugden and
Mark, 1977) (Tosato, 1991).
The imortalzation process consists of two major phases, the first being initial B-cell
activation, which is triggered by attachment of the virs to the cell surface. The cell is
activated to leave the GO phase and enter the G1 phase, and is accompaned by expression of
activation molecues such as Blast-2 (CD23) (Thorley-Lawson and Man, 1985) (Thorley-
Lawson et aI., 1985). The seond phase of immortalization consists of the establishment of a
state of permanent blastogenesis requiring the expression of EBV gene products.
The importance of understandig the imune mechanms responsible for the control of
EBV induced B cell proliferation in ma is undersore by an ever growig list of EBV-
associated lymphoproliferative syndromes.
linked l lif rative s drom . The initial description of this syndrome
came from studies involving three familes in which an X-linked imunodeficiency to EBV
resulted in fatal inectious mononucleosis in young male family mem (Bar et aI., 1974)
(Provisor et aI., 1975) (Purtilo et aI., 1975). Most cases occur at around 2-5 years of age, and the
common clical course is that of an acutely fulminant process which initially resembles acute
1M (Okano et aI., 1991). The genetic mutation in the XLP syndrome has now be mapped, to
the Xq25 region of the X chomosome (Skare et aI., 1987). The genetic defect associated with
XLP remai unown but may be related to regulation of the intense CD8 T cell cytotoxicity
initiated by acute EBV infection. Prior to EBV infection, males with the XLP mutation have
normal cellular and humoral imune responss to bacterial and viral infections, with the
exception of EBV. Dug primary EBV infection approximately 75% of affected males die
with a fatal inectious mononucleosis syndrome, usualy secondary to extensive liver destruction
(Hamilton et al., 1980) (Sullvan and Woda, 1989). At autopsy, about 15% of individuals with
fatal 1M demonstrate a lymphoproliferative disorder described as imunoblastic sarcoma of B
cells, Burkitt' s lymphoma and other non-Hodgki B cell lymphomas. In the 30% of affected
males who survive primary EBV inection, all develop coon variable imunodeficiency,
characterized by recurrent infections, hypogamaglobuliemia, and 20-40% of these surviving
males develop lymphoproliferative disorders, includig lymphoma (Sullvan et aI., 1980)
(Sullvan et aI., 1983).
Prima Imunodeficiency seas . Shortly after the discovery of XLP, Epstein-Barr
virs was recogned as a potential caus of severe infections and lymphoproliferative
disorders in imunodeficient individuals. The medical literature is now replete with reports
of fatal EBV-containing lymphomas developing in individuals with severe combined
imunodeficiency following thymus transplants (Reece et aI., 1980) (Hanto et aI., 1981)
(Crawford et aI., 1980) (Crawford et aI., 1981), and boe marow transplants (Shearer et aI.
1985).
Burki s L ma. Burkitt's lymphoma is the most co childhood malignancy
in equatorial Africa, and was first described in 1958 by the British sugeo Deni Burkitt
(Burkitt, 1958). This unistakable tuor typically presents in the jaws of young patients, and
the majority of endemic cases oc in discrete geographic climates located along a belt across
Africa lying 100 north and south of the equator (Burkitt, 1962). Since the initial description of
the climatic distribution of this tuor, a biological vector was implicated in its etiology.
Fortuitously, a pathologist, M.A. Epstein attended a lecture given by Dr. Burkitt in 1961, in
which he described th bizarre cancer. With tuor biopsies provided by Dr. Burkitt, Epstein
set about the task of searching for a vir to explain the etiology of this lymphoma. Three
years later, Epstein and colleagues described a new herpesvirus present in most Burkitt
lymphomas, now known as Epstein-Barr virs (Epstein et aI., 1964).
Burkitt lymphoma is characterized by specific, reciprocal chomosomal translocations
involving the c-myc locus on the long ar of chomosome 8 and one of the imunoglobul loci on
chomosome 14, 2 or 22 (Bornam et al., 1988). The juxtaposition of c-myc next to a heavy- or
light-chain imunoglobul promoter is a necessar although not sufficient step in the
development of BL. Additional factors are likely provided by EBV, as there is alost 
unversal association of EBV with the endemic form of Burkitt' s lymphoma, thus lending much
support to the tuorigenc potential of this virs (deThe et aI., 1978). The abilty of EBV to
growth-transform human B cells (Pope et aI., 1968), along with the potential to induce
malignant lymphomas in new world monkeys (Shope et aI., 1973) make EBV a strong candidate
for contributig the remaig transforming factors in the multistep process of BL development.
In fact, EBV infection preceeds development of endemic BL as clonal EBV genomes exists in a 
tuor cells, implicatig EBV's role in malignant conversion. While evidence for an etiologic
role of EBV in BL is convincing, it is not yet conclusive (Epstein, 1978) (Henle et aI., 1978).
Greater than 95% of endemic BL tuor cell contai copies of the EBV genome (Ziegler
1981) (Miler, 1990), while only 15-20% of sporadic (outside high incidence areas) cases of 
contai EBV genomes (Burkitt, 1967). Recent findings suggest this latter figure may be as high
as 45% (Razzouk et aI., 1996). Analysis of the EBV geome terminal repeat frequency in
endemic Burkitt lymphomas has shown that the tuors originate in the lineage of a single
EBV-inected B cell (Raab-Traub and Flyn, 1986) (Brown et aI. , 1988) (Neri et al., 1991).
Initial attempts to defie the cell surface phenotype of BL tuors were hampered by
the inconsistent characteristics of in-vitro grown BL cells (Favrot et aI., 1986). Subsequent work
demonstrated that fresh tuor biopsies consistently displayed a homogeneous surface
phenotype including the pan B cell marker CD20, the coon acute lymphoblastic leukemia
antigen (CALLA, CDlO), and the BL-associated antigen (CD77) (Rooney et aI., 1986).
Additionally, unike in-vitro grwn BLCLs, fresh BL biopsy cell do not express the B cell
activation antigens CD23, CD30, CD39, and CD70 and the cell adhesion molecules LFA-
(CDlla/18), ICAM-1 (CD54), and LFA-3 (CD58) (Gregory et aI., 1988). The fresh BL tuor
biopsies which retain this restig B cell phenotype (latency type-I) also differ from BLCLs
(latency type-II) in the expression of EBV latent genes (Rowe et aI., 1986) (Rowe et aI., 1987).
While in-vitro propagated BLCLs typically express six EBNA proteins and two latent
membrane protein, newly explanted BL cells typically express only EBNA-1 (Gregory et aI.
1990) (Sample et aI., 1991). This tightly restricted EBV latent gene expresion in BL cells, is
liely the result of inactivity of the Wp and Cp promoters in BL cells Gansson et aI., 1992), and
the us of a newly described EBNA-1 specific promter (Fp/Qp) located in the BamHI-F/Q
fragment of the genome (Sample et aI., 1991) (Schaefer et aI., 1991). Interestingly, the serial
passage of endemic BL cell lies (type-I) in-vitro results in the transition to a more BLCL-like
phenotype (type-II), associated with the full spectr of EBV latent gene expression
resemblig BLCLs (Rowe et aI., 1987) (Gregory et aI., 1990). BLCLs and BL cells grwn in-vitro
can also be induced to switch from one form of latency to another depending up culture
conditions. The limited expression of EBV latent genes in BL cells, along with reduced
expression of MHC class-I antigens (Masucci et aI., 1987) and lack of adhesion molecules likely
contibutes significantly to the abilty of these cells to escape T cell-mediated destrction
(Rooney et aI., 1985).
Recently, a fourth form of EBV latency be described in tuor cells of smooth muse
origi (leimyosarcomas) occug in young people with AIDS and organ transplant recipients
(McClain et aI., 1995) (Lee et aI., 1995). This new form of EBV latency (type-IV) is
characterized by EBV latent gene expression restricted to EBNA1 and 2, suggestig that
imunosuppression plays a major role in the pathogenesis of these tuors which express the
imunogenic EBNA2 protein. The following diagram demonstrates the more restricted form of
EBV latency (type-I & II) observed in (top), as compared to the less restricted form of
latency (type-II) displayed by most EBV infected cells propogated in vit (bottom), in the
absence of imune reguation.
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Post-trans lant L roliferative Disease. Virus-specific CTL are unable to
eliminate EBV from the body, yet they are essential in preventig EBV-mediated B-
lymphoproliferation. A variety of imunocompromid states are associated with increased
num of EBV-infected B cells in the peripheral blood, which can progress to polyclonal
masses or even monoclonal lymphomas. The incidence of posttransplant EBV lymphomas rises
sharply with the degree of imunosuppression, and are encountered all too often in persons
with secondar imunodeficiency such as that due to chonic imunosuppresion to prevent
allograft rejection (Hanto et aI., 1985). Phenotypically, most post-transplant lymphomas are
polyclonal, imunoblastic and often resemble the type-II latency described for BLCLs, and
accordingly, express all or most EBV latent genes, B cell activation markers, and cell surface
adhesion molecules. EBV-induced lymphoproliferation has bee described
imunocompromi renal (Crawford et aI., 1980), cardiac (Bieber et aI., 1984), and liver
allograft recipients (Starzl et aI., 1980), and recipients of boe marow (Sullvan et aI., 1978)
and thymic epithelium transplants (Reece et aI., 1980). In recipients of bone marow
transplants, EBV-associated lymphomas are generally confined to recipients of T-cell-depleted
allografts. Fortuately, these EBV+ donor-derived imunoblastic lymphomas have recently
be shown to regress when recipients are treated with leukocytes derived from the original
marrow donors (Papadopoulos et aI., 1994) (Rooney et aI., 1995) (Heslop et al., 1996).
Approximately 6% of individuals receiving renal allografts develop de novo
malignancy (Pen, 1978) (Hanto et aI., 1981). It is now recogned that renal allograft
recipients receiving cyclosporin- imunosuppressive therapy are at increased risk for
developing malignant lymphoma, likely a result of cyclosporin-mediated inibition of long-
term T cell memory to EBV (Crawford et aI. , 1980). Support for this hypothesis comes from
studies demonstratig the abilty of cyclosporin-A to promote the outgrowth of EBV-
transformed B cell lines in-vitro (Bird et aI., 1981) (Rickison et aI., 1984). Stil more
convicig is the observation that post-transplant lymphomas frequently regress 
discontiuation or reduction of imunosuppressive therapy, often without subsequent graft
rejection (Starzl et aI. 1980). The development of lymphomas in imunosuppressd
individuals also extends to the use of imunosuppresive therapy in the treatment of rheumatic
disorders. Several studies have reported an increased risk of large-cell lymphoma in patients
with rheumatic disease who were treated with azathioprine or cyclophosphamide (Kinlen
1985). Similarly, two patients developed EBV-associated malignant lymphomas durg
methotrexate treatment, and in each case the tuor regressed following the withdrawl of
methotrexate (Kamel et aI., 1993).
AID & N Hod ki' s L homa. In 1982, prior to the identification of HIV, four
cases of Burkitt' like lymphoma (undifferentiated, monoclonal B cell) were described in
homosexual men in San Francisco (Ziegler et al., 1982). The imunoblastic monoclonal, Burkitt-
lie phenotye of these tumors alowed for easy distinction from the EBV-induced polyclonal
imunoblastic lymphomas which oc in allograft recipients. Since 1982, EBV-induced
lymphoprolierative disorders and non-Hodgki' s lymphomas (NHL) have been shown to occur
approxiately 60-100 fold more frequently in the setting of imunodeficiency associated with
HIV infection (Beral et al., 1991) (Levine, 1992). In fact, a larger study conducted in Los Angeles
county from 1984-1992 showed that EBV was associated with 39 of 59 (66%) HIV-related
systemic lymphomas (Shibata et aI., 1993). Analysis of EBV terminal repeats in these
lymphomas again confed their monoclonal origi, and c-myc rearrangements were noted in
40%. Evaluation of EBV latent gene expression in the HIV-related lymphomas revealed a
unque pattern of expression, restricted to EBNA-1 and LMP- , not previously described in B
cells.
Given the profound imune defects in HIV -infected patients, along with the known
role of CTL in controllg EBV-induced proliferation, it is not surriing that the num 
EBV-infected B cells in the peripheral blood of those with AIDS is higher than the general
population (Birx et al., 1986).
Infection with HIV is also associated with a markedly increased risk for developing
non-Hodgki' s lymphoma, which increases stil further with longer survival and declining
CD4 counts (Beral et aI., 1991). AIDS associated NHL, usually of B cell origi, is a relatively
late manifestation of HIV infection (Levine, 1990), and is now considered an AIDS defining
condition (Ziegler et aI., 1988). However, une the monoclonal Burkitt's type lymphomas,
AIDS related NHL ranges from polyclonallymphoproliferation to monoclonal lymphoma, and
is not unormy EBV associated (McGrath et at, 1991). For tmown reasons, the majority of
EBV-associated NHL in AIDS patients have presented as primary CNS lymphomas
(Shiramizu et at, 1992).
Hod ki' s Disease. EBV genomic DNA was fist reported in Hodgki' s disease in 1987
(Weiss et at, 1987). Recent evidence supports a strong role for EBV in the pathogenesis of HD
where EBV geomes have be detected in tuor material in 19-50% of HD cases, and in situ
hybridization has localized the EBV DNA to the malignant Hodgki' Reed-Sternberg cells.
EBV appears to be more tightly lied to "Western" HD cases, where the genome is present in
up to 50% of cases (Pallesen et al., 1991). The reported presence of monoclonal EBV geomes in
HD suggests that EBV inection preceeds clonal cellular proliferation. Expression of the small
EBV-encoded RNAs, EBERl and EBER2, is a consistent finding of EBV associated HD, and
EBNA1 protein can be detected in 70% of these cases (Grasser et at, 1994). As with Burkitt'
lymphoma, the association of EBV with HD appears to vary geographically, as 94% of
classical HD occuring in Per contain EBV transcripts within the Reed-Sternberg cells (Chang
et at, 1993). Healthy western populations are infected with predominantly tye-1 EBV
(Sixbey et at, 1989), and not surprisingly, the majority of EBV detected in HD is type-
(Gledhil et al., 1991). In contrast, there is an almost equal frequency of type-1 and type-2 EBV
in HIV-associated NHL (Boyle et at, 1991) and endemic Burkitt' s lymphoma (Young et aI.
1987). The type of EBV latency in HD has been evaluated by PCR and in-situ hybridization of
EBV specific latent gene transcripts, and most resemble the type-II latency descibed in
nasopharyngeal carcinoma (Deacon et at, 1993) (Grasser et at 1994). In Hodgkin'
lymphomas, EBNA-1 is expressed from the BamHI Q promoter, as in NPC and BL, while
expression of other EBNAs is prevented by the silent BamHI Cp and Wp promoters. LMP-1 and
LM-2 transcripts are consistently detected in these EBV-positive Hodgki's lymphomas,
irrespective of the histologic subtype. However, cuent inormation suggests the link between
EBV and HD may apply to only certai histologic subtyes, as the frequent presence of EBV in
HD is usually associated with only the mixed cellularity and nodular sclerosing subtyes.
While the majority of EBV associated Hodgki' s disease tuors express several
imunogenc viral protein, cellular imunty against EBV is often impaired in this setting.
Curiously, both LM1 and LMP2 contai known CTL epitopes (Khana et aI., 1992) (Murray et
aI., 1992) and would be expected to facilitate imunologic control of HD tuors expressing
these protein. In one study, HLA class I-restricted EBV-specific CTL were demonstrated in 3
of 3 EBV- tuors, whereas cultus from 6 of 6 EBV+ tuors were either noncyotoxic or
displayed only LAK-type activity (Frisan et aI., 1995). In evaluating the EBV -specific
reactivities present in tuor biopsies, a high prevalence of CD4+ cell (CD4/CD8 3) was
detected in half of the EBV+ cases but only 1 of 5 EBV- HD cases. While general impairment of
EBV-specific CT responses is not a general feature of HD, these findings suggest that tuor
associated suppression of EBV-specific CTL responses may playa major role in the pathogenesis
of EBV+ HD tuors. One possible explanation for the impaired CTL activity in this setting
may be the result of HD tumor cell expressing viral antigens which deliver inibitory signals
and render EBV-specific T cells anergic. However, unike the phenotye of latency type 1 cells,
these Hodgki' s RS cells have many charactristics of professional antigen-presentig cells,
including high levels of the costimulatory molecule B7 (Harding et aI., 1992).
EBV A ociated T Cell L homas. EBV-associated T cell lymphoproliferative
disorders are now being recogned more frequently, including EBV-associated T-cell
lymphomas (Su et aI., 1991) (Chen et aI., 1993), and EBV-infection of both neoplastic and non-
neoplastic T-Iymphocytes in virus-associated haemophagocytic syndrome (Kawaguchi et aI.
1993). Analysis of EBV expression indicates that EBV-infected T-cell lymphomas represent
clonal expansions of single EBV-infected T cells with a pattern of gene expression distinct from
Burkitt' s lymphomas or posttransplant lymphomas but similar to EBV expression in
nasopharygeal carcinomas. Similarly, a monoclonal expanion of EBV-infected T-cells 
in EBV-associated haemophagocytic syndrome, and the EBV-infected T cells represent a range
from preneoplastic to overtly malignant proliferations.
Non-Lymphoid EBV Diseases
Naso eal ma. Worldwide, nasopharyngeal carcinoma is relatively
rare, however it is one of the most coon cancers in southern China with age-adjusted
incidence rates of up to 55 per 100,000 (Ho, 1978). However, une Burkitt's lymphoma, the
association of EBV with NPC is highly consistent in both low- and high-incidence areas
(Andersson et aI., 1977), in fact, EBV is present in every anaplastic nasopharyngeal carcinoma
cell.
A wealth of new evidence contiues to strengten the role of EBV as the primary
etiologic agent in the pathogenesis of nasophargeal carcinoma (Pathmanathan et aI., 1995).
The presece of a single clonal form of EBV in preinvasive lesions such as nasopharyngeal
dysplasia or carcinoma in situ, indicates that EBV-induced cellular proliferation precedes the
acquisition of invasiveness of these tumors. Nasopharyngeal carcinoma cells express a specific
subgroup of EBV latent protein, including EBNA-1 and two integral membrane proteins, LMP-
and LMP- , along with the BamI-A fragment of the EBV genome (Brooks et aI., 1992) (Bus on
et al., 1992). While EBNA-2 is essential for the transformation of lymphocytes, its absece in
preinvasive neoplasia and nasopharyngeal carcinoma indicates that EBNA-2 is not required
for altered epithelial cell growth (Young et aI., 1988). In light of the newly described
molecular lin between LMP-1 and cell growth (Mosialos et aI., 1995), the universal presence of
LMP-1 in NPC makes it a likely prerequisite to this multistep neoplastic transformation.
Briefly, LMP-1 is known to miick activated receptors by aggregating in the plasma membrane,
and allowing the cytoplasmic tail to interact with and activate TRAF3, a TNF-associated
factor involved in growth signalig. A compilation of the evidence supportg this theory is
summarized in a recent editorial (Kieff, 1995).
The signficance of identifying a lik between prer lesions and EBV inection is
undersored by realizing that cuent efforts to improve imunty to EBV-infected cells may
eventually be used to prevent the development of nasophargeal carcinoma.
Smooth M le Tumors Aids & Li er Trans lantation. In addition to malignant
lymphomas, children with AIDS experience an unusualy high incidence of smooth muse
tuors (leiomyomas and leiomyosarcomas) (Chadwick et aI., 1992). Ordinarily, the incidence
of leiomyomas in children is extremely low, however, the recent demonstration that EBV can
infect smooth-muscle cells in AIDS patients, may help explain how EBV contrbutes to the
pathogenesis of these leiomyomas (McClain et aI., 1995). Stil further convicig evidence for
an etiologic role of EBV in the development of neoplastic lesions is provided by the recent
description of smooth-muscle tuors contaig clonal EBV, developing in three children after
liver tranplantation (Lee et aI., 1995).
Oral Hair Leuk lakia. Another EBV-induced disease in adult AIDS patients is oral
hairy leukoplakia (OHL), an unusual wartlke disease of the lingual sqous epithelium.
Virus replication is evident only in the upper layers of of the epithelium, and is effectively
inibited by acycloguanosine. Interestingly, the OHL lesions appear to be relatively specific
for HIV -related imunodeficiency, as OHL is only rarely observed in patients with other
imunodeficiencies (Epstein et aI., 1991).
Patterns of EBV Gene Ex ression In Normal and Neo lastic Cells
Cell T In-vivo n-vitro Latenc EBV Gene Ex ression
Burkitt' s Lymphoma In vivo EBNA-
Burkitt' s Lymphoma In vitro III EBNA1 , 2, 3A, 3B, 3C, LP
LMP-
Lymphoblastoid In vitro III EBNA1, 2, 3A, 3B, 3C, LP
Cell Line LMP-
Peripheral Blood In vivo EBNA-
Cell
+/-
LM2
Nasopharyngeal In vivo EBNA- , LMP- , 2
Carcinoma
Hodgki' s Lymphoma In vivo EBNA- , LMP- , 2
AIDS- NHL
Post- Transplant In vivo III EBNA1 , 2, 3A, 3B, 3C, LP
Lymphoma LMP- , 2
Cell Lymphoma In vivo EBNA- , LMP- , 2
Leiomyosarcoma in vivo EBNA-
EBV -specific cytotoxic- T -cells
Phenotype of effector cells. The most likely route of primary EBV infection is via the
oropharyngeal epithelium, where vir can also infect susceptible B lymphocytes within the
pharyngeal lymphoid tisue (Sixbey et aI., 1984). Dug the initial 30-50 day incubation
period, EBV replication and dissemination oc throughout the lymphoreticular system and
are accompaned by attendant imune abberations. Early in the cour of illness, non-EBV-
specific cell-mediated imunty is depressed, as measured by cutaeous anergy and depressed
proliferative responses to antigens and mitogens (Mangi et al., 1974).
During the first few weeks of cliical illness, an impressive mononuclear lymphocytosis
is present which consists primarily of activated, cytotoxic- Iymphocytes (Rickison, 1986)
(Tosato and Blaese, 1985) (Tomkon et aI., 1987). Log after the clinical symptoms of
infectious mono subside, CD8+ virs-specific memory-T-cell remain in the peripheral blood of
EBV imune individuals and retain the abilty to suppress the outgrowth of autologous EBV-
transformed B-Iymphocytes (Svedmyr and Jondal, 1975) (Thorley-Lawson et aI., 1977) (Moss et
aI., 1978). Correspondig T cell preparations from EBV seronegative donors have no such
activity. Confirmation of the T cell identity of the EBV-imune lymphocytes comes from
studies demonstratig that PBMC from acute 1M donors, when depleted of NK activity by
erythocyte-Ab rosettig, preferentially lyse chromium-labeled autologous lymphoid cell lines
carrying the EBV genome (Royston et aI., 1975). Cytotoxic T cell recogntion of EBV-infected
cells is known to be:MC class-I restricted (Moss et aI., 1981), having been confirmed in blockig
studies involving mA to HLA determants (Wallace et aI., 1981). Surprisingly, while the
virus-specific T-Iymphocytes remain for the life of an individual (Rickison et aI., 1981), this
profound and stable imune response is stil insufficient to totally eliminate virs from the
body. In fact, EBV-induced lymphoproliferative disease is only rarely witnessed in the human
host, attestig to the powerful imune control over this potentially oncogenc viru, which at
the same time permits lie-long EBV persistence. The impressive biologic properties of EBV
underscore our need for a more thorough investigation of the target strctues recogned by the
cytotoxic T cells which mediate surveilance against EBV induced lymphoproliferative
disorders. In ths sense, infectious mono represents the ideal model system to study the balance
between EBV and the human host, which usually culminates in successfu control of the virus.
Unfortuately, there is no EBV vaccine available for use in humans.
Latent p teins recogned QY CD8+ memo:c CTL. The discovery of antigen-specific T
cells directed against a virus with the abilty to induce malignant B cell proliferations in 
prompted early efforts to identify the postulated lymphocyte detected membrane antigen
(LYDMA) target stucture expressed m EBV-transformed B lymphocytes (Moss et aI. , 1981). A
major advance in our abilty to study EBV imunity came from the discovery that EBV -specific
Iymphocytes can be expanded into cell lies or cloned in-vitro by direct stimulation with
autologous EBV-inected B lymphocytes and recombinant IL-2 (Svedmyr et aI., 1974) (Sugamura
and Hinuma, 1980) (Rickison et aI., 1981) (Wallace et aI., 1982) (Slovin et aI., 1983) (Bishop et
aI., 1985) (Moss et aI., 1992). The majority of EBV-specific cytotoxic- Iymphocytes are CD8+
and thus express T-cell-receptors (TCR) which recogne viral peptides in the context of self
:MC class- I molecules. Accordingly, in-vitro restimulated effector T cells have bee
extensively utied as imunologic probes to identify the EBV-encoded molecular components
of L YDMA.
Early efforts to identify L YDMA focd m the latent membrane protein LMP-
including one study in which a 10 amo acid peptide (residues 43-53) from LMP-1 was
demonstrated to specifically stimulate EBV-specific CTL (Thorley-Lawson and Israelson,
1987). In a subsequent study, a less well defied region of LMP-1 was determed to contai at
least one CT epitope (Murray et aI., 1988). In the latter case, target cells were derived by
expression of the individual EBV latent genes EBNA- , 2, LP and LMP-1 in the EBV negative
, Loukes. These investigators clearly demonstrated the :MC restriction of the CT as only
LMP expressing cells carrying the HLA-A2 or B4 class I alleles were recogned as targets in
chomium release assays. Additionally, a trcated version of LM-1 (Tr-LMP), mising the
amo terminal 128 amo acids, was not recogned in this same system, suggestig an amino
terminal location for this LMP-1 epitope.
At around the same time EBV -specific CTL were shown to be capable of precise
imunologic discrimation between target cells expressing EBNA proteins derived from either
type-lor 2 EBV strains (Moss et aI., 1988) (Miko et aI., 1991). Based up differential
recogntion of EBV-transformed B lymphocytes, the EBV latent protein EBNA- , 3A, 3B and
3C were shown to contai EBV type specific epitopes, which likely explain the reported EBV
type-specific T-cell responss (Rowe et aI., 1989). In order to more effectively identify the
latent proteins responsible for this T-cell-mediated type-specific-recognition, effector T cell
clones established by stiulation with autologous BLCLs were tested for their ability to lyse B
cell blasts infected with recombinant vaccinia constrcts expressing single EBV latent genes or
incubated with EBNA peptides. The EBV -specific CT clones recogned type-specific
epitopes with EBNA- , 3A and 3C, as well as type-common epitopes within EBNA-2, 3A, 3C
LP and LMP-1 (Khana et aI., 1991) (Khana et aI., 1992). The EBNA-3A and 3C proteins were
recogned most frequently (11/14 donors) by the CTL clones while 11 CTL epitopes were
localized within EBNA-l. Interestingly, the specificity of a large num of EBV-specific T
cell clones (68%) could not be identified, suggestig the nee to scee a more comprehensive
panel of EBV latent proteins for CTL epitopes. The imunodominance of the EBNA3 family of
latent protein described for these EBV-specific CTL clones has also be confed with
polyclonal EBV-specific T cell lines (Murray et aI., 1992). In this latter study, EBV-specific
CTL from 14/16 donors recogned target cells expressing EBNA-3C. It is worth pointig out
that both EBNA-3B and LMP-2 sensitized target cells to EBV-specific CTL-mediated lysis,
suggestig that all latent proteins except EBNA-1 serve as targets for CTL recogntion.
This same group had earlier examined the cytotoxic T cell responss in two other EBV
imune donors (Murray et aI., 1990). The EBV latent protein EBNA- , 3A, 3B and LP were
expressed in target cells under the control of the vaccinia virs p7.5 promoter, and two donor
CTL responses were mapped to epitopes in EBNA-2 and EBNA-3A. In retrospect, this work
established an important experimental approach that is now being extended to all of the EBV
latent proteins in an effort to identify the imunodomiant EBV epitopes recogned within
the general population.
One the first EBNA-encoded CTL epitopes identified was described by Burrows, who
tested 76 peptides derived from type-1 EBV latent proteins EBNA- , 3A, 3B and 3C for their
abilty to sensitize type-2 BLCLs to lysis by an EBV type-1-specific CTL clone (Burrows et aI.,
1990). One 25 amo acid peptide of the 76 tested, (residues 329-353) from EBNA-3A, was
recognd in the context of HLA-B8. In a similar series of experiments 58 peptides derived
from the EBV latent proteins EBNA- , 3A, 3B and 3C were tested for their abilty to sensitize
target cells to lysis by a panel of EBV -specific CTL clones. In this case, one tye-common
peptide derived from EBNA-3C was identified, which was recogned in the context of HLA-
BW44 (Burrows et aI., 1990).
EBV derived oligopeptides have also be us to induce secondar cytotoxic T cell
responss in-vitro (Schmidt et aI., 1991). Three peptides derived from EBV latent proteins
EBNA-2 (QLSDTPLIPL TlFVGENTGV), EBNA-3A (TET AQA WNAGFLRGRA YGIDLLRTE)
and EBNA-3C (EENLLDFVRFMGVMSSCNNP) sensitized PHA stimulated blasts to lysis by
EBV-specific CTL. The EBNA-2 epitope was recogned in the context of HLA- , while the
restriction elements for the other two pep tides were not determed.
In a series of peptide screg experiments conducted by Miko et.aI.
imunodomiant EBV -specific CTL epitope, represented by peptide 68 from the tye-1 virus,
was mapped to EBNA-3A and recogned in the context of HLA-B8. The authors further
demonstrated that peptide 68 was not expressed as a fuctional CTL epitope by type-1 LCLs
inected with the EBV B95-8 isolate. This finding points to a major weakness inerent in trying
to identify CT epitopes by screeg panels of virs encoded peptides synthesized in vitro
Although capable of being recognized by CTL clones, these peptides do not necessarily represent
the naturally processed, biologically relevant pep tides presented in vivo (Misko et aI., 1991).
Such peptide based vaccine strategies, while capable of inducing an imune response, would not
necessarily be imunologically relevant and would serve 11 actual protective fuction against
the pathogen.
Perhaps the most signficant changes in our understanding of cell-mediated imunity to
EBV comes from the work described in this thesis and that recently presented by other groups.
Ou previously described results (Beaulieu and Sullvan, 1994), now expanded to include the
evaluation of 35 acute 1M patients demonstrate that while the virus-specific primary CTL
response is broadly directed against the full spectrm of latent proteins, includig EBNA1, the
memory CTL response, which essentially lacks EBNA1 reactivity, is directed primarily
agaist the EBNA 3 proteins (3A, 3B, 3C). CT from 7 of the 35 acute 1M patients evaluated
recogned EBNA1 expressing targets, and in 4 of these 7 patients, EBNA1 was an
imunodomiant antigen. The detection of only one EBNA1-specific memory CT response
among the 32 patients tested may help explain how latently infected B cells in-vivo,
expressing only EBNA1, escape CTL recogntion and thus might serve as a reservoir for viral
persistence and/or reactivation. Interestingly, since ou initial description of EBNA-1 specific
CTL, another grup has subsequently described a CT clone which recognes a :MC class-
restricted CTL epitope with EBNA-1 (Khana et aI., 1994), however, the EBNA1-clone does
not lyse the autologous BLCL. Thus, the in-vivo role of this clone is unown, but initial
indications suggest the presence of signcant numbers of these memory T-cells specific for this
EBNA-1 epitope.
To date, the search for EBV-encoded CTL epitopes has focd primarily m EBV
antigens expressed in BLCLs, using memory CTL reactivated in-vitro. The development of an
effective subunt vaccine wil requie knowledge of CTL responss in acute as well as latent
viral infections, and necessitate that we determine whether EBV strctural proteins contai
important CTL epitopes relevant to imune control durg primary infection. The significance
of recent findings are discussed in the context of EBV persistence and imune escape.
EBV Vaccines
The multitude of evidence implicating EBV in the etiology of a variety of human
neoplasms has made appealig the prospect of developing a viral-based vaccine effective
against human cancers. In endemic regions of the world, vaccination of infants against EBV
would potentially reduce the incidence of Burkitt's lymphoma, as well as nonendemc
Hodgki' s lymphoma, NPC, EBV-associated T cell lymphomas and leimyosarcomas, while
vaccine administration in developed countres would prevent the development of acute 1M in
young adults. With an anual U.S. incidence of acute 1M estimated at 100,000 cases (Evans and
Niederman, 1989), EBV causes significantly more illness than mumps, for which a vaccination
strategy exists. Another potentially beneficial us of an EBV vaccine is in XLP males, 70% of
whom experience an acutely progressive, fatal course of 1M during primar EBV inection.
While primary EBV infection stimulates both intense humoral and cell-mediated
imunity, each component of this imune response serves a very specific purose. Vaccines
against virses generally aim to induce humoral imunty against viral structual proteins
which neutralize infectious virs, and thereby limit spread to unected cells. In contrast,
cytotoxic-T-cells recogn and lyse latently infected cells which present processed viral
peptides m their cell surface. This latter form of imunty against EBV is particularly
important as latently infected cells remai in the peripheral blood for life and serve as a
reservoir for viral persistence and/or reactivation to lytic replication and viral shedding.
Thus, efforts to design an effective vaccine against EBV should include components capable of
inducing humoral and cellular imunty againt both lytic and latent gene products.
Identification of ential vaccine anti ens. Antibody absorption experiments
provided the initial evidence that EBV membrane antigens (MA) are responsible for the
induction of neutralizing antibodies (Pearson et aI., 1971). Similarly, early work m the
development of a subunt vaccine agaist EBV focd m the abilty of partially purified 
preparations to induce neutralizing antibody against EBV. The MA complex is compried 
four glycoprotein (gp350, gp250, gp85, gp78) three of which are known to induce neutralizing
antibody (Hoffman et aI., 1980) (Thorley-Lawson and Geilinger, 1980), and two of which
promote ADCC (Pearson et aI., 1979) (Khyatti et aI., 1991).
resent in the membranes of EBV -inected cells
GI co rotein EBV Neutralizin ADCC
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Adapted from (Wallace et aI., 1991).
The most abundant protein m the outer surface of EBV is gp350/220, and most of the
human EBV neutraliing IgG antibody response is directed against this glycoprotein (Thorley-
Lawson and Poodry, 1982) (North et al., 1982). Accordingly, much emphasis has bee placed m
producig a gp350/220 based subunt vaccine which wil induce neutralizing antibody and
ADCC (Thorley-Lawson and Edson, 1979) (Hoffman et aI. 1980) (Thorley-Lawson and
Geilinger, 1980) (Wallace et aI., 1991). Most recently, CD4+ cytotoxic T cell clones have bee
described which recognize multiple epitopes within the gp350 molecule (Wallace et aI., 1991).
Additionally, multiple studies have now identified cytotoxic T-cell epitopes in all EBV latent
proteins except EBNA- , and several peptide epitopes have been precisely defined (Khana et
aI., 1992) (Murray et aI. , 1992) (Masucci et aI., 1993). The significance of identifying these CTL
epitopes is underored by the recent description of EBV peptide epitopes which sensitize
Burkitt' s lymphoma cells to lysis by EBV-specific CTL (Khana et al., 1993).
Studies with based vaccines. Gp35 is one of the most abundant late viral
proteins present in lytically infected cell plasma membranes and the most abundant protein 
the outer surface of the virs coat. Importantly, most of the human EBV neutralizing antibody
response is directed against gp350 (Thorley-Lawson and Poodry, 1982) (North et aI., 1982).
Thus, gp350 is the major EBV lytic-cycle gene being purued in the development of a subunt
vaccine. In anal studies, imunation with partially purified gp350 antigen induces EBV-
neutralizing antibody which protects a portion of cotton-top tamarins againt a normally
lethal, lymphomagenic challenge with EBV (Epstein et aI., 1985). Further support for the
anti-tumor role played by EBV-neutralizing antibody came from work in which gp350-based
imune complexes were us to imun and effectively protect cotton-top tamarins against
EBV challenge (Morgan et aI., 1988). In this latter study, protection agaist EBV-induced
lymphoma closely correlated with levels of neutralizing antibody in the se of imuned
animals.
Interestingly, these findings were partially refuted by demonstration th a 
imunation of marosets with mA affiity-column purified gp350 did not protect against
EBV in spite of high virus-neutralizing titers (Epstein et aI., 1986). This fiding suggests that
in addition to neutralizing antibody, other imune mediators, such as CTL, may be required to
prevent the development of EBV-associated lymphomas. In order to overcome the observed
variations in imunty induced by various gp350 antigen preparations, the gp350 gene was
inerted into a vaccina virs vector to allow for the homogeneous expression and post-
translational processing of this glycoprotein. Curiously, the gp350 vaccinia constrct did not
induce EBV -neutralizing antibody but did protect cottontop marosets against
lymphomagenic dose of transformg EBV (Morgan et aI., 1988). This unexpected finding
clearly suggested the need to exame the cell mediated imune response against this major
EBV glycoprotein.
Results of more recent in-vitro experimentation have heightened interest in gp350. A
panel of gp350-specific CD4+ T-cell clones from an EBV-imune donor were tested for their
proliferative response to a series of trcated gp350 molecules expressed from recombinant DNA
vectors in rat GH3 cells, using autologous B-LCLs as antigen presentig cells (Wallace et aI.,
1991). One T-cell clone recognized a peptide spaning amino acid residues 61-81 of gp350, while
three other clones responded to peptides spang amo acid residues 163-183. An obvious
conclusion drawn from this study is the need to scee a variety of gp350-specific T-cell clones
from many EBV-imune donors in order to asses the wider inuence of HLA molecule
polymorphism upo gp350 epitope choice. This concept has a direct bearing upo the work
described in this thesis and our results support the presence of gp350-specific CTL which likely
serve to limit virus spread during primary EBV infection.
linical im lica of EBV va . The identity of the EBV gene products which
elicit the aggressive T-cell response during acute 1M, and which are responsible for the abilty
of cytotoxic- T -cells to caus regression of EBV -transformed cells remains unown and under
intense investigation. Along these lines it is important to note that unlike Burkitt'
lymphomas which typically express only select EBV latent gene products, the lymphocytes
present in post-tranplant lymphoproliferative disorders display the same spectr of latent
EBV gene products se in B cells immortalized in vitro. These findings suggest th a t
development of a vaccine based up recogntion of antigens expressed in EBV -transformed B-
cells in vitro wil liely confer protection against EBV-induced lymphoproliferative disorders
in imunosuppress patients. Whether an EBV vaccine wil even be effective in
imunosuppressed individuals remai to be seen. Simarly, vaccine-primed responses against
latency type-I infected B cells, expressing EBNA- , have the potential to promote imunity
against phenotypically similar Burkitt's lymphoma cells.
Curent understandig of antigen processing and presentation would lead one to predict
that the dominant EBV epitopes for cytotoxic T cell recogntion wil be determed, in part, by
an individuals own HLA alleles and wil be independent of the origial location (membrane
cytoplasm, nucleus, etc. ) of the product in the cell. Much remain to be done before the list 
EBV epitopes can be considered complete. Using the recombinant vaccinia system described
herein, along with access to a diverse panel of acute 1M patients and convalescent blood donors,
should allow the systematic identification of the imunodomiant epitopes of EBV which
wil be most useful in the rational design of an effective EBV vaccine.
CHAPTER II
MATERIALS AN METHODS
Experimental Design
A major chalenge to ou understading of viral latency and imune escape involves a
gap in our knowledge regarding the identity of virs encoded protein which provide epitopes
for recogntion by virus-specifc cytotoxic- T -lymphocytes. In this regard, acute infectious
mononucleosis (1M) represents an ideal model system to study virus-specific, cell-mediated
imunty. Acute 1M is a self-limited illess characterized by the appearance of " atypical"
lymphocytes (CD3+ /CD8+ /HLADR+) which are responsible for virus eliination and provide
lie-long imunity to Epstein-Barr virus (EBV). The experimental procedures outlined in this
section were designed to identif the EBV-encoded latent gene antigens which induce a primary
CTLresponsedurg acute 1M and which maintai EBV-specific memory CTL responses durg
convalescence.
Lysis of virally inected cells by CD8+ cytotoxic- Iymphocytes is antigen-specific and
MHC class-I restricted, thus all experiments designed to identi EBV antigens were performed
using autologous target and effector cells. Blood from acute 1M patients and healthy EBV
seropositive donors served as a soure of peripheral blood lymphocytes to generate bul CTL
cultures and target cells. Lymphocytes were isolated from whole blood by Ficoll-Paque density
centrifugation and T- and B-cell enriched populations were obtained by AET-sheep red cell
rosette selection. Autologous B cell blasts served as a source of most target cells and individual
EBV latent genes were introduced by inection of target cells with recombinant vaccinia virus
constrcts. Expression of individual EBV gene products in target cells was confed by both
western blot and imunofluorescence. Primary CT responss to EBV were evaluated in
standard 51Cr release assays using freshly isolated, T-cell enriched PBMC from acute 1M
patients as effector cell. Memory CTL responses to EBV were evaluated with bulk CTL cultues
generated by in-vitro restimulation with autologous B-LCLs. FACS analyses were routinely
performed m bul cutues of effector CT populations in order to more clearly characterize
their phenotype. Lastly, monoclonal antibody blockig studies and cold target competition
assays were performed in order to accurately identify the antigenic and :MC components
responsible for target cell recogntion and lysis.
Patients
The Student Health Services at the University of Massachusetts, Amerst campus,
served as the soure of acute inectious mononucleosis patients. Students presentig with
symptoms consistent with acute 1M and having a positive mono-pot test (presence of
heterophile antibody) were inormed of the study and offered an opportuty to participate.
Clical diagnosis was based up the presence of fever, swollen tonsilar and cervical lymph
nodes, hepatomegaly, splenomegaly and atypical lymphocytes in the peripheral blood.
Atyical lymphocytes were enumerated from fresh peripheral blood smears and identified by
their large size, eccentrc nuclei and abundant irregularly contourd cytoplasm. All patients
electig to participate in the study provided written informed consent prior to their enrollment.
Serological evaluation of antibody titers to EBV-related antigens was also performed m each
patient in order to confirm the diagnosis and characterize the stage of infection as either acute
transitional or convalescent. Additionally, all study participants with a serologically
confired diagnosis of acute/tranitional 1M included in this study were born between the years
1970 and 1975 and therefore were not imund agaist smalpox (ie. 11 previous exposure to
vaccinia virus). Five tubes of venous blood (four 15 ml vacutainer tubes contaig soum
heparin and one 10 ml tube containg SST gel and clot activator, Becton Dickion, Rutherford,
NJ.) were drawn from each patient m four separate occasions spang a period of six to eight
weeks. The first three acute 1M blood samples were obtaied within 10-14 days of the first
positive heterophile antibody test and durg the initial two weeks of symptomatic ilness,
these samples were refered to as "acute bloods . The fourth blood samples were drawn
approximately 6-8 weeks following the first positive monospot test, and in the majority of cases
after all clinical symptoms had subsided, this sample was refered to as the "convalescent
blood". Acute bloods served as the source of in vivo -activated cytotoxic- T-Iymphocytes (CTL)
used to identify EBV-encoded CTL antigens recognd durg the primary imune response to
EBV infection. Ina similar maner, the convalescent blood served as soure of memory CTLs
used to investigate the specifcity of the memory CTL response to EBV. Normal, healthy EBV-
seropositive and EBV-seronegative volunteers (laboratory workers) between the ages of 18 and
48 served as the control population. Control samples were collected and handled in an identical
maner to the acute 1M samples.
EBV rolo . In order to conf a diagnosis of acute infectious mononucleosis and
defie the stage of infection, one ml of serum obtained during the initial patient evaluation was
submitted to the clinical serology lab at the University of Massachusetts Medical Center for
analysis of EBV-specific antibody titers (anti- , anti-VCA IgM, anti-VCA IgG and anti-
EBNA). Patients with a serologically confed diagnosis of acute 1M or acute/transitional
status were included in this study.
EBV in typ g by DNA P lifi n. Saliva samples were collected from
acute 1M patients using an "OraSure" oral specien collection device (Epitope Inc., Beaverton
OR.) and placed into a 5 ml tube contaig 0.5 ml of specien buffer. PBS was added in the
amount required to dilute the origial saliva sample by 50%. Virus was precipitated from the
diluted saliva sample by addition of 1/2 volume of precipitation buffer: OAM NaCI, 30% PEG-
8000 (Fisher Scientific., Fair Lawn, NJ.) and the mixture placed at 40C overnight. Precipitated
virs was collected by centrifgation at 800 x g for 30 miutes at 40C. DNA was prepared
(Kawasaki, 1990) by resuspenion of the precipitate in 20 f.l of proteinase K lysing buffer: 50
ro KCI, 10 ro Tris-CI pH 8. , 2.5 ro MgCI2, 0.5% Tween- , 0.5% NP-40 and 100 f.g/ml
proteinase K. Virs was digested at 700C for 1 hr and the proteinase K was inactivated by
heating to 950C for 10 miutes. All chemicals were purchased from Sigma Chemical Co., St.
Louis, MO. Ten f.l of this DNA suspenion (equal to 250 f.l of saliva) was subjected to PCR
amplification.
EBV strai tying by PCR ampliication of DNA from 106 unfractionated PBMCs has a
highly variable outcome, however, PCR amplification of EBV DNA from 106 SRBC-rosette
depleted peripheral blood B cell is routiely diagnostic of the inectig EBV strain. Venous
blood served as a soure of B cell and was collected (see sample collection and lymphocyte :1;
isolation) from acute 1M patients at the time of saliva collection. Briefly, an enriched B cell
population was obtaied by collection of the non-rosette formg fraction of PBMCs subjected to
rosette selection with AET-treated sheep red blood cells. DNA was prepared (Kawasaki
1990) by resuspenion of 106 B-enriched cells in 100 f.l of proteinase K lysing buffer. Cell
suspensions were incubated sequentially at 700C for 1 hr and 950C for 10 miutes. Ten f.l of this
lysate (equal to 105 B-enriched cells) was subjected to PCR amplification. Appropriate controls
consist of EBV+ and EBV- cell lines including: Ramos; EBV negative B cell line, Namalwa; EBV
type-1 Burkitt lymphoma line, and Jijoye; EBV type-2 Burkitt lymphoma line.
The PCR amplification method us to subtye EBV strains is based up the us of a
pai of conserved priers and strain specific probes derived from regions within the EBNA3C
gene (Sample et aI., 1990). Oligonucleotide primers and probes were synthesized by the Nucleic
Acid Facilty at UMMC.
PCR ampliication primer 5' AGAAGGGGAGCGTGTGTTGT 3'
PCR amplification primer 5' GGCTCGTTTTTGACGTCGGC 3'
EBV tye-1 specific probe 5' GAAGATTCATCGTCAGTGT 3'
EBV type-2 specific probe 5' CCGTGATTTCTACCGAGAGT 3'
PCR ampliication was carried out in a 50 III reaction volume contaig 10 III of DNA
sample, 1 Jl of each primer, 0. Jl of each dNTP, 50 ro KCI, 10 ro Tris-CI pH 8.3, 2.5 
MgCl2 and 1 U of Taq DNA polymerase (Perki Elmer, Norwalk, CT.). Samples were subjected
to 35 cycles of amplification in an Ericomp Programable Cyclic Reactor (Ericomp Inc., San
Diego, CA.). Each cycle consisted of: denaturation at 950C for 1 miute, anealing at 5S0C for
1.5 miutes and extenion at nOc for 2 miutes. with a final extension at nOc for 5 miutes,
The amplified products were analyzed by polyacrylamide gel electrophoresis and
autoradiography using y_32p labeled strain-specific probes (Bretter et aI. , 1992) derived from
EBNA3C.
:MC Class I tisu . HLA class I tisue tying of acute 1M patient PBMCs was
performed by the Tissue Typing Facility at the University of Massachusetts Medical Center.
Freshly isolated PBMCs, or occasionally, established B lymphoblastiod cell lines (B-LCLs)
served as a source of cell for HLA tying. Freshly isolated PBMCs (3x106 cells) were washed
in 15 ml of phosphate buffered salie (PBS) and resuspended in 1 ml of RPMI-1640 contaig
20% human AB serum (ABS) (Advanced Biotechologies Inc., Columbia, MD.) and 20 U/ml rIL-
2 (Boehringer Maneim. , W. Germany). When B-LCLs or other established cell lines were
us for tisue typing, cutues were fed m the day prior to samplig to enur a viability of
:;90%. Next, lx107 cells were washed once in PBS and resuspended in 6 ml of RPMI-1640
containing 10% ABS. Three ml of this cell suspenion (5x106 cells) was placed in each of two
polystyrene tubes (Comig Industries., Comig, NY.) and submitted for tisue tying.
Isolation of lymphocytes from peripheral blood
Human peripheral blood from acute 1M patients and healthy controls was drawn by
veinpuncture into either 50 ml Luer-Iok syriges (Becton Dickion., Franklin Lakes, NJ.
contaig 500 unts of heparin (10 U/ml whole blood) or alternatively into four 15 ml
vacutainer tubes contaiing sodium heparin (Becton Dickison., Rutherford, NJ.). Heparinized
whole blood was diluted with an equal volume of PBS and 35 ml of the PBS/blood mitue was
gently layered onto a 10 ml cuhion of 200C ficoll-Paque (Pharmacia Fine Chemicals.
Piscataqay, NJ.) in 50 ml polypropylene tubes. Lymphocyte separation was achieved by
centrifgation at 1600 rpm (500 x g) for 30 miutes at 200C (Maluish and Strong, 1986). Excess
supernatant was aspirated from the tubes and the viable mononuclear cell layer was harvested
from the Ficoll-PBS interface. PBMCs were washed twice in sterile PBS and cells collected by
centrifgation at 1600 rpm (500 x g) for 10 miutes. Washed PBMCs were resuspended at 2x106
cells/ml in RPMI-1640 contaig 15% FBS, 2 ro L-Glutamine, 2-mercaptoethanol (2-ME)
(Sigma Chemical Co., St. Louis, MO.) 10 l gentamcin and 0.25 g/ml fugione (Gibco BRL, Life
Techologies Inc., Grand Island, NY.). Fresh PBMC cutues were grwn in a 3iJC humidified
incubator supplied with 5% C02.
SRBC-rosette aration f T- and B- . Sheep red blood cell (SRBCs)
(Colorado Seru Co., Denver, CO.) were pretreated with 2-aminoethyliothouronium bromide
(AET) to enhance bindig to the CD2 molecule m T cells (Madsen and Johnon, 1979). AET
solution was made as follows: 5 gms of AET was dissolved in 100 ml of distiled water and the
pH adjusted to 9.0 with 4N NaOH. The final volume was brought to 125 ml with distiled
water and the solution sterile fitered though a 0.22 micron disposable fiter system (Nalge
Company, Rochester, NY.). Th volume of AET solution was us to treat 20-40 ml of packed,
washed SRBC or 120 In of a SRBC suspenion as recieved from Colorado Seru Co. The
solution was used only on the same day it was made and excess AET solution was discarded as a
several day old solution was observed to lyse the sheep red cells.
Freshly isolated whole PBMC from acute 1M patients and normal control donors were
mied with AET-treated SRBCs to form T-cell/SRBC rosettes which were separated into
SRBC-rosette positive and negative populations via Ficoll-Paque density centrifugation.
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Approxiately 1x107 PBMC in 10 ml of RPMI-1640 were mixed with 3-5 mls of a cold 10% AET-
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\I,SRBC suspension and centrged at 800-1000 rpm (200 x g) for 5 miutes. The supernatant was
removed and the cell pellet was placed m ice for 30 miutes. Next, cells were gently
resuspended in 10 ml of RPMI-1640 by titing the tube back and forth and the final volume was
brought up to 35 mls with 200C PBS. The PBMC/SRBC suspension was then layered onto 10 
';1'
of a 200C Ficoll-Paque cushion in a 50 ml polypropylene tube and centrifged at 1600-1800 rpm
(500-600 x g) for 20 miutes at 200C. Non-rosette formg cells (mostly B cells) were collected
from the Ficoll/PBS interface and washed once in 5-10 volumes of PBS. Rosette formg T -cells
were harvested from the cell pellet and washed in 5-10 volumes of PBS. SRBCs present in both
the T-enriched and B-enriched pellets were lysed by addition of 5-10 ml of an ice cold NH4CI
solution: 0.83 gm NH4Cl/100 ml H20, pH adjusted to 7.3 with KHC03 and after 1-2 miute
incubation, the remaig lymphocytes were washed twice in 5-10 volumes of PBS. Red cell
lysis was apparent by the solution beomig dark red and transparent. The cell pellets were
resuspended in RPMI-1640 and viable cells counted via trypan blue exclusion. Double- and
triple-color fluorescence activated cell sortg (FACS) Gackson and Warer, 1986) was
performed to enumerate T and B cells.
Preparation of target cells
atio f B ll asts. B-cell blasts were chose as targets cell for 51Cr release
assays as they are a natural host cell for EBV and are easily generated from fresh or frozen
PBMC (Fothergill et aI., 1982) (Khana et aI., 1991). Lymphocytes were isolated from whole
blood by Ficoll-Paque density centrifgation and T cell were removed by rosette selection with
AET-treated sheep red blood cells as described above. The B cell enriched fraction was then
depleted of monocytes by allowing the cells to adhere to plastic for 1 hr at 3iJC (Splawski and
Lipsky, 1991). The non-adherent B cells were collected and staied with a panel of
fluorochome-conjugated monoconal antibodies for surface marker phenotype analysis. The
enriched B cell population served as a soure for generatig anti-IgM-stimulated B-cell-blasts
~~~
and for establishing EBV-transformed B-Iymphoblastoid cell lines (B-LCL).
The enriched B lymphocytes were cutured at a concentration of 1-2x106 cell/ml in
RPMI-1640 contaig 10-15% ABS, highly purified human recombinant 20 U/ml rIL- , 50-100
U/ml rIL-4 (Genzyme., Cambridge, MA.), 1- g beads/106 cells rabbit anti-human IgM (
chain specific) coated acrylamide beads (Irvine Scientific., Santa Ana, CA.). Following cuture
for 48-72 hr, the B-cell blasts served as suitable targets for infection with vaccinia virs
constrcts. The ideal conditions for generatig B-cell blasts (l g IgM-beads/106 cells, 100U/ml
rHu-IL-4 and 20U /ml rHu-IL-2) were confirmed by FACS analysis.
ation f B- od cell lies ( . All B-LCLs were established by
inecting peripheral blood mononuclear cells (PBMC) with EBV-contaiing culture supernatants
from the EBV type- producer cell line; B95- (Nilsson et aI. 1971) (Tosato, 1991).
Unfractionated PBMC served as a source of restig B cells. Unstimulated B cells and not B cell
blasts were us here as EBV inects resting B cells in preference to activated B lymphocytes
(Aman et aI., 1984). B95-8 supernatant was produced by inoculating 100 ml of RPMI-1640 with
1x106 cells/ml exponentially growing B95-8. The cuture was incubated in a humidified 370C,
5% C02 incubator for 5-10 days without additional feeding. The EBV-containg culture
supernatant was harvested by centrifgation for 10 miutes at 1600 rpm (500xg). The
supernatant was then passed through a 0.45-Jl filter and 1 ml aliquots contaig 102_103
transforming unts/ml were stored frozen at -800e. New B-LCL lies were intiated by infecting
107 unractionated PBMC or 2x106 enriched B cells in 2-3 ml of RPMI-1640 with 0.5 ml of B95-
supernatant stock. Newly inected cultures were incubated at 3J'C for 2-3 hr and fed with 5 ml
of RPMI-1640 containg 15% FBS. Memory CTL from EBV-seropositive individuals typically
prevent the outgrowth of EBV immortalized B cells in vitro and were usually either removed
by SRBC-rosetting or functionally inactivated with cyclospori (Tosato et aI., 1982)
(Bejarano et aI., 1985) (Rickion et aI., 1979). When unfractionated PBMC were used,
cyclosporin A (O. g/ml) was added to the media during the first several weeks after intiatig
the culture (Rickison et aI., 1984). Newly established cultures were carefully observed for the
appearance of proliferating clumps of cells, characteristic of EBV-transformed B cells.
Proliferating cultues were expanded by twice weekly feedings with RPMI-1640 contaig 10%
FBS and cell density was maintained at 1-2x106 cell/mI. A complete list of established B-
LCLs us in this work and their :MC class-I haplotype is shown in Table 2. For long-term
storage, aliquots of each lie were frozen in RPMI-1640 containing 10% FBS and 10% DMSO.
Generation of HTL V - transformed T-cell lines. HTL V - tranformed T-cell lies were
generated by co-cultivation of PBMC with the HTL V -1 secretig MT -2 cell line as described
previously (Mer! et aI., 1984) (Nutman, 1991). Briefly, PBMCs were isolated from heparinized
whole blood by Ficoll-Paque density centrifugation. Phytohemagglutin (PHA)-blasts were
generated by placing unfractionated PBMC at 106 cells/ml in RPMI-1640 contaig O.5mg/ml
PHA (Buroughs Wellcome., Research Triangle Park, Ne.) and incubatig at 370C for 72 hrs.
As a source of HTLV-1, one half as many mitomycin-C treated (50 g/ml for 1 hr at 370C) MT-
cells were added to the PHA-stimulated T cells. Growth of the tranformed T cells was
maintained by addition of 10-20 U/ml rIL-2 to the media. These T cell lines remaied IL-
dependent and were tyically ;:95% CD4 positive.
Gen ration rima human fibroblast line . As a source of human dermal fibroblasts,
3- ski biopsies were obtained from healthy donors. Tissue samples were placed in 100
2 tisue cutue plates and 1-2 ml of a lOx trsin solution: 2.5 mg trpsin/ml in Tris-NaCI
pH 7.5, Gibco BRL, Grand Island, NY., was added. The tissue was teased apart using two
sterile scalpels and subsequently examed under the microscope to enur that the fibroblasts
had been freed from remaing clumps of tissue. The trypsin/cell suspenion was diluted in 10
ml of PBS and the fibroblasts were collected by centrifgation at 1500 rpm (400 x g) for 5
miutes. The supernatant was removed and the cells were resuspended in 1-2 ml of growth
medium: RPMI-1640 contaig 20% FBS, 4m L-glutame, 1m Na-Pyruvate, O.lmM non-
essential amo acids, 30J.g/ml heparin, 25 ng/ml each of acidic and basic recombinant human
fibroblast growth factor (Sigma Chemical Co. ) 60J. 2-mercaptoethanol and lOJ.g/ml
gentamicin. Cells from each biopsy specimen were then placed into 3-4 wells of a 24 well plate
and grown in a 370C, 5% C02 humidified incubator. One to two weeks of incubation tie were
tyically required before substantial growth was observed. Successfully established lines were
alowed to grow until cell covered the bottom of a tisue culture flask and the monolayers were
harvested and expanded by preparing a single cell suspeion using a 1x trypsin solution: 0.
mg trsin/ml PBS. Excess fibroblasts were frozen in RPMI-1640 plus 10% DMSO and stored in
liquid nitrogen unti needed.
Growth of vaccinia virus stocks
The recombinant vaccinia vectors encoding single EBV genes utilzed in this work were
kidly provided by Dr. Ellot Kieff. Table 3 lists the recombinant vaccinia vectors along with
names and sizes of the inserted EBV open-reading frames. Details of the vaccinia vector
constrction can be found in (Murray et aI., 1990) (Khana et aI., 1992).
Gro th of cinia crd cks. CV -1 cells were grwn to 90% confuency in
Mial Essential Medium (MEM) plus 10% FBS, and washed in PBS prior to infection in order
to enhance virus absorption. High titer vaccina virus stocks were diluted to 106_107 pfu/ml in
plain ME and 5 ml were added to each 150 cm2 flask of CV-1 cells. Virus was allowed to
absorb for two hours in a 370c incubator with occasional rockig. Infected monolayers were fed
with 30-40 ml of fresh MEM contaig 5% human AB se (ABS) and allowed to incubate for
48-72 hours. Dug this incubation the cytopathic effect (CPE) of the vir was apparent as
the monolayer of adherent cell round-up and sloughed from the surface of the flask. Virus
stocks were prepared from these matue cutues by several freeze/thaw cycles when CPE was
evident in 80-90% of the CV-1 cells. The matue cultues were frozen at -200C over night,
partially thawed at room temperature and the slurry shaken vigorously several ties in order
to scrape all cells free into the media. The cell debris was collected in a low speed centrifge
for at 1200 rpm for 10 miutes and the pellets resuspended in 2 ml of ME. To release cell-
associated virs, the cell suspenions were subjected to three quick freeze/thaw cycles by
alternate submersion in a dry ice-ethanol bath and a 370C water bath. Additional vir was
released from the cell pellet by treatment with trypsin. Fifty J.I of lOx tisue cutue trypsin
solution was added to each 2 ml cell suspeion and incubated at 370C for 30-45 miutes. The
crude vir stock was dispensed in 100 J.I aliquots and frozen at -800C with titers typically in
the range of 108 pfu/ml. This virs was us only to seed new stock cutures. Purified virs
stocks us to infect target cells were prepared by sucros gradient centrifugation of the crde
stocks.
Sucrose adient urification of vaccinia vi stocks. Preparation of purified vaccinia
virs stocks requied more startig material than for crde virs stocks, typically five or more
150 cm2 flasks of CV-1 cells were infected with each vaccinia constrct. The cell pellets
obtained from the monolayers undergoing CPE were resuspended in 1m Tris-HCl pH 9.
instead of ME. The cell suspenions were subjected to several rounds of freeze/thawing and
treatment with trsin as was done in preparing the crde stocks. Vir was then separated
from cell debris by high speed centrifgation though a sucrose cushion. A 10 mI cuhion of 36%
sucrose made in 1mM Tris-HCL pH 9.0 was placed in the bottom of each Oak Ridge centrifge
tube and the virs preparations, in a final volume of 20 mls, were laid m top. The tubes were
centrifged at 20 000 x g for 80 miutes and the supernatant removed by aspiration. Virus
pellets were resuspended in 2 ml of 1mM Tris-HCl pH 9.0 with resultig titers in the range of 2 x
109 pfu/mI. The sucrose gradient purified virs stocks were used for inection of target cell.
Titration of vaccinia virs s ocks. Virus stocks were titered via a plaque formg assay
on monolayers of adherent cells. CV -1 cells were grwn to confuency in 6 well plates and usd
as the indicator cell lie. CV -1 monolayers were washed with ME and 1 mI of various
dilutions (10-3 to 10-7) of virs were added in duplicate to the wells. The vi was allowed to
absorb for 2 hrs at rom temperature with periodic shakig. The inocum was then removed
and replaced with 4 ml of a 400C mitue contaig equal parts of 2x plaque assay media:
MEM plus 5% ABS and 2% Seaplaque agarose (Sigma Chemical Co.). The agar was allowed to
set at rom temperature for 15 miutes and the plates incubated at 3f'C for 48 hrs. Culture
wells were then overlayed with 2 ml of X-gal solution (Sigma Chemical Co.) contaig 500 mg
gal/ml in 1% Seaplaque. Plates were developed overnght in a 3f'C incubator and plaques in
duplicate wells were counted and averaged to determine viral titers.
Expression of recombinant vaccinia-EBV constructs in target cells
Primary human fibroblast lines, HTLV-1 transformed human T cell lines and anti-IgM
stimulated B-cell blasts were infected with recombinant vaccinia vir constrcts at a
multiplicity of infection (MOl) of 5:1 to 10:1 at 3f'C for 1 hour. Following infection, cells were
incubated for 4-24 hour to allow for expression of the vaccinia-encoded EBV latent gene
product. At four hour intervals a portion of the inected cells were harested for either western
blot or imunofluorescence analysis. EBV-encoded proteins were detected with either
polyclonal human se from EBV seropositive donors or when available, a mA against the
specific EBV protein.
Imunofluore t detecti n of EBV nuclear ens. Fibroblast lines grwn to near
confuency in ME plus 15% FBS were harvested by trypsinization and plated at low density
onto 8-chamber tisue cutue slides (Nunc, Inc. Napervile, IL.). Fibroblasts were again grwn
to near confuency at 370C in a humidified 5% C02 incubator, washed in 0.2M PBS pH 7.2 and
infected with vaccinia constrct at an MOl of 10:1. Virs was allowed to adsorb to the
fibroblast monolayer for 1-2 hrs at 370C. Excess virs was removed by washing individual
wells with PBS and the inected cells were fed with fresh ME and allowed to grw for 4-
hrs. Prior to imunofluorescent staing, al cells were first washed 3 ties in Hank's Balanced
Salt Solution (HBSS) without Mg2+ and Ca . Slide preparations of non-adherent cells (K562
and B-LCLs) were made by placing 10-20 III of a cell suspension contaig 2-5 x 1() cells in each
well of an 8-well slide. Slides were air dried overnight, fixed in a 40C mitue 
methanol/ acetone (50% v Iv) for 15 miutes and washed several ties in PBS contaig 1 
FCS. Prior to specific staing, all cells were permeabilized with 0.5% NP40 in PBS plus 1 
FCS for five miutes at 200C and washed once more in PBS. Donor se from EB V
seropositive/vaccinia seronegative individuals served as a soure of EBNA-specific primary
antibody. Al donor seru was heat inactivated at 560C for 30 miutes prior to us in order to
inactivate complement. Complement free serum was diluted 1/1001/500 in HBSS and 10-20 III
was added to each well and allowed to incubate for 30 miutes in a humidified 370C incubator.
The slides were then washed by soakig twice for 5 miutes each in HBSS with low speed
stirring. Washed slides were ried in distiled water and 15-20 III of a 1/10 dilution of EBV
negative, vaccinia negative human se was added to each well. This EBV- /V ac
served as a source of human complement. Slides were then incubated at 370C in a moist
chamber for 30 miutes followed by several washes in PBS and ried in distiled water.
Detection of specific imune complexes was achieved by addition of 15-20 III of a 1:100 dilution
of goat anti-human C3 FITC-conjugated mAb. Slides were incubated with the FITC-conjugated
mAb for 30 mi at 3f'C in a moist chamber and again washed as described above. Coverslips
were applied to the air dried samples using a solution of glycerin/Hank' s BSS (1:1). Slides
were examined and photographed at 400-1000 X with a Zeiss Axioplan fluorescent microscope
(Zeiss Inc. West Germany).
Imunofluorescent detection of EBV la membrane rotein 1. The LMP1-specific
mA S12 was provided by Dr. Ellot Kieff. Cell samples were prepared in 8-well chamber
slides as described above for the detection of EBNAs (Winchester and Ross, 1986). To block
nonspecific binding of antibodies to the cell membrane, the fied cells were first incubated with
2% goat se diluted in HBSS for 30-60 miutes at 370C. Slides were washed by sequential
submersion in HBSS and distiled water for 5 miutes each, without allowing slides to dry
completely between the various steps. As a primary reagent, the LMP-1-specific, mure mA
S12 was added to each well at a 1/50 dilution and allowed to incubate for 1-2 hrs at 370C.
Following this incubation, the slides were again washed in HBSS and distiled water. As a
secondary / detecting reagent, FITC-conjugated goat anti-mouse Ig was added at a 1:20 dilution
and incubated at 3f'C for 30 miutes. The slides were washed a final time, dried completely
and a coverslip placed over the sample using a solution of glycerin/Hank' s BSS (1:1). Cells
were photographed at 400-1000 X using a Zeiss Axioplan fluorescence microscope (Zeiss Inc.
West Germany).
Imunoche cal detectio f EBV gp350/220. Ths procedure was carried out in a cell
suspension at 40C and une the staing protocols for LM-1 and the EBNAs, these cells were
not fixed prior to staing (Winchester and Ross, 1986). Approximately lx106 cells were
harested from a vigorously growing culture and washed several ties in cold PBS. Cells were
first treated with a 1/100 dilution of a murine anti-gp350/220 mA 72A1, and incubated at 40C
for 30 miutes. The cell were then washed in ice cold PBS to prevent capping of the antibody
on the cell surface. As a secondary reagent, the cell were treated with a 1/20 dilution of FITC-
conjugated goat anti-mouse Ig and again allowed to incubate for 30 miutes at 40C. Excess FITC-
conjugated Ab was removed by thee washes in cold PBS and the cells were resuspend in 50-100 .1"1' ',:.
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. 1"11JlI of this same solution. Ten JlI of the stained cell suspension was placed m a slide and covered
with a coverslip. The slides were examed as above. I .
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Imunoblo ection of EBV nuclear anti ens. Expression of vaccina encoded EBV
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genes was evaluated in a variety of human cell lines includig primary human fibroblast lines,
HTLV-1 tranformed T cell lines and anti-IgM stiulated B cell blasts (Garfin, 1992). oi"
I:I
Recombinant vaccina virs constrcts were added to the cell suspeions at an MOl of 10:1 and
incubated at 370c for 1-2 hr to allow for virs adsorption. Total celllysates were prepared by
harvestig sequential fractions of the infected cutues at 4, 8, 12, 16 and 24 hrs. Briefly, 2- 11,1
1)11
5x106 cells were collected via centrifugation and the volume of the cell pellet was estimated.
Approxiately ten volumes of sample buffer was added to the cell pellet and mixed vigorously. 1;111
The sample bufer contaied 2% SDS, 100 mM dithiothreitol, 60 mM Tris pH 6.8 and 0.01%
bromophenol blue. Samples were boiled for 3-5 minutes and chomosomal DNA was sheared by
repeated passage through a 20-gauge and subsequently a 26-gauge needle. The samples were
then centrifged at 10,000 x g for 10 miutes, supernatant recovered and any inoluble pellet
discarded.
The protein samples prepared in this maner were separated by SDS polyacrylamide
gel electrophoresis and transferred to nitrocellulose paper via semi-dry electrophoretic
transfer. The transfer buffer contaied 190 mM glycine, 25 mM Tris-base pH 8.0 and 20%
methanol. In general, proteins were transfered from the 6x8 an gels for 2-4 hrs at 50mA/ gel.
The nitrocellulose blots were washed several times in PBS prior to blockig non-specific binding
sites with a Blotto/Tween solution: 5% non-fat dry milk, 0.2% Tween-20 and 0.02% sodum
azide in PBS for 1-2 hrs at room temperature. The blots were washed twice for 5 miutes each 
PBS + 0.1% Tween. Seru from EBV seropositive donors was us as a source of primary
antibody which was diluted 1/100 - 1/50 in Blotto/Tween and allowed to incubate with the
blot for 1-2 hr at 200C. Longer incubations typically increased sensitivity. Blots were washed
in 2 changes of PBS + 0.1% Tween-20 wash buffer for 5 miutes each, followed by two more
washes in alkaline phosphatase wash buffer. The alkaline phosphatase wash buffer
contaied 150 NaCI, 50 ro Tris-base pH 7.5 and 0.1% Tween-20. Alkaline phosphatase
conjugated goat anti-human IgG (Tago, Inc., Burligame, CA.) was us as the
secondary/detection antibody which was diluted to a concentration of 1-2mg/ml in alkaline
phosphatase wash buffer + 5% non-fat dry milk. Blots were incubated with the secondar Ab
for 1-2 hr at rom temperature with agitation and the excess antibody-conjugate thoroughly
removed by washig the blot several ties in alkaline phosphatase wash buffer. Blots were
developed by incubation in a solution contaig the substrates for the alkaline phosphatase
enzyme, bromochloroindoyl phosphate and nitro blue tetrazolium (BClP /NBT) (Kirkegaard &
Perry Labs Inc. Gaithersburg, MD.). The washed blots were placed in substrate solution and
allowed to develop at rom temperature with agitation unti bands were sufficiently dark.
Development typically took about 5-10 miutes and was stopped by riing the blots in PBS
contaig 20 mM EDTA.
Imun lot etection of EBV latent membrane rotein 1. As described above for the
imunoblot detection of EBNAs (Garfin, 1992) The LMP1-specific mure mA S12 was us 
a primary reagent, kidly provided by Dr. Ellot Kieff. Alkaline phosphatase-conjugated
goat-anti-mouse antibody was used as the secondary reagent (Tago Inc. Burligame, CA.).
Preparation of effector cells
Various T lymphocyte-enriched populations were us as effector cells in 51Cr release
assays which differed primarily in whether or not the CTL were restimulated in-vitro, and by
the source of antigen used for restimulation. Whole PBMC preparations from acute 1M patients
and healthy controls routiely contai signicant num of CD16+ natural kiler (NK) cells,
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which were removed by AET-SRBC selection of T cell and monoclonal antibody (mAb) directed
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complement mediated lysis of NK cells.
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Nat ral kiler ll d . All whole PBMC preparations and T cell-enriched
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populations which served as effector cells in 51Cr release assays were specifically depleted of
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NK cell by mAb directed complement mediated lysis (Kanof, 1991). The cells were thoroughly
washed in PBS, collected by low speed centrifgation and resuspended at 5x107 cells/ml in 40C
RPMI-1640 contaig 0.3% BSA. Media contaig FBS was avoided as it significantly
increased nonspecific cell lysis. MAb Leullb (anti-CD16, 0.05 Ilg/106 cells, Becton Dickison
San Jose, CA.) was added and the cell suspeion and incubated for m ice for 30-45 miutes.
Cell were washed twice in 25 volumes of ice cold PBS and resuspended in 2 ml of cold RPMI-
1640 plus 0.3% BSA. Lyophilzed rabbit se (Accurate Chemical and Scientific Corp.
Westbury, NY.) which served as the source of complement, was resuspended in 5-6 ml of RPMI-
1640 plus 0.3% BSA and fiter sterilzed by passage through a 0.45Jl Acrodis PF fiter
(Gelman Sciences., An Arbor, MI.). The sterile complement suspeion was added to cells at a
final concentration of 2x107 cells/ml and the mitue was then incubated for 45-60 miutes in a
3J'C shakig water bath. The complement treated cell were washed in PBS, collected via
centrifugation and resuspended at 1x106 cells/ml in RPMI-1640 supplemented with 15% FBS
and 101lg/ ml gentamcin.
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tio f EBV -spec ty CT c . Previous studies on the cell-mediated
imune respons to Epstein-Barr virs conducted in ou lab demonstrated that lysis of EBV
infected cell was primarily mediated by CD3+ /CD8+ HLA Class-I-restricted T cells
(Tomkson et al., 1987). Thus, this procedure describes the in-vitro expanion of a population
of activated, EBV-antigen-specific CTLs. Freshly isolated PBMC from healthy EBV
seropositive donors were used as a sour of virus-specific, memory T-cells. Lymphocytes were
separated from whole blood by Ficoll-Paque density centrifgation as described earlier. Bulk T
cell cutues were initiated with an enriched T cell fraction obtaied by one round of SRBC-
rosette selection, followed by depletion of NK cells with mA Leullb plus complement.
Cultures were initiated by stimulatig 5x107 enriched T cells (responder cells) with 1.25x106
mitomycin- treated (50 Ilg/ml) autologous BLCLs (stimulator cells) (Strang and Rickison
1987) (Wallace et al., 1982) (Sugamura et al., 1981) (Sugamura and Hinuma, 1980).
Th intial stimulation was always carried out at a responder to stimulator ratio (R:S)
of 40:1. The high R:S ratio provides optium conditions for generatig an antigen-specific T-
cell-mediated response (Walace et al., 1982) by minimzing excess antigen and eliatig the
non-specific stiulation of either cross-reactive or lower affinity T cell receptors (Svedmyr et
aI., 1974). Responder cells were then diluted to a concentration of 106 cell/ml in RPMI-1640
contaig 15% FBS, 2m L-Glutamine, 50J1 2-mercaptoethanol, 1Ollg/ml gentamcin,
25Ilg/ml fugione. Two ml of th cell suspenion were then added to each well of a 24 well
plate and incubated in a 370C humidified incubator supplied with 5% C02 for 5-6 days. Next,
one half of the media was replaced with fresh RPMI-1640 contaig 15% FBS, 20U /ml rIL-
2mL-Glutamine and 501l 2-mercaptoethanoI. On day 8- , half of the media was replaced
with fresh media contaig 40U/ml rIL-2 (20U/ml final) and the cutue incubated for an
additional 2-4 days. On day 10-14 after initiating the cultue, responder cells were re-
stimulated with mitomycin C treated autologous B-LCLs at a responder to stiulator (R:S)
ratio of 3:1 and fed with fresh RPMI-1640 contaig 20U/ml rIL-2. Beyond this point cultues
were maintained with twice weekly feedings and restimulated weekly with autologous B-LCLs
at a R:S ratio of 3:1.
Target cell specificity of the responder cells was tested after the cutue had bee
maintained for at least 18 days, typically after three or more stiulations with B-LCLs.
Responder cells were harested and tested for their abilty to lyse a variety of target cells as
measured in a standard 51Cr release assay. Target cells consisted of both EBV positive- and
EBV negative-cell lies as well as :MC class-I matched (autologous) and :MC class-
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T l ocy from acute 1M patien . Several independent groups of
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investigators have described the high levels of apoptosis observed in cutues of activated
CTL (CD8+ /HLA-DR+) from acute 1M patients (Uehara et aI. , 1992), (Moss et aI., 1985).
These highly sensitive cells can be rescued from apoptotic cell death by in-vitro cutue in the
presence of exogenously added IL-2 (Akbar et aI., 1993), (Cohen, 1991). The initial steps
involved in preparation of cytotoxic T cells from acute 1M patients was similar to that of
convalescent donors described above. PBMC were first enriched in T cells via one round of
SRBC-rosetting followed by mA Leullb/complement depletion of NK cells. T cell enriched
populations were grwn at 106 cells/ml in RPMI-1640 supplemented with 15% ABS, 20U/ml
rIL-2 , 501i 2-mercaptoethanol and 2m L-Glutame. The enriched T cell cutues were
typically maintained for 48-72 hrs without restimulation, in a 370C humidified atmosphere
contaig 5% C02. The virus-specific lytic activity of this T-enriched cutue was readily
detected on day one of culture and could be maitaied for up to 2 weeks without restimulation.
Virus-specific lytic activity could also be maintaied for up to 1-2 month by periodic
restimulation with an empirically determined dilution of OKT3 ascites, as a source of anti-CD3
mAb, and rIL-2. The surface marker phenotye of CTLs prepared in this maner were routinely
95-98% CD3+, 60-80% CD8+ and 20-40% CD4+
Rec mbinant vaccinia-EBNA1 stiulated bul TL cultues. This method was devised
to selectively stimulate and expand EBV-specific class-I restricted CTL which specifically
recognized an as yet undentied epitope within the EBNA 1 protein. The soure of PBMCs for
these experiments came from a diverse panel of donors having varing characteristics with
respect to stage of EBV infection, vaccina imunzation status and antigen specificity of their
memory CTL response to EBV. PBMCs from varous donors were handled differently depending
upon the donors' stage of EBV inection, acute vs convalescent. Activated T cell isolated from
acute 1M patients undergo apoptotic cell death if deprived of IL-2 and therefore these cells
were supplemented with rIL-2 at the time of initiating the cultures. In contrast, bul CTL
cultues derived from convalescent donors are not prone to apoptosis and were therefore
deprived of IL-2 until the 5th-6th day of cultue. In order to expand an antigen specific
population of CT in vitro, best results were achieved when the repondig cells were
stimulated with antigen and initially deprived of exogenous IL-2. Ths procedure favors the
survival of only those T cells specifically stimulated by the antigen of interest. Antigen
specific T cells activated by the initial stimulation readily expand when supplied with IL-2 m
day 5-6. Stimulator cells consisted of autologous B cell blasts or B-LCLs infected with the
vaccinia-EBNA1 construct and fixed in aldehyde. The stimulator cells were inected with the
vaccinia-EBNA1 constrct at an MOl of 5, incubated at 370c for 1 hr, fed with fresh RPMI and
then grwn for 12-16 hrs so as to allow for expression of the EBNA1 protein. Vac-EBNA1
expressing cells were then subjected to aldehye fixation, which inactivated the vaccinia virus,
prior to the use of these cells as a source of antigen. The chemical reactivity of P-formaldehyde
with proteins is well established and involves reductive methylation and cross-lig 
lysine residues by reaction with the free e-amino groups (Pancake and Nathanson, 1973). In the
work described here various methods of alehyde fixation were evaluated in an effort to
minimze any modification of the native EBNA1-MHC antigenic strctue and/or
I '
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costimulatory molecues m the antigen presentig cell. Formaldehyde fixation of cells
(Maccario et al., 1992) consisted of resuspending the cells in a 0.5% solution of formaldehyde for
10 miutes followed by several washes in PBS. However, an alternative, more gentle
glutaraldehyde fixation method was utilzed for the majority of experients described here
(Hosken et aI., 1989) (Hapel et aI., 1980). Following 12-16 hrs of vaccinia infection, cells were
incubated in 50 g/ml mitomycin-C for 1 hr at 370C, washed twice in PBS and resuspended in 1
ml of plain RPMI. Freshly prepared 2% glutaraldehyde (Grade I, Sigma Chemical Corp. ) was
added to a final concentration of 0.05% and the cells vortexed gently for 15 seconds. Aldehyde
fixation was stopped by addition of an equal volume of 0.2M L-Lysine (Sigma Chemical Corp.
followed by a one miute incubation. The fixed cells were washed twice in 25 volumes of PBS
and used as stiulator cells. In all cases PBMC cultures were stimulated at an initial R:S ratio
of 40:1 with subsuent stimulations at a R:S ratio of 3:1 once weekly thereafter. Beyond the
5th-6th day of incubation, all cultures were maintained in the presence of 20U /ml rIL-2. Target
cell for 51Cr release assays included unixed stimulator cell among the panel.
The following figure is a schematic sumary of the various stimulation procedures 
to generate the effector cells outlied in this section.
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Chromium release assays
Infection of tar et cells with vaccinia-EBV constrcts. Recombinant vaccinia virus
constrcts encodig single EBV genes were used to introduce EBV proteins into non-EBV infected
cell lies in order to generate targets for 51Cr-release cytotoxicity assays (Khana et aI., 1991).
Actively dividing cells serve best as targets for inection with vaccinia constrcts as they are
readily infected and promote high levels of vaccinia driven gene expression. Target cells were
':'
always grown in media supplemented with human ABS and not FBS. T- and B-cell blasts were
" ; :
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harvested from actively dividing cultues, washed thoroughly in PBS and collected by
:' I'
" I'
:1'''
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centrgation for 5 miutes at 1000-1200 rpm in a Beckman GPR centrifge using a GH- 7 rotor.
j ., , , ' .
The viabilty of unected target cells was always ::90% by trypan blue dye exclusion. In order
 :: :. . 
to increase viabilty, collection of cell on a Ficoll-Paque cushion was someties necessary. The
target cell pellets were resuspended in RPMI-1640 supplemented with 5% ABS at a
concentration of 5x106 cells/mI. A volume of approximately 100-200 l of this cell suspenion
i'1".
,.,
(0. 1x106 cells) was needed for each vaccinia constrct to be tested. Vaccinia virs constrcts
'''
1.1
were added to target cell at an MOl of 5:1 (50 1 of a lx109 titer stock) and incubated at 370C for
YL"
"!;'
2 hr to allow for vir adsorption. The infected cells were washed in PBS to remove any : 1'. I
''''
I:''
excess vir, fed with several ml of RPMI-1640 contaig 5% ABS and incubated at 370C for
!, -
12-16 hrs. Target cells were collected via centrifgation at 1000-1200 rpm for 3-5 miutes and
' w
all but 200 l of the supernatant was removed by aspiration. The cells were then radiolabeled
by addition of 100 Ci of 51Cr-Na2Cr04 at 100 Ci/target (Dpont N.E.N., Boston, MA.) and
incubated at 370c in a shakig water bath for 1-2 hrs. Radiolabeled cells were then washed
twice in 5 ml of PBS and collected by centrifugation at 1200 rpm for 3-5 mi. The washed cells
were resuspend at 1x105 /ml in RPMI-1640 supplemented with 5% ABS and 100 l (lx104 cells)
was placed in each test well of a 96 well round bottom microtiter plate.
Chomium r lea ssays. The cytotoxic activity of the various lymphocyte effector
populations was evaluated in a standard 51Cr-release assay (Whiteside et aI., 1992). The
assays were carried out in round bottom 96 well microtiter plates contaig lx104 51Cr-Iabeled
target cells seeded into each well. Approximately 0.5-1x106 cells were infected for each
vaccinia constrct to be tested. Targets were inected with recombinant vaccina constrcts at an
MOl = 5:1 to 10:1 and incubated for 16-20 hrs at 3J'C to allow for sufficient expression of the
introduced EBV gene. Target cells (0.5-lx106) were 51Cr radiolabeled by incubation with 100
f.Ci of 51Cr for 1-2 hr at 370C. Radiolabeled targets were washed twice in PBS, resuspended at
a concentration of lx105 cells/ml in RPMI containg 10% ABS and 100 f.l (lx104 cells) added to
each well of a 96 well round-bottom plate. All effector/target combinations, including
maxum and spontaeous release wells, were set-up in triplicate. Typically, effector cells
were added to well contaig targets at various ratios rangig from 0.5:1 to 50:1 (5x103 - 5x105 'II',
effector cells/well). The actual num of vaccinia constrcts tested and the effector:target
(E:T) ratios us for each assay varried slightly from patient to patient depending upo the
number of effector and target cells available. The assay plates contaig effectors and targets
were centrifged briefly at 800 x g, incubated for 4-6 hrs at 3J'C, recentrfuged and 100f.1 of
supernatant harvested from each well for countig in a y-counter (Beckman Intrents, model
5500B). Spontaneous release of 51Cr was quantitated by incubatig target cells in media alone,
in the absence of effector cells. Maxum release of radioactivity was determined by
quantitatig the radioactivity in a 50 f.l aliquot of the original target cell suspenion. Percent
specific 51Cr release was calculated as follows: % specific release = 100 x ((sample cpm) -
(spontaneous cpm)) /((maxum cpm) - (spontaneous cpm)).
Spontaneous 51Cr release did not exceed 25% of the maximal incorporation for any of
the data shown. Criteria for significant lysis were that exceeding background lysis by at least
10%. More tyicaly, specific lysis exceeded background lysis by ::25%.
Inibition of CTL-mediated kilin monoclonal antib . Monoclonal antibody
blockig studies were undertaken to defie the cellular phenotye of the cells mediating lysis.
Inibition of cytotoxic activity was achieved by adding various dilutions of mA stock solution
(ascites or hybridoma culture supernatant) to lx104 51Cr labeled targets in 100 III of media for
30 miutes, after which varous num of effector cells in 100 III of media were added. The
inibitory effect of the mAb on cytolysis was assessed following a 4-6 hour 51Cr release assay
as previously described. Inibition was calculated as: % inbition = 100 x ((cytotoxic activity
of effector cells in the absence of mAb) - (cytotoxic activity of effector cells in the presence of
mAb)J / (cytotoxic activity of effector cell in the absence of mAbJ.
Cold tar et c etition assa . In effort to identify the :MC class-I restriction
molecule and viral protein specifically involved in antigen recogntion, cold target inhibition
studies were performed. Cells us as cold target competitors consisted of a variety of EBV or
Vac-inected and uninfected, unlabeled "cold" target cell, which were added at 10 fold excess
to compete with radiolabeled targets in a standard 51Cr release assay. Cold targets sharing
MHC/peptide antigen complexes with "hot" targets compete as targets for antigen-specific
lysis and thereby reduce lysis of radiolabeled target cells. Target cell were labeled with 51Cr
as described previously and 1x104 hot targets in 50 III of RPMI were added to each well of a 96-
well plate. To competitor wells, 1x105 cold competitors in 50 III of media was also added. Fifty
III of media was added in place of competitor cells to wells us to measure specific release.
Various numbers of effector cell in 100 III of RPMI were added to all specific release wells and
cold competitor wells. For maum release wells, 150 III of media was added to the hot
targets in place of effector cells and 100 III of this cell suspeion was harvested for analysis in
a y-counter. Well used to measure spontaeous release were set-up in a similar maner to the
maxium release wells, except that only the cell free supernatant was harvested for countig.
Effector cells (5x105 cells in 100111) were added to all wells except the maxum and
spontaneous release wells. The final volume per well was 200 l in all cases.
Cytofluorographic analysis
Double and triple color cytofluorographic analysis was performed m a fluorescence
activated cell sorter (FACSScan, Becton Dickison, Mounta View, CA.). Cell staiing was
accomplished via the direct method using antibodies conjugated to either fluorescein
isothocyanate (FITC), phycoerythrin (PE) or percp (PCP) (Jackson and Warner, 1986). Prior to
staiing, all cells were washed in ice cold PBS contaig 0.2% soum azide (PBS/ azide) and
resuspended at 5x107/OO in cold PBS/azide. For each set of surface markers to be evaluated
approximately 1x106 cells (20 1 of the cell suspenion) were incubated with 20 l of each mA
at 40C for 30 miutes. Following this incubation, the cells were washed in 2-3OOs of ice cold
PBS/azide to remove excess antibody and cells were collected by centrifugation at 1200 rpm for 3
mi at 40C. Stained cells were aldehyde-fixed by a 10 miute incubation in 0.5 00 of 0.
paraformaldehyde at 40C. Fixed cells were washed in 2-3 ml of PBS/azide, collected via
centrifgation and resuspended in 0.5 00 of PBS/azide. Background fluorescence was
determined using FITC, PE and PCP-conjugated goat anti-mouse antibodies as controls.
Monoctes were excluded from the analysis by placing an electronic window around the
lymphocyte population based upon their characteristic low angle forward and 900 light scatter
properties.
Reagents
ecomb ant vaccinia virs vecto . The vaccinia-EBV constrcts us in these studies
were provided by Dr. Ellot Kieff. A detailed description of the vaccinia virs constrct
encoding the different EBNA genes (except EBNA-1) has been published previously (Murrayet
aI., 1992) (Khana et al., 1992) (Murray et aI., 1990). All EBV sequences were derived from the
B95.8 (type-lor A) strain of the virus. Regarding the Vac-EBNA1 constrct, the Ssp1 fragment
from the pTF7-5:EBNA1 plasmid was inserted into the pSCll plasmid opposite the P7.5
promoter for EBNA1 expression. While EBNA1 expression is under control of 17 DNA
polymerase, the baseline expression of EBNA1 is almost identical to that observed in B-LCLs
(Khana et aI., 1991). All constrcts contain sufficient genetic material to encode the relevant
full-length EBV protein. vaccinia constrct contaig 11 EBV latent genes and a
dysfuctional thymidine kiase gene (Vac-TK-) was us as a negative control. Table 3
contai a complete list of vaccinia constrcts used in these studies.
,,,
Established cell lines & corresponding MHC class-I haplotypes. See table 2.
Monoclonal antibodies & corresponding antigen specifcities. See table 4.
Recombinant human lymphokies and growth factors
Growth Factor Use in Cultue Source
In-vitro growth of Boehringer Maneim
rHu IL- cytotoxic T cells W. Germany
Generation of Genyme,
rHu IL- B cell blasts Cambridge, MA.
Acidic- F ibrob las t Establishment of primary Sigma Imunochem.
Growth Factor human fibroblast lines St. Louis, MO.
Basic-Fibroblast Establishment of primary S. Biochem. Co.
Growth Factor human fibroblast lies Cleveland, OH.
Imunobeads: Rabbit anti-human I coated acr lamide beads. Anti-IgM coated
acrylamde beads were used as a source of solid-phase stiulation for the generation of human
B cell blasts. Beads (#15377H) were added to SRBC rosette negative B cell suspenions at a
concentration of 2Jlg/ml and were purchased from Irvine Scientiic, Santa Ana, CA.
Mis aneous R ts: AET- ed eep ed cell . Sheep red blood cells (SRBC)
(Colorado Seru Co. Denver, CO.) were received in 60 ml aliquots which were diluted 1:2 in
RPMI-1640 and stored at 40C for up to two weeks. The SRBC were treated with AET as follows:
120 mls of SRBCs were washed twice in several volumes of PBS and collected via centrifugation
at 1200 rpm for 10 miutes. The washed SRBCs were resuspended in 125 m1 of 370C AET
solution (see AET solution below) and incubated in a 370C water bath for 15-20 miutes. If the
AET /SRBC suspeion did not darken, the pH of all solutions was checked and the procedure
repeated. The red cells were then washed twice in PBS and pelleted at 1200 rpm (400 x g) for 5-
10 minutes. The AET-treated red cells were then resuspended at a concentration of 10% vol/vol
in RPMI-1640 contaig 10% FBS (Sigma) and gentamicin (lO g/m1, Gibco).
amoethylisothouronium (AET) bromide solution was made as follows: Five gram
of AET was dissolved in 100 mls of distiled water and the pH adjusted to 9.0 with 4N NaOH.
The fial volume was brought to 125 m1 with distiled water and the solution sterile filtered
though a 0.22 micron disposable filter system (Nalge Company, Rochester, NY.). Ths volume
of AET solution was us to treat 20-40 m1 of packed, washed SRBC or 120 m1 of a SRBC
suspension as recieved from Colorado Seru Co. The solution was usd only m the same day 
was made and excess AET solution was discarded as a several day old solution was observed to
lyse the sheep red cells.
Rab t co Lyophilzed rabbit se was us as a soure of complement for
monoconal antibody/complement mediated depletion of specific lymphocyte subsets. The
lyophilzed rabbit se was disolved in 5-6 m1 of plain RPMI-1640 and fiter sterilzed by
passage through a 0.45Jl fiter before use. Reconstituted complement (#ACL3221) was freshly
prepared for each set of depletions and was purchased from Accurate Chemical and Scientific
Corp., Westbury, NY.
ki bi its. Human ski biopsies were obtaied from healthy donors to generate
primar human fibroblast cultues. Thee and four mm ski biopsy punches were us to obtain
biopsy material from the anesthetised lumbar region of HLA class-I typed donors. Biopsy
punches (# 443-50) were purchased from Baker Cumins Pharaceuticals Inc., Miami, FL.
CHAPTER 
RESULTS
EBV strain tying by DNA-PCR
The infectig strain of EBV (type- or type-2) was determined for twenty-seven
patients with a confirmed diagnosis of acute inectious mononucleosis. A representative assay
is shown in Fig.1: PCR amplified products from saliva and partially-purifed B cell were
hybridized with type-1 (panel a) or type-2 probes (panel b). PCR products from EBV positive
cell lies, Namalwa (type-1), and Jijoye (type-2), were us as positive controls and the EBV
negative cell lie, Ramos was us as a negative control. No cross hybridization occu and
the patients were successfully typed. Of the 27 patients tyed, 26 (::96%) carried EBV type-
while only one patient (0:4%), Dowda, was infected with type-2 EBV. A sumar is presented
in Table 1.
Isola on of T- and B- ocytes. AET-SRBC rosette selection was us to isolate
highly enriched populations of T- and B-lymphocytes from all patient samples described in
this study. SRBC-rosette selected T cells were used as a sour of cytotoxic T cells and the non-
rosette formg B-cell enriched fractions were us as a source of HLA-matched target cells.
The SRBC-rosette positive population from AI patients was analyzed by FACS and consisted
mainly of CD3+ (95-98%), CD8+ (50-80%) T cells which were us as a sour of efffector cells
in 51Cr release assays. The SRBC-rosette-negative population consisted maily of CD19+
(80%) B cell which were us both to established EBV-tranformed B lymphoblastoid cell
lies (BLCL) and to generate B-cell blasts which were subsequently infected with recombinant
vaccinia vir constrcts and us as targets in the 51Cr release assays. Fig. 2 shows a
representative set of FACS data for whole PBMC, rosette (+) and rosette (-) subpopulations.
Expression of single EBV gene products in target cells
Imun uorescenc ection f EBV gen . Expression of specific EBV gene
product in the various target cells was demonstrated by imunofluorescence. Typically, 85-
95% of target cells inected with vaccinia constrcts at an M.O.!. of 10 expressed high levels of
the specific EBNA protein. Human fibroblasts infected for 12-16 hrs with vaccinia constrcts
encoding EBV nuclear antigens contaied high levels of the specific EBNA protein as detected
by imunofluorescence using pooled polyclonal human se from EBV-seropositive /vaccinia-
seronegative donors (Fig. 3c-3h). The EBV-negative T-cell line; CEM, served as a negative
control and did not show the typical nuclear staining pattern characteristic of cell expressing
one of the EBNA protiens (Fig. 3a). Fibroblasts infected with a control vaccinia constrct Vac-
TK-, contaig no inert, alo showed 11 nuclear staing (data not shown). EBV-transformed
LCLs were included as positive controls which routiely displayed large, brightly stained
nuclei along with th, pale, unstained cytoplasm (Fig. 3b).
Hum fibroblasts infected with recombinant vaccinia vectors encocg the EBV
membrane protein LMP1, (Vac-LMP1), were stained with the LMP1-specific mA S12. The
kietics of LMP-1 expression is shown in Figures 4c-4f. LMP1 was detectable as early as 4-5 hrs
and levels rose steadily for over 12 hrs. Typically, protein levels rose for 24-36 hr following
infection, but cell viabilty decreased rapidly at these later ties (data not shown). An
infection tie of 12-16 hr was used to prepare target cell for 51Cr release assays as this length
of inection allowed an optium balance between levels of protein expression and cell
viabilty. Fibroblasts infected for 12 hrs with the control vaccinia constrct Vac-TK- served as
a negative control (Fig. 4a). EBV-transformed B-LCLs were us as a positive control, which
displayed pale, unstained nuclei along with the characteristic brightly staining patches on the
cell membrane (Fig. 4b).
Expression of the major viral coat glycoprotein gp350 was demonstrated by staining
recombinant vaccinia vector inected fibroblasts with the gp350-specific mAb 72A1. See Fig. 4h
for expression of Vac-gp350 and Fig. 4g for V ac- TK- which served as a negative control.
Several unsuccessful attempts were made to demonstrate expression of the Vac-LMP2A constrct
in target cells by imunofluorescence using pooled polyclonal human sera. A mous mA
specific for LMP2A now exists but was not available for use at the tie of these studies.
Imunoblo detection of EBV gen roducts. Expression of the proper sized E B V
proteins encoded by the recombinant vaccina vectors was demonstrated by Imunoblottg.
Blots contaig extracts from fibroblasts, MI lies and B-cell blasts inected with
recombinant vaccinia constrct encodg EBNA protein were probed with polyclonal human
se from EBV-seropositive/vaccinia-seronegative donors. Blots contaig extracts from
cells infected with vaccinia constrcts encoding LMP1 were probed with the LMP1-specific 
S12. Protein expression in the various cell tyes tested did not differ qualitatively nor
quantitatively and thus only the results using B cell blasts are shown. Expresion of EBNA1 in
target cells was demonstrated as a single, fait band at the expected M.W. of 78 kDa, typically
appearing at times greater than 16-20 hr following inection (Fig. 5a). Expression of EBNA2A
was readily detected as a single, 86 kDa band at 8 hr post-infection and levels of protein
increased over the 24 hr duration of the experiment (Fig. 5b). The vaccinia constrct encodg
EBNA-LP produced a series of bands of varying M.W. rangig from 20-45 kDa (Fig. 5c).
Expression of the vaccina constrcts encoding EBNA3A, 3B, 3C and LM1 all followed similar
kietics; a single band of the expected M.W. appeared at 4 hr post-inection and rose
thoughout the duration of the 24 hr experiment (Figs. 6a-6d).
Several unsuccessful attempts were made to demonstrate expression of the Vac-LMP2A
constrct by imunoblot using polyclonal human sera as the priary reagent. Under none of the
various condition tested was there evidence that the protein was being properly expressed to
any detectable level. Similarly, several attempts were made to demonstrate expression of the
. J
Vac-gp350 constrct using the gp350-specifc mA 72Al. On one occassion a band 
approximately 200 kDa (unglycosylated gp350 = 220 kDa) was present in lanes containing
extracts from Vac-gp350 inected cells which had not be heat denatured prior to
electrophoretic separation (data not shown).
Cytofluorographic analysis of EBV -primed CTL
Primar EBV inection is accompaned by a profound expanion of peripheral blood
lymphocytes, which gradually regress durg convalescence. FACS analysis was utilied to
more precisely describe specific changes in T cell subsets which accompany the maturation of
cellular imunity to EBV.
Acti n mark exp sion m + T cells durg acute 1M. The:MC class-
molecue HLA-DR is not expressed m restig T cells and thus, in the surface marker studies
described here, was used as a marker to identi activated T cells. Similarly, CDllb (Mo-1) is
a marker expressed m previously activated, but not naive, T cell and thus served here as a
marker for long-term memory. Whole PBMC from acute 1M patients and healthy controls were
staied with fluorochome conjugated mAbs specific for CD8, HLA-DR and CDllb and subjected
to triple color FACS analysis. Selection of CD8+ cell was followed by two color separation of
CDllb+ and HLA-DR+ cells. In comparison to healthy adult controls, acute 1M patient PBMC
contaied a four to five fold increase in the percentage of activated CD8+ /HLA-DR+ T cells
(Table 5). Freshly isolated PBMC from acute 1M patients also contai markedly elevated
levels of CD8+ /HLA-DR+ /CDllb+ triple positive T cells which are not present in PBMC from
healthy controls (Fig. 7). Triple color surface marker analysis performed en sequential PBMC
samples (days 1 4 and 8) from a representative acute 1M patient (GRIBR) is shown in Fig. 8.
The population of triple positive cells (CD8/HLA-DR/CDllb) reached peak levels very early,
around day one (quadrant 2) followed by a relatively rapid and sustaied loss of the HLA-
marker over tie in all acute 1M cases studied. Worthy of note is the sustaied expression of
CDllb resultig in a shift in the percent of double positive cells (CD8/CDllb) occupyig
quadrant 1 m day 8. The relatively rapid decrease in HLA-DR expression m CD8 T cells
following the acute phase of primary EBV infection is easily observed when compared to a
marker not expressed at high levels on the activated CD8 cell, such as CD57 (Fig. 9).
A sumar of the mean percent of CD8 cells expressing HLA-DR and CDllb marker
combinations on initial blood samples from seven acute 1M patients and four healthy donors is
shown in the table below.
Sudace Marker Combination Acute 1M Patients n-7 Healthv Controls (n-4)
Total: CD8+ /HLA-DR+ 52.3% +/- 11.7 9% +/- 1.0
CD8+: HLA-DR+/CDllb+ 46.4% +/- 8. 3% +/- 2.
CD8+: HLA-DR-/CDllb+ 13.1% +/- 2% +/-
CD8+: HLA-DR+/CDllb- 22.4% +/- 8. 9% +/- 3.
CD8+: HLA-DR- /CDllb- 18.0% +/- 8. 79.7% +/- 6.
Quantitative changes in the percentage of cells expressing each surface marker were
also followed over tie. The mean percent change in activation marker expression m CD8 cells
from three acute 1M patients, over a 10-12 day tie period, is shown in figue 10. While the
percentage of CD8 cell expressing HLA-DR dropped by greater than 30% over 10-12 days, the
percentage of CD8 cells expresing CDllb (Mol) dropped by only 5%. The net result is a decrease
in the size of the activated, cytotoxic T-cell pool (CD8+ /DR+ /CDllb+) and an increase in the
size of the long-lived, restig, memory T-cell pool (CD8+ /DR- /CDllb+
These fidings were extended by independent two color FACS analysis of HLA-DR and
CDllb expression m CD8+ T cell from three groups of individuals including: 1) acute 
patients at the earliest stage of EBV infection, 2) acute 1M patients at 6 weeks following initial
presentatio with symptoms, and 3) EBV seropositive individuals at greater than 6 month
post primary EBV inection. The results shown in Fig. 11, demonstrate a signficant drop in
HLA-DR expression at 6 weeks following acute 1M, whereas a similar drop in CD11b (Mo-
expression did not occur until some tie between six weeks and six month. Th data appears to
support the theory that CD11b represents a marker for long-lived imune memory cells, and
wil be described more fully in the discussion section.
n mark r e ess in-vitro p emory CTL. The percentage of in-
vitro restimulated CTL which express HLA-DR (60-70% positive) was found to be similar 
that of the in-vivo primed CTL, however, unlie the in-vivo activated CTL, expression 
Cd11b was essentially absent from the in-vitro primed CTL. In fact, levels of CD11b m in-vitro
propagated CTL were observed to drop by 80% in as litte as 8 days in cutue (data not shown).
Thus CD11b is not an accurate marker for identiing memory T cells propagated in vitro.
EBV-specific HLA-restricted CTL in peripheral blood of EBV-seropositive
donors
When freshly isolated, whole PBMCs from EBV-seropositive donors were us 
effector cells in 51Cr-release assays, target cell lysis occu independent of the presence 
EBV antigens or HLA class-I molecules m target cells. In Fig. 12a, the NK-sensitive targets
K562-neo (HLA-) and K562-A2 (HLA-A2) were lysed in direct proporton to the num 
SULJO PBMC (effector cells) added. In contrast, the EBV-infected cell lies SULJO-BLCL
(autologous) and BYRKE-BLCL (allogeneic) were not lysed to any measurable extent even at
the highest E:T ratio of 50:1.
In contrast, when whole PBMC from EBV-seropositive donors were restimulated in-
vitro with the autologous BLCL, lysis of HLA-matched EBV-inected cells increased relative
to the non-specific lysis of EBV-uninfected, HLA-mismatched targets. A representative
experiment is shown in Fig. 12b. In addition to kilig the NK-sensitive targets K562 and HSB-
, the BLCL-restimulated PBMC (bulk CT cuture) also lysed the EBV-infected, HLA-
matched autologous BLCL in preference to the EBV-negative (MT2) or HLA-mismatched
targets (Allo). The specificity of target cell lysis by these bul CTL cutues was further
improved by enriching the cutue for T cells, and depleting NK cells prior to in-vitro
restimulation. The results in Fig. 12c show that target cell lysis was restricted to the
autologous BLCL (EBV infected, HLA class-I matched) and that all HLA-mismatched targets
(Allo, K562, HSB-2), regardless of EBV status, were not lysed. Attempts to generate EBV-
specific CTL lies from two available EBV-seronegative donors resulted in the expanion of a
population of effector cells which mediated low levels of non-specific target cell lysis in an
EBV antigen independent and non-HL class I restricted maner. See Fig. 12d. Thus, EBV-
seropositive individuals have EBV-specific CTL in their peripheral blood which can be grwn
in-vitro by stimulation with autologous BLCLs.
EBV-speci ic CT roblasts and B ll blasts e sin sin le EBV genes. EBV-
specific CTL cultures were established from EBV-seropositive donors and tested as effector cells
in 51Cr release assays against various target cell types infected with recombinant Vac-EBV
constrcts. Fibroblasts and B cell blasts infected with vaccinia constrcts encodg the EBV
latent proteins (EBNA- , 3B, 3C, LMP-1) were specifically recognd by the EBV specific
memory CTL, Figs. 13a-d. Additionally, autologous BLCLs (positive controls) were efficiently
lysed, while allo-BLCLs, unected target cells, and targets infected with the vaccinia
constrct V ac- TK (negative controls) were not significantly lysed. Both the fibroblasts and B
cell blasts expressed the introduced EBV genes and were lysed by EBV-specific CTL, although
the B cell blasts proved to be the easiest target cells to work with, as they are quickly and
easily generated in large numbers.
In-vivo activated CTL derived directly from the blood of acute 1M patients
display EBV -specificity and HLA-restriction in-vitro
Tar et l sis b acute 1M CTL is anti en-s ecific and HLA class-I restricted. Whole
PBMC from acute 1M patients contai large num of in-vivo activated CD8+ CT which do
not requie in-vitro restimulation prior to their us as effector cells. Bulk T-cell enriched
preparations contaig primarily activated CTL were obtaied by SRBC-rosette selection
from whole PBMCs. Non-HLA-typed effector cell populations prepared in this maner
mediated high levels of killing against EBV -infected BLCLs in preference to EBV -uninfected
''',
HLA-identical T-cell lies (MT2) Fig 14a. These crudely prepared, bul CT cutues stil
contai significant num of NK cells and thus also mediate high levels of NK-like kiling
against the NK-sensitive target K562, Fig 14a.
In-vivo activated, SRBC-rosette selected CTL preparations derived from HLA-typed
acute 1M patients mediate higher levels of lysis against HLA-matched than HLA-unmatched J,!
BLCL targets, Fig 14b. Removal of NK cells from the T-cell enriched population in Fig 14b
provided a CTL preparation which mediated lysis of only EBV-infected, HLA-matched target
cells (Aliar-BLCL) Fig 14c, and not EBV-infected, HLA-mis-matched (BLCLs) or HLA-
negative targets (K562). This target cell lysis is directed agaist EBV antigens and not allo-
derived strctures, as th same bulk CTL preparation specifically lysed only Aliar-derived B-
" ,
cell blasts (Allo) infected with Vac-EBV constructs expressing EBNA-3B and LMP-1 Fig 14d.
These activated CTL are highly IL-2 dependent and can be maintained in cutue for
several weeks in the presence of rIL-2 (20U /ml) alone. Non-specific stiulation by anti-CD3 in
addition to rIL-2 allowed long term (several months) maintenance of these activated T cells.
CTL from Acute 1M atients l se tar et cells ex ressin sin le EBV genes. The
specificity of the primary CTL response to EBV inection was evaluated in 35 acute 1M patients.
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Enriched populations of in-vivo activated, CD8+ CTL from al 35 patients recognized and lysed
autologous B cell blasts expressing single EBV gene products. In-vivo primed CTL recogned a 
eight EBV latent proteins, including EBNA-1 and the lytic cycle glycoprotein gp350. Primary
CTL responses were frequently directed agaist as many as 4-5 EBV proteins, with greater than
90% of respones including one or more of the EBNA-3 protein, and 60% recogning EBNA-
alone. Importantly, nie of the 35 pateints examed had CTL which lysed Vac-EBNA1
infected targets, and similarly, 7 of the 35 patients had CTL which lysed Vac-gp350 infected
targets. A composite representig the spectr of primary CT responss to EBV from six
individual acute 1M patients is shown in Fig. 15, and details of CTL responses for all 35 patients
is included in table 6. Percent specific lysis values for patients with significant cellular imune
responses against EBNA-1 are included in table 7, and simlarly, results for gp350 specific lysis
are in table 8. Mium criteria for significant target cell lysis included; spontaneous 51Cr
release from targets c: 25%, and individual target cell lysis had to exceed Vac-TK (negative
control) lysis by 10% in order to be considered significant.
In-vivo rimed EBV -s ecific TL are CD8+ class-I restricted. The cellular phenotype
of the in-vivo pried effector cells us in the above 51Cr release assays were shown by
monoclonal antibody (mAb) blockig experiments to be CD8+ /Class-I-restricted. Anti-class-
antibody (BBM.1) treatment of target cells reduced lysis by an average of 50-80% (Fig. 16a)
while mA directed against class-II molecules m target cells had 11 such effect (data not
shown). Similarly, anti-CD8 mAb treatment reduced target cell lysis by an average of 40-70%
(Fig. 16b) while mAb against CD4 molecules had little or no effect (data not shown).
Determination of cell surface phenotype of the in-vivo pried effector cells by FACS
analysis confired the mAb blockig studies described above. Representative data from acute
1M patient "Marro" are shown in Fig. 17. As depicted here, all T cell enriched cutues us 
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effector cells contained a major T cell subset (60-80%) which stained with mA to CD3/CD8. A
more complete phenotye analysis of effector cells, including activation markers, is included in
section F of the results.
In- itro rim d memory CTL fr scen 1M atients reco redominantl
EBNA3 anti ns. The memory/seondar CTL response to EBV was evaluated in 32 acute 1M
patients at 6-8 weeks following primary inection. PBMC from convalescent donors do not
contain signficant num of activated, EBV-specific CTL, and thus all PBMC cultues were
restimulated with the autologous BLCL prior to us as effector cells. Target cells consisted of
autologous B cell blasts inected with vaccina constrcts encoding single EBV genes. In contrast
to the primar response, memory CTL responses measured in individual patients were generally
restricted to one or two EBV antigens, and usualy included one of the EBNA3 protein. 
composite of representative results from four patients is shown in Fig. 18. At the two extremes
some patients appeared to have identical primary and secondar CTL responses to EBV (Figs.
19a-b) while others demonstrated markedly different primary and secondar CTL responss
(Figs. 19c-d).
In contrast to the primary T cell respons, 11 memory CTL responses were detected
againt gp350 and only one of 32 patients had memory CTL which displayed significant lytic
activity against EBNA-1 expressing targets. The primary CTL respons by this patient was
directed agaist EBNA 3A, 3C and LP, while the memory response was directed against EBNA
, 3C and LP (Figs. 20a-b). These unque results, while potentially very important, could
not be repeated as no further PBMC samples were available from this patient. A complete list
of acute 1M patient primary and secondar CTL responss is shown in Table 6. together with 
graph comparg the percentage of patients respondig to a given EBV antigen in primary 
secondar CTL responss (Fig. 21). These results demonstrate that the primary and secondar
CTL responses to EBV are marked by the overwhelmg imunodomiance of protein in the
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EBNA3 family (EBNAs 3A, 3B, and 3C).
Recombinant vaccinia-EBNA1 stimulated CTL
EBNA1 tiulated CT from EBV sero ositive vaccinia sero ositive donors. In
order to preferentially stimulate and expand EBNA1-specific memory CTL, PBMC from four
EBV-seropositive/vaccina seropositive donors were primed with autologous B blasts or BLCLs
infected with a recombinant vaccina vector encoding EBNA-l. CTL responss when stimulated
:,,'/ 
with either Vac-EBNA1 inected B blasts or Vac-EBNA1 infected BLCLs were directed against
:11.
;1.11'
either vaccinia gene products or to EBV in general, with little or 11 clear indication of an I ,:
EBNA1-specific CT response. Representative data shown in Fig. 22a were generated using ;"'f'...Ir.I:o
CTL stimulated Vac-EBNA1 infected B blasts and demonstrate lysis of all target cells infected
!I'lI-
::.
with either control (TK) or EBNA-1 encodg vaccinia constrct (E1). The two autologous
I ,!!1\11.1. 
targets not inected with vaccina constrcts were not lysed to any signifcant degree, indicating I' ::.
a primarily vaccinia domiated CT response. The results shown in Fig. 22b were generated ..1. r' I
'01 " I : II
with CT which had be stiulated with autologous BLCLs inected with the Vac-EBNA1 ('1:,'1'1' 
constrct. In this case the CTL lyse both the vaccinia inected as well as vaccinia unected
!11t:
BLCLs. In contrast, only the vaccinia infected B blasts and not the unected B blasts were
Ii ' r;'111
,:..u f:1
lysed. These results indicate that the CT respons was directed against both vaccinia and
--':
It. ..
ti+( 
:J:'
EBV encoded antigens, agai, with no clear preference for EBNA1 expressing targets. u J;
Vac-EBNA- 1 stimulated CTL from acute 1M ent . Restimulation of PBMC from
acute 1M patients was accomplished in a similar maner, with the exception of the tig 
exogenous IL-2 addition. Activated CTL from acute 1M patients are IL-2 dependent and were
thus supplemented with IL-2 at the initiation of cultures, unike PBMC from normal donors
which were deprived of IL-2 for the first 5-6 days of in-vitro stiulation. Freshly isolated
PBMC from acute 1M patients were stimulated with Vac-EBNA1 infected B blasts and target
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cell lysis was evaluated with a variety of vaccinia infected and unected targets. Results
from a representative experiment using PBMC from a vaccinia-seronegative, acute 1M patient
Levro are shown in Fig. 23. Lysis of the autologous B blasts and BLCLs increased by 8.6% and
12.5% respectively, when infected with the vaccina construct encoding EBNA 1, as compared to
the control vaccina construct Vac-TK. It is worth notig that freshly isolated PBMC from this
acute 1M patient did not initally demonstrate significant lysis of EBNA1 expressing targets
over the control V ac- TK inected targets. The memory CTL respons to EBV measured in this
patient was directed to EBNA3C and was included here for the purose of comparison.
Identification f an ure by cold tar et etition as . In an effort to further
expand the apparent EBNA1-specific component of the "Levro" bulk CTL cultue (shown in fig.
23), three additional stiulations were carried out with Vac-EBNA1 inected B blasts. The
target cell specificity of this cuture was evaluated in a cold target competition assay.
Radiolabled "hot" targets consisted of autologous B blasts inected with either the V ac- 
(control) or Vac-EBNA1 constrcts. Cold competitor cells consisted of unabled, autologous B
blasts inected with the Vac-TK construct. Cold competitor cells were mied with 51Cr labled
targets at a ratio of 10:1 and the Vac-EBNA1 expanded, effector CTL were added at ratios ..1
1:1 or 5:1. The Vac-EBNA1 expanded CTL lysed both the Vac-TK and Vac-EBNA1 targets
':1
equally well and likewise the cold target competitors reduced lysis of both targets by 50-70%
(Fig. 24a). In order to determe whether EBV expressing targets could serve as cold
competitors, a similar assay was performed using a panel of partially HLA-matched BLCLs 
cold competitors. The results shown in Fig. 24b demonstrate that as above, the majority of
target cell lysis was directed to vaccinia encoded antigens. V ac- TK infected cells served as
efficient cold competitors whereas the EBV infected BLCLs did not prevent lysis of the
chromium labled targets.
The results of standard chomium release assays and cold target competition assays
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demonstrate that target cell recogntion by Vac-EBNA1 expanded CTL was dependent 
vaccinia encoded antigens. Classically, virs specific T cells provide long term imunty 
viruses but, ths vaccinia specific, in-vitro stimulated response was obtained with PBMC from a
vaccina seronegative donor, leaving to question the identity of the cell mediatig target cell
lysis. Dual color FACS analysis revealed that the Vac-EBNA1 expanded effector cell culture
consisted primarily CD3+ /CD4- /CD8- /CD16- /CD19- /HLADR+ /CD45RO+ /TCRap-
/TCRyo+ T cells. The table below sumares the percentages of cells bearing selected CD
markers and the FACS contour plots are contained in Figs. 25-26.
Percentage of Vac-EBNA1 Expanded Cells Bearing Selected CD Markers
CD Markers % Cells Stained CD Markers % Cells Stained 
CD3+ 95. CD3+ /TCRap+
CD19+ CD3+ /TCRap- 96.
CD16+ CD3+ /TCRyo+ 83.
CD3+ /CD8+ 27. CD4+ /TCRyo+
CD3+ /CD4+ CD8+ /TCRyo+ 16.
CD3+ /CD8- /CD4- 66.5 CD16+ /TCRyo+
CD3+ /CD56+ 59.5 CD8+ /CD56+ 17.5
CD3+ /CD56- 35. CD8+ /CD45RO+ 24.
CD3- /CD56+ CD8- /CD45RO+ 71.1
CD3+ /CD57+ 1.3 CD8+ /CD45RA +
CD45RO+ /RA- 84. CD8+ /HLADR+ 24.5
CD45RO+ /DR+ 89. CD8- /HLADR+ 69.
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CHAPTER IV
DISCUSSION
rtan TL unty ainst EBV. Experiments of natue have demonstrated
that individuals lackig the abilty to produce antibody handle most viral inections quite
well, but are significantly more susceptible to bacterial inections. In contrast, individuals
with genetic deficiencies in their abilty to mediate cellular imune fuctons are unusualy
susceptible to a variety of viral inections. The latter condition directly pertain to EBV as
exemplified by nature s lessons with "David the bubble boy" (XSCID) (Renne, 1993) and the
now well described Ducan family of XLP males (Purtilo et aI., 1975) (Sullvan and W oda
1989).
While CTL playa major role in the control of acute viral infections, most imunzation
strategies ai to induce neutralizing antibody against glycoprotein or structural antigens
present m the vir coat. The effectiveness of this approach is limited in the setting of
persistent/latent infection, where virus is cell associated and the major viral coat glycoproteins
are generally not expressed. Thus, vaccine strategies to prevent persistent infection should aim
to induce CTL-mediated imunty against viral-encoded latent proteins. In this regard, a
decade has now passed since the initial description of antigen recogntion by CTL, involving
proteolytic fragments of viral proteins associated with cell surface HLA class-I molecules
(Townd et aI., 1986), and since that time, virs encoded, 9-12 amo acid peptide-epitopes
have been described for many virses (Oldstone, 1991), including EBV (Masucci et aI., 1993).
Accordingly, CT are well suited to control persistent infection, as they posses the
capacity to mediate lysis of virally infected cells with very low levels of cell surface-
associated viral antigen. In fact, CTL likely require 11 more than 100-500 viral peptide-MHC
class-I complexes for activation and lysis (Demotz et aI., 1990) (Christnick et aI., 1991).
Importantly, CT are effective against many immediate-early or early viral proteins which
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are trancribed prior to strctual proteins and vir assembly (Oldstone, 1989). Thus, the
abilty of CT to destroy latently infected cells is particularly usefu in the elimination of
these potential virus factories.
Since the increase in number of circulatig CD8+ lymphocytes during acute 1M correlates
closely with a rapid declie of EBV inected B cells in the peripheral blood, it was of interest
to identify the EBV encoded antigens recogned by cytotoxic T-cells which control the spread
of Epstein-Barr virs durg primary infection. To this effect, we studied the development of
virus-specific CD8+ lymphocyte responss in college students with acute infectious
mononucleosis. Following a prodromal period of several weeks, newly EBV infected patients
present with sign and symptoms of acute 1M and their peripheral blood contai greatly
elevated levels of activated CD8+ T cells which, like the memory CTL response to EBV, we
now know is HLA class-I restricted and directed at EBV latent gene products. Ou results
represent the first such description of the EBV -specific CTL responss in the settg of acute
infection, which wil be usefu in the rational design of an EBV vaccine.
Prima vs memory esponse . The medical interest in EBV is based up the
abilty of the virs to cause both severe acute infections as well as lymphoproliferative
diseases. The ai of the research presented here is to determine the origi of antigenic
peptides for the induction of EBV imunity by utiling vectors encoding individual EBV latent
genes. Thus, in searching for viral epitopes with relevance for the imune control of acute and
chonic EBV infection, we first gave consideration to the stage of viral replication durg
which the antigens which elicit protective CD8 T lymphocyte responses are likely to be
expressed. The criteria for defing imunodomit antigens of a large virs such as EBV
require the application of several fudamental principles, including (1) the generation of CTL
by natural in vivo inection followed by antigen-free propagation of sensitized CD8 T
lymphocytes with IL-2; and (2) batch testing of a defined panel of viral protein for their
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capacity to sensitize target cells to CTL-mediated lysis. Unfortuately, the importance of the
first principle is frequently ignored, which may lead to a false impression of the actual
imunodomiant T cell response to a pathogen.
Our results demonstrate that during primary EBV inection, the CTL-mediated response
is directed agaist all 8 latent proteins, including EBNA-1 (7 of 35 patients). To ou knowledge,
these results represent the first systematic analysis of EBV-specific CT durg acute 1M.
Importantly, with regard to vaccine development, greater than 90% of acute 1M patient CTL
, :
recognize one or more EBNA3 proteins, and a full 60% recogne EBNA-3C.
Ou data also show that 20% of acute 1M patients have CTL which lyse gp350
expressing targets. This fiding is not all that surriing given the high levels of virus
replication, and thus gp350 expression, durg primary EBV inection. Additionally, several
previous studies have verified the role of T cell in inbitig cells expressing EBV replicative
antigens, includig gp350 (Bejarano et aI., 1988) (Bejarano et aI., 1990). The most likely
explanation for the paucity of reported gp350-specific CT activity involves the methodology
us to generate activated CTL effector cells. Virtually all EBV-encoded T cell epitopes
defined to date have be identified using in-vitro re-stimulated memory CT rather than
strictly in-vivo activated EBV-specific CTL. Importantly, memory CTL lies generated by in-
vitro stimulation with the autologous BLCL are not exposed to gp350, as the major vir coat 1,,
glycoprotein gp350 is not expressed in latently infected B cells.
Ou results describing the memory CT respons to EBV are consistent with those
reported by other groups (Masucci et aI., 1993), and show that a given individuals CTL response
to EBV is typically a composite of reactivities directed against a variety of latent antigens. In
contrast to the priar cellular imune response to EBV, we found the memory CTL response to
be directed against a more restricted group of EBV antigens. While most CT responses were
directed againt the higher molecular weight nuclear antigens, EBNAs 3A, 3B, and 3C, CTL
also recogned EBNAs 2, and LP in addition to LMP-1 and - , albeit at lower frequency than
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the EBNA-3 family. Thus, while the EBNA-3 proteins were clearly imunodomiant here
also, an EBNA-1-specific memory response was observed in only one patient, and 11 gp350-
specifc CTL responses were detected, likely a result of BLCL-mediated stimulation (BLCL do
not express gp350).
Memory T cell responss to EBV were evaluated in 32 patients, only one of which
demonstrated measurable cytotoxic activity against EBNA-1 expressing targets. Curiously,
this patient did not demonstrate an EBNA-1-specific primary CTL response. Unfortunately,
this patient dropped out of the study for unown reasons and PBMC were not available 
conf these results. In a somewhat analogous situation, while many patients had very
similar primary and memory CT responses, a sigificant num of individuals demonstrated
only miimally overlapping primary and memory CT responss. These observed differences
may reflect a combination of in-vivo "affiity maturation , or more correctly, avidity selection
toward the imunodomit EBNA- family, which may be further promoted by re-
stimulation in-vitro with the autologous BLCL.
In general, the overall levels of lysis were typically greater in primary CTL assays as
compared to memory CTL assays, whie net lysis, or "specific lysis" was usually greater in the
memory CTL assays. We attribute this difference to the higher levels of background (non-
specific) lysis present in the primary CTL assays. Importantly, the same criteria for
determiation of signcant lysis were applied to both primary and memory CTL assays; ie. (1)
spontaneous 51Cr release .:25% (usually .:0% for most assays), and (2) specific lysis ;:10%
above background (V ac- TK) lysis.
As stated earlier, our findings are in keeping with the concept that the T cell response
to a given protein or pathogen is frequently foc m one to three epitopes (Adorini et aI.,
1988) (Perkis et aI., 1991), however, it is not known whether this imunodomice is a
reflection of unequal presentation of peptide/MHC complexes by inected cells, or strictly a
matter of TCR affinity for various Ag/:MC combinations. The discrepancy between ou
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measured primary and memory CT responss to EBV may be a reflection of the fiding that
changes in peptide antigen/MHC class-I density durg the cour of viral infections can serve
to modulate T cell responses. While, relatively strong CT responss may oc durg periods
of extensive expression and presentation of viral antigen, durg the later phases of imune
responses, CTL activity to a given antigen may be reuced as a consence of lower
concentration. This concept also applies to the role of CD8 in CTL recogntion, which shows an
inverse correlation with Ag/MHC density requirements (Shimonkevitz et aI., 1985). Here, the
selection of in-vivo protective memory CTL bearing very high avidity TCR can occu
independent of CD8, which allows for later recogntion of vir inected cells expressing low
levels of Ag/:MC complexes.
In addition to the quantitaive effects of Ag/:MC concentration m CT activation just
described, qualitative changes in Ag/MHC complexes have alo been suggested to influence CTL
activity (Matko et aI., 1994). While clustered HLA class-I molecules are readily detected 
activated nornal B and T cells, as well as B and T lymphoblasts lies, class-I clusters are absent
from restig Band T cells. This has be interpreted to suggest that activation induced HLA-
clustering may partially explain why both anti-viral and allo-specific CT are able to kill
lymphoblasts and virs tranformed cells more readily than restig lymphocytes. In this
context, it would be interestig to determine whether latency type-II EBV-tranformed B cells
have cell surface HLA-clusters while latency type-I EBV-transformed B cells in vivo, have
only HLA-monomers, contrbutig to imune evasion.
A num of more specific imune mechanms exist which may account for our
measured discrepancy between primary and memory CT responss to EBV. For example,
peripheral deletion of EBNA1-specific CTL may occu durg the exuberant primary CTL
response to EBV, which is plausible given that activated CD45RO+ T lymphocytes in acute
infectious mononucleosis lack bcl-2 expression and undergo apoptotic cell death (activation-
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driven deletion) (Uehara et aI. , 1992) (Tamaru et aI., 1993). In fact, during acute EBV infection,
the predomiant subset of cell in the peripheral circulation are CD45RO+ /CD8+ /bcl-
Importantly, many of these apoptosis prone, activated CT can be rescued from cell death 
addition of exogenous IL-2 to the in vitro cutue medium, resultig in increased expression of
bcl-2 (Akbar et aI., 1993). If EBNA-1-specific CTL do exist transiently durg the primary
imune response, exactly why they would be preferentially deleted later m remains unown,
but may be a result of the persistent and alost exclusive expression of EBNA-1 antigen by
latency type-I EBV-transformed B cells (covered in detail later).
In contrast to peripheral deletion, the CTL may persist in an anergic state, as suggested
by one group who has shown that with respect to anergy, many matue CD8+ T cell ini tiall y
proliferate extensively, and then die or beome anergic and remai refractory to TCR
stiulation, even in the presence of exogeous IL-2 (Rocha et aI., 1993). Additionally, it has
bee demonstrated that anergy is maitaied in vivo uness the inducig antigen is removed
(Ramsdell and Fowlkes, 1992), and that clonal anergy of matue T cell can be reversed in the
absence of antigen (Rocha et aI., 1993). A convicig example of this phenomenon involves an
experiment in which peripheral T cells from female anti-HY TCR trangenic mice are
transferred to syngeneic IU/IU male mice (Rocha and von Boehmer, 1991). The recipient mice
have 11 T cells of their own, allowing the behavior of the transferred T cells to be readily
studied. The HY-specific T cells, which recogn HY in the recipient males, initially
proliferate for five days followed by the dissappearance of most but not all cells. The
remaining HY-specific T cell are nonresponsive to TCR-mediated signals, even in the presence
of added IL-2. Thus, these cells become essentially unresponsive or anergic following an initial
antigen induced growth phase. Importantly, when the remaig anergic cells are transferred
back to female mice for prolonged periods of time (i.e. antigen free mice), HY responsiveness
retu, implying that persistent stimulation with antigen is requied to maintain this
nonresponsive state. Obviously, removal of antigen is an unlikely event for cells anergic to an
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authentic self-antigen. Thus it is somewhat perplexing that B7 transfection of self-tuors also
induces imunty to self-tuors lackig B7 (Chen et aI., 1992) (Townd and Allson, 1993).
Could this represent reversal of the anergic state? In this context, the persistent expression of
EBNA 1 in small, restig B cell following primary inection, may both induce and maintain T
cell anergy to this viral protein. The absence of B7 on latency type-I EBV tranformed B cells in
vivo makes the concept of EBNA-1 anergy induction all the more appealg.
In the settig of acute viral inection, the distinction between anergy and peripheral
deletion may not be necessar, as clonal anergy has been suggested to represent a prelude of the
,... :
contiuum leading to clonal elimiation (Kroemer and Martinez, 1992) (Schwartz, 1992).
Functionally, most form of tolerance probably represent clonal deletion, with or without a
i:.
preceeding proliferative phase, and in this sene, clonal deletion rather than anergy, may
"'
better explain the disappearance of EBNA1-specific CT activity following the primary
!' r; '-I
:ill'
response, especially in light of evidence suggestig that some anergied CD8+ clones retain
;::.
their cytolytic abilty (Otten and Germai, 1991) (Go et aI., 1993). Thus, durg TCR
",,.
recogntion of antigen, positive and negative signals mus be balanced in order to gude cell
survival or cell death, as imunologic memory against other EBV proteins is retained
);-.j!\",
following acute inection. At present, the mechanm which allows in vivo activated T cells to
,,,.  
retu to a restig state and survive is unown. One possible explanation has bee offered I"..
rt.V.I,
involving signaling through the B7/CD28 costimulatory pathway, which is analogous to the
,\.
survival of germinal center B cells following surface Ig crosslig by CD40 (Liu et aI., 1991).
Thus, how are the EBV-specific memory cell selected? One step toward answering 
question comes from evidence mentioned earlier indicating that the relative sensitivity of
CD8+ T cells to inibition with anti-CD8 mA provides a rough measurement of TCR affinity
for Ag/MHC (MacDonald et al., 1982). In general, most CTL recovered during the height of the
primary imune response are readily inibited by mAb to CD8, suggestig a predomiantly low
affinity CT response. Ths concept is also in keeping with ou results. In contrast to the
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primary response, the majority of CD8 T cell recovered several month following the initial
antigen prig are relatively resistant to inibition byanti-CD8 mAb. Accordingly, unlike
many of the CTL present durig the priary imune response to a virs, memory CT appear to
have higher avidity interaction with target Ag/:MC strctures, which fuction more or less
independent of CD8 (Hil et aI., 1992). However, in contrast to B cells, T cells do not undergo
affinity maturation by somatic hypermutation, but rather appear to matue by preferential
survival of CT bearing high affinity TCRs. Application of this concept to primary EBV
inection would suggest that the EBNA-1-specific CTL present durg primary inection merely
represent short-lived, low-affinity CTL.
The differences in TCR affinity of primary vs memory CTL described above, have a
direct bearing upo the interpretation of data generated using these effector cell populations.
Accordingly, one should consider whether it is correct to refer to lymphocytes prepared at the
end of the priar response to infectious virs as newly formed memory cells, or are they more
properly termed effector cells? In a review by J. Sprent, the author suggests the latter term of
effector cells is more accurate (Sprent, 1994). Likewise, lymphocytes recovered several weeks
after the primary imune response should be referred to as a mitue of effector and memory
cells. Here, one is confonted with the dilemma of phenotypically distingushing between
these two cell types. The difficulty arises because memory T cells display many of the surface
activation markers present on effector T cells. A rather popular theory invoked to explain this
phenotypic similarity would suggest that memory T cells actually represent semi-activated
cells engaged in low-grade responses to persisting antigen.
Currently, the debate over the importance of antigen in maitaiing long-term memory
remais unesolved. Direct evidence that memory depends m antigen persistence comes from
the reported rapid decay (days to weeks) in memory responss when primed lymphocytes are
transferred to antigen naive hosts (Gray and Matzinger, 1991) (Oehen et aI. 1992).
Importantly, antigen introduction into the naive host results in the maintenance of memory.
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Stil others, have suggested that the paradox of why CD45RO+ population contai the
pried/memory CTL pool yet expresses low levels of bcl-2 and are susceptible to apoptosis, can
be reconciled by the theory that contiuous restimulation of memory T cells is necessar 
increase bcl-2 expression (Akbar et aI., 1993). Equally convicig evidence that long-term
survival of CD8+ memory cell can occur in the absence of antigen comes from unpublihed data
by Jameson and Ahed (Sprent, 1994). The authors have demonstrated that LCMV-specific
CTL taken 3 month after antigen primg survive greater than 1 year following adoptive
transfer to LCMV naive mice, and show little or no decrease in prer frequency. Given th a t
the majority of evidence suggestig maitenance of memory requires contiued presence of jr'
primg antigen rests largely on studies with cells taken with 2 month of primg, it may be
J;,'
more accurate to suggest that antigen persistence appears necessary for the survival of
effector / early memory cells but may not be requied for long-term memory cell surival.
Similarly, Rocha et aI. have demonstrated that in the absece of antigen, anergic T
cell can persist for several month in recipient mice, which subsequently convert to functional
activity and behave like memory T cells (Rocha et aI., 1993).
The memory response to EBV includes CTL specific for al of the EBV genes expressed in
latently infected cells, with the exception of EBNAl. The generally accepted view to explain
this finding proposes that latency type-I EBV-transformed B cells in vivo serve as a
imunologicaly protected reservoir for EBV persistence and reactivation. What remains
unown is why these cell are noniunogenc. Consequently, cells which escape the tightly
restricted EBV expression characteristic of type-I EBV latency, proceed to type-II latency and
express a broader array of EBV latent protens which serve to restimulate and thereby maintain
the memory population of EBV -specific CTL. Based up the data contained in this
dissertation, one might extend this hypothesis to include the concept that type-I latently
infected B cells, which lack cell surface B7, serve as a constant soure of costimulator negative
EBNA1 antigen which maintain an EBNA1 nonresponsive state.
114
In order to explain EBV persistence, numerus investigators have speculated for over a
decade on the absence of T cell epitopes ecoded by EBNAl. The data in this dissertation along
with the recent description of an EBNA1-specific CD4+ CTL clone (Khana et aI., 1994) suggest
otherwise. We canot state with certaity the fate of EBNA1-specific CT present durg the
primary imune response to EBV, but this work does demonstrate the importance of
interpretig findings strictly within the context under which they are derived. In other words,
experients performed with in-vitro primed CTL have dicounted a role for EBNA-1-specific
CTL which may not accurately reflect in-vivo imune events. This message is nicely captured
in a review titled 'subversion of the imune system by pathogens' (Marrack and Kappler
1994), "we leared a lot about the properties of imunty to materials such as sheep red blood
cells
, ...
most of the principles that are the foundation of modern imunology were learned with
these models....however
, ...
in real life, most infectious organms have spent their milons of
years of coevolution with the imune system developing mechanms of manipulating the
system. The upshot is that 11 invading organm behaves exactly like a sheep red blood cell
and, if imunologits really want to understand how infectious diseases interact with their
hosts, they have to study the disease and host themselves. Artifcial substitutes simply wil
not do." In fact, the over-expression of EBV genes via vaccinia vectors fits right into this
category.
An appropriate example reflecting the accuracy of in-vitro models is the recent
demonstration of discrepancy between in vitro measurable and in-vivo virs neutralizing CTL
activity (Speiser et aI., 1992). The authors set out to determie the in-vivo relevance of T cells
exhibiting crossreactivity in-vitro and the respective role of the TCR affnities involved.
Analysis of high and low avidity T cell activities both in-vivo and in-vitro, demonstrated
highly specific class-I restricted CTL responses in-vivo and lysis of virus infected target cells
in-vitro. In contrast, these same CT were:MC crossreactive and less descrimatory against
targets expressing high :MC/ Ag densities (peptide pulsed) in proliferative assays. Thus,
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relatively high affinity TCR are required for virs neutralization in-vivo, while in-vitro T
cell responses to peptide coated targets involve engagement of low avidity TCR with broader
specificity, calling into question their biological relevance. One possible explanation for this
phenomenon involves the unphysiologically high concentration of peptides presented durg
in-vitro assays (Miligan et aI., 1990).
Importantly, the above results also demonstrate a correlation between TCR avidity and
the density of antigen/MHC class-I complexes. Ths is not surprising, given that the avidity 
T cells for their targets is a direct result of TCR and accessory/adhesio molecule interactions.
In fact, in-vitro measured CTL activities must be interpreted cautiously, as low avidity
TCR/:MC-Ag specificities may be detected under certai experimental in vitro conditions ::h
which are below the physiologically relevant threshold requied for in-vivo CTL fuction. ; 1 \"
Accordingly, whie it is possible that low avidity, crossreactive T cells provide some antiviral
Jj I
protectio in vivo, it is equally plausible that they merely represent biologically irrelevant,
in-vitro measurable T cell activities. Thus, knowing that :MC/ Ag density can inuence T cell
responses, we must at least consider this as a possible explanation for the EBNA1-specific CTL
activity measured in our in-vitro primary CTL assays. As stated earlier, CTL likely requie 1'
1'-..
more than 100-500 viral peptide-MHC class-I complexes for activation and lysis (Demotz et
aI., 1990) (Christnick et aI., 1991) and importantly, type-I latently-EBV-infected B cells in
-11
';\'
vivo express very few EBNA-1 molecules (10-20).
,"'
Low levels of EBNA-1 protein in-vivo may also promote imune escape as the degree of
CTL degranulation has been demonstrated to be directly proportional to peptide/MHC density
(Kane and Mescher, 1993). It appears that empty class-I molecules can also provide additional
CD8-mediated signalg required for T cell activation under conditions of either subthreshold
levels of anti- TCR mA or subthreshold levels of :MC/ Ag complexes. Thus, potential target
cells with low Ag/:MC density must provide additional costiulatory signal in order to
induce CTL degranulation, and these additional signals can be provided by "bare" :MC class- I
'''"
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molecues. This is particularly relevant to Burkitt's lymphoma cell and latency type-
I EBV
transformed B cell in vivo, which lack the costimulatory molecule B7 and have very 
low
levels of:MC class-I molecues m their cell surface (Masucci et aI., 1987) (Miyashita et aI.
1995). Thus, while Ag/:MC density may directly inuence CT responsiveness, it is equally
clear that costiulatory signals also play an important role (Jenkis et aI., 1990). Crossling
of the TCR in the absence of CD28 ligation by B7 stiulates T cell activation followed by
apoptosi . Importantly, B7 is expressed only on activated B cells (Clark and Lane, 1991), and is
not present on latency type-1 EBV inected B cells in-vivo.
Ou results demonstrate that the in-vivo activated CD8+ CTL present durg primary
,..
EBV inection clearly includes a large EBV-specific HLA-restricted component. Recent
 "
evidence suggests that the currently accepted understanding of the ultimate fate and 
fuction of
these in-vivo primed CTL may be incorrect. Traditional methods for generating EBV -specific T I'I\.
, J "
cell lies involves in vitro stiulation of memory CTL with the autologous BLCL. A relatively
frequent outcome of such effort is the generation of CT lies which proliferate in respons to
BLCL stiulation, but which do not lyse the 51Cr-labeled BLCLs in cytotoxicity assays (Hil et
aI., 1995). Importantly, superinection of the autologous BLCL used to stimulate the CTL, with
- .
"'c,
recombinant vaccinia virus encoding EBV nuclear proteins, confers susceptiblity to lysis by these
CTL. The authors of ths particular study have interpreted their findings to suggest that many
f-('
tJ"'
: .
or all of the "alloreactive" and other "nonspecific ally activated" CTL present durg acute
EBV infection, may after all be EBV-specific but require ths additional antigen to demonstrate
EBV-specificity in vitro. There is goo evidence to support this interpretatio which may
serve to explain why autologous BLCL do not competitively inibit lysis mediated by many of
the "nonspecific ally activated" CD8+ CTL present during acute EBV infection. We believe this
interpretation to be correct and support the authors contention that screenig for these CTL wil
likely demonstrate that the majority of activated CD8+ T cells present durg acute EBV
infection are in fact EBV-specific. Thus, one must remember that the usual procedures us 
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screen for EBV-specific CTL would preclude identification of CTL with this effector phenotype,
suggestig that published data m EBV-specific CTL should be considered incomplete. This
concept is particularly important here, as we have identified EBNA1-specific CT activity
present durg acute EBV inection which, with one exception, canot be demonstrated in the
memory CTL respons by the usual methods used to screen for memory CTL.
In contrast to the paucity of inormation m the specificity of viral antigen recogntion
by activated lymphocytes durg primary EBV infection (Strang and Rickion, 1987) (Strang
and Rickion, 1987), there is an abundance of inormation m the EBV-specific memory T cell
repons (Masucci et aI., 1993). In fact, in a recent review m cellular imunty to EBV, the
author states that "the early nonspecific respons to EBV-carrying imunoblasts that
characterize the primary infection is followed by the appearance of a persistent, specific T cell
imunty" (Masucci and Emberg, 1994). In this regard, Dr. Abul Abbas has suggested that
because B7 is such a potent stiulator for CD8+ cells, overexpression of B7 m activated B cells
may lead to T-lymphoproliferation of CTL which kil or at least inibit activated B cells
(Abbas, personal communcation). While there are clearly many activated CTL of unown
antigen specificty present durg acute 1M, ou data demonstrate that the primary imune
response is also EBV -specific, and in many respects ths broadly reactive primary CTL response
closely reflects the eventual, matured memory CTL response.
In ou work we did not evaluate the fine antigen specificty of individual CTL clones,
and thus we canot rule out the possibilty that the EBNA1-specific CTL activity we observed
with in-vivo activated CTL may represent allospecific CTL, which display cross-reactivity to
EBNAl. Many grups (Strang and Rickion, 1987) (Yang et aI., 1989), including 
(Tomkon et aI., 1989), have described the massive stimulation of allospecific CT durg
acute 1M, and likewise, many have described the simultaneous presece of EBV -specific CTL
during primar inection (Strang and Rickion, 1987). Similar experients in mure systems
have suggested that durg acute virs infection, viral peptides presented by self :MC may
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look like alloantigen to some CTL, resultig in the activation of low-avidity, virus-specific
CTL which cross-react to alloantigen (Nahil and Welsh, 1992). Additionally, allospecific
CTL which cross-react with viral antigen may playa role in the lysis of virus-inected cells
early durg infection, when viral titers are highest, and prior to the expanion of high
affinity, virus-specific CTL. That many of the early virus-specific CTL are of low affnity 
confed by a 50% reduction of vi inected targets byanti-CD8 (Nahil and Welsh, 1993),
suggestig low affity interaction dependent on CD8 accessory molecule interaction. Thus, it is
entirely possible that in-vivo-activated allo-specific CTL contrbute to the control of primary
EBV infection, and further that their TCR avidities are likely too low to sustai these cross-
reactive cells durg the higher avidity memory CTL respons. This phenomenon could
certainly explain the sequential disappearance of both allo-specific and low avidity, virus- I '
specific CT as the imune respons to virs inection subsides. Whether or not ou observed
EBNA1-specific CTL activity resides in such a low affity CTL population remains unown.
linical si ifican e of EBNA-1 e ression in mali ancies. EBNA1 is the only viral
protein consistently expressed in all EBV associated malignancies, and as yet there has be 
accepted/convincing demonstration of EBNA-1-specific CTL (Masucci and Ernberg, 1994). . :H
Clearly, evasion of any host CD8+ CT respons against EBNA-1 is essential to EBV
persistence. The most complete viral evasion mechanm described thus far involves the
establishment of tre viral latency, typifed by HSV and VZV, where infected host cells
contain the viral genome, but do not express any viral proteins (Marrack and Kappler, 
1994).
EBV utilzes a similar, though less complete mechanm of viral escape, whereby EBV
establishes a type-I latent state in B cells, characterized by tightly restricted viral gene
expression limited to EBNAl. Recent data suggests that the inabilty to detect EBNA1-
specific CTL lies in the inibition of antigen processing conferred by the internal Gly-Ala
repeat of EBNA1 (Levitskaya et aI., 1995). The authors suggest that this highly selective
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strategy of viral escape would favor the long-term persistence of EBV-inected cell without
inducing imunosuppression, thereby alowing for the maitenance of memory responss geared
toward suppressing the uncontrolled proliferation of EBV -transformed lymphoblasts. This
concept is in keeping with the long accepted view that resistance of cells expressing EBNA1 to
CTL-mediated rejection is a critical requirement for EBV persistence, yet it does not sufficiently
account for the lack of CTL mediated rejection of EBV positive Hodgki' s lymphoma or NPC
cells, which express two highly imunogenc viral proteins (LMP-1 and -2) in addition to
EBNA1 (Grasser et al., 1994). Thus, other imune escape mechanms must exist to account for
EBV persistence and the development of BL, NPC and HD in imunocompetent individuals
(Frisan et aI., 1995).
Eviden e a ain the tenc of EBNA- ic CTL. The search for EBNA1-
specific imunty has generated much scientific interest, and many believe EBNA1 does not
contai CTL epitopes. However, the majority of published studies have not be specifically
designed to identify EBNA1 CTL epitopes and thus much of this belief is based upo a lack of
evidence (Khana et al. , 1992) (Murray et al., 1992).
The earliest indication that EBNA1 may be a poor target for CTL recogntion came from
studies describing the abscence of CTL activity against Burkitt's lymphoma cells which
expressed EBNAl. Subsequent work in a mouse tuor rejection model demonstrated that unlike
LMP1, expression of EBNA1 did not confer imunogenicity to non-imunogenc mure
carcinoma lies (Trivedi et aI., 1991) (Trivedi et aI., 1994). These results have generally bee
interpreted to imply that EBNA1 would also be non-imunogenic in human.
Possible lanations for the re orted abscence of EBNA-1-s ecific CTL. It is entirely
feasible that the reported inabilty to demonstrate EBNA1-specific CTL activity is due to some
unown technical obstacle, resultig in repeated description of an "in-vitro artifact" For
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example, the us of BLCL to restimulate memory CTL likely favors the outgrowth of CTL
specifc for the imunodomiant EBV antigens, of which EBNA1 may not be included.
As mentioned above, recent data suggests the mechanm responsible for the absece 
EBNA1-specific CT may lie in the inibition of antigen processing conferred by the internal
Gly-Ala repeat of EBNAl. The Gly-Ala repeats encompas approximately one third of the
EBNA1 protein and the majority of the antibody respons to EBNA1 is directed against this
repeat sequence. In target cells generated by inertion of the EBNA1 Gly-Ala repeat into the
EBNA4 (EBNA3b) gene, target cell lysis by an EBNA4-specific CD8+ CT clone (epitope 416-
424) was reduced by an average of 50% over wildtype EBNA4, but never completely eliminated.
Similarly, independent overexpression of EBNA1 did not prevent recogntion of Vac-EBNA4
(3b) infected fibroblasts by the CD8+ CTL, but rather reduced lysis by 30-50%. Thus, the Gly-
Ala repeat in EBNA1 appears to reduce target cell lysis directed agaist protein contaiing
the repeat, but does not signicantly affect the the recogntion of other viral protein. While
this mechanism would liely reduce the potential for EBNA1 directed CT lysis, the levels of
lysis observed here agaist proteins contaig the the Gly-Ala repeat, correlate closely with
the levels of EBNA1 mediated lysis detected in ou studies (10-25% specific lysis at a MOl of
10:1). Thus, the Gly-Ala repeat of EBNA-1 is likely to be only partially responsible for the
lack of identified EBNA-1-specific CTL.
The complexity of events involved in foreign antigen processing and presentation to
CD8+ CTLs has provided DNA virses with ample opportuty to interfere with and prevent
viral antigen recogntion. A com mechanm employed by several DNA vires involves a
reduction in the synthesis of new :MC class I molecules. The adenovirs E1a product
downreguates :MC class-I heavy chain transcription (Paabo et aI., 1989), and the herpes
simplex virs VIl protein exerts a more general inibition of host cell protein synthesis.
Along these lies, down-regulation of HLA class-I molecules, by some unown mechansm, has
be proposed as another mechanm of EBNA-1 imune escape in Burkitt' s lymphoma cell
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lies (Masucci et aI., 1987). Similarly, downegulation of cell adhesion molecues LFA-3 and
ICAM-1 in EBV -positive Burkitt's lymphomas has been proposed to underlie tuor cell escape
from virs-specifc T cell surveilance (Gregory et al., 1988). Subsequent work has demonstrated
a major role for ICAM-2 in the recogntion of BL cells by CTL, with little if any contrbution
from BL-associated LFA-3 or ICAM-1 (Khana et aI., 1993).
Many vires have also evolved sophisticated mechanms to interfere with the
assembly and transport of peptide/MHC class-I complexes. For example, inibition of
TAP1/TAP2 transporter gene expression by adenovirs 12 prevents effective antigen
presentatio by reducig the delivery of peptides to the ER for bindig to class-I molecules
(Rotem-Yehudar et al., 1994). Similarly, Herpes Simplex virus-1 encodes an immediate-early,
cytosolic protein ICP47, which mediates its inibitory effects by blockig the delivery of
antigenic peptides to the site of Ag/:MC assembly, causing the retention and degradation of
empty class-I molecues in the endoplasmic reticulum (York et aI., 1994) (Hil et aI., 1995)
(Fru et aI., 1995). Many believe ths mechansm may be responsible for the overall paucity of
HSV-specific CTLs identiied thus far, and may help explain the predomiance of CD4+ over
CD8+ HSV-specific CTL observed in vivo. The notion that ICP47 represents an efficient
inibitor of CD8+ T lymphocyte responses in humans, and may therefore foster CD4+ responses,
is particularly intriguing given the recent description of a CD4+ EBNA1-specific CT clone
(Khana et aI., 1994). While the effector CTL used in our assays were predomiantly CD8+, we
did not specifically deplete CD4+ cells and accordingly the EBNA1-specific target cell lysis
observed in our primary CT assays could theoretically reflect CD4+ T-lymphocyte mediated
cytotoxicity. The description of this CD4+ EBNA 1-specific CT clone suggests that future
attempts to evaluate EBV-specific CTL should be performed with both NK (CD16) depleted,
and CD4+ depleted effector cell, and include cold target competition studies.
Interestingly, inibition of antigen presentation by ICP47 is species specific as well as
cell tye specific, as ICP47 does not inibit antigen presentation in HSV -1 infected murine cells
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and simlarly does not prevent antigen presentation in EBV -infected human B cells.
Discrepancies between results derived in humans and mice, such as with ICP47, serve to
remind us of the risks inerent in attemptig to extrapolate results from work in mice to that 
human systems. This issue is poignant here, as already mentioned, the inabilty to generate
EBNA1-specific CTL in EBNA- imuned mice (Trivedi et aI., 1991) (Trivedi et aI., 1994)
has bee interpreted to imply that EBNA1 would also be non-imunogenc in human. The
danger in makg this assumption is demonstrated by the described disparity in the
imunodomiant CD8+ CT response to mure CMV, which differs substantially from CD8+
human CMV response in terms of antigen specificity.
Similar to HSV, both human and mure CMV interfere with :MC class-I expression
and CTL recognition. Mure CMV achieves this via expression of an early gene which
specifically blocks the transport of peptide-charged :MC class I complexes to the cell surface
:1"
(Hengel et aI., 1994). Similarly, human CMV evades T lymphocyte recogntion by down-
regulating :MC class- expression via their retention and rapid degredation in the It,.I "
":V
endoplasmic reticulum (Beersma et aI., 1993). Despite these adverse effects m the class-
antigen presentation pathway, CD8+ CTL playa crucial role in the imune respons to both ::::d
HSV and CMV, highlighting the adaptabilty of the human imune system in overcomig
.'''1....
" '
complex obstacles presented by virses. Interestingly, the effect of this CMV early protein m
::,.
antigen presentation in mure cell can be overcome by IFN -y, which mediates a 25 fold
increase in the synthesis of MHC class I molecules.
Mutation of potential EBNA1 epitopes is unikely to playa role in explaining the
absence of EBNA1-specific memory CTL. While mutation of individual antigenic epitopes
recogned by CD8+ CT have be reported for EBV, it has only occu within a HLA-All
restricted EBNA-3b epitope, and confed to a geographic area where All is a very coon
allele among the population (deCampos-Lima et aI., 1993). In general, the EBV genome is
highly stable and antigenic drift is not considered to be a co nor significant factor in
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imune evasion by EBV.
Secreted viral proteins can also interfere with host imune responses. For example,
EBV encodes an imediate early gene BCRF1, which is homologous to human IL-lO (Hsu et aI.
1990), and has be shown to stimulate B cell growth, downregulate expression of the cell
surface B7 costiulatory molecule (Ding et aI., 1993) (Schandene et aI., 1994) (Wilems et aI.,
1994), and inibit the activation of CTL by suppressing macrophage activation and Th1
lymphokie production (deWaal-Malefyt et aI., 1991). IL-10 has also be shown to inhibit
IL-2 secretion by T cell clones and purified peripheral blood T cells following stimulation with
anti-CD3 mAb plus fibroblast associated B7 (deWaal-Malefyt et aI., 1993). Thus, IL-10 exerts
its effects m the imune response by both reucig the expression of B7 m APCs and by
inibiting some B7-mediated T cell activation events. However, IL-lO does not inibit the :r\
reactivation of memory CTL responses to BLCLs in-vitro (Bejarano et aI., 1992), suggestig tha t
the reported expression of th gene durg EBV lytic infection may target this mode of escape
to the replicative phase rather than the latent phase of EBV infection.
Lastly, a more general and potentially very important mechanm of imune evasion
by EBV-infected cell expressing EBNA1 involves the poor imunogenicity of restig B cells
which do not express the adhesion or costimulatory molecues necessar for the effective
triggering of EBNA1-specific CT (Miyashita et aI., 1995). Importantly, rather than
activatig resting T cells, resting B cells tolerize them to specific antigens (Parker, 1993) (Clark
and Ledbetter, 1994). Consequently, crosslig of CD28 m T cells by B cell-associated B7
prevents specific unesponsiveness or apoptosis that would otherwise oc following
stiulation of the T cell receptor (Harding et aI., 1992). CD28 is expressed m 80% of resting
peripheral T cells (Linsley et aI., 1990), and blockig CD28/B7 interaction durg antigen-
specific stimulation of T cells results in a state of antigen-specific T cell unesponsiveness,
which can prolong cardiac allograft survival (Lin et aI., 1993), induce tissue graft tolerance in a
pancreatic islet cell graft model (Lenschow et aI., 1992), and inibit T cell-dependent antigen-
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specific imune responses in vivo (Linsley et aI., 1992).
Ou re lts d onstrati EBNA- vity Evaluation of EBV-specific CTL
responses stiulated durg primary EBV inection in 35 acute 1M patients revealed EBNA-
specific responses in 7 patients (table 7). Effector cells, prepared from in-vivo primed PBMC,
were rosette selected with SRBC and depleted of NK cells by anti-CD16 mA plus complement.
Effector cells prepared in this maner were analyzed by FACS analysis and consisted of
predomiantly CD3+ /CD8+ /HLA-DR+ /CDllb+ /CD4- /CD16-. Additionally, the majority of
target cell lysis mediated by these effector cells could be blocked by anti-CD8 mAb and/or anti-
class-I mAb, while anti-CD4 mAb had little or no effect. These findings are consistent with the
presence of a population of EBNA-1-specific CD8+ CTL durg primary EBV infection, which
liely bear low affinity TCR and are almost uniformy absent from the higher-affinity EBV-
specific memory CTL population.
tegration of ou results ithin context of eviden e or h otheses in literature. Recent
evidence suggests that small, high-buoyant-density peripheral blood B cells represent the EBV
reservoir in healthy virs carriers. These B cells express only EBNA1 in the absence of other
known viral products (Chen et al., 1995), and are believed to maitai stable levels of EBNA1-
specific antibodies thoughout persistent infection. More importantly, we now have goo
reason to believe that the unique regions of EBNA1 represent potential target epitopes for CTL
responses, since they encode several pep tides capable of inducig expression of :MC class I
molecules in mure and human cell lies with defective transporters of antigenic pep tides
(Stuber et aI., 1995). Thus, published speculation that EBNA1 does not contain pep tides
capable of binding to MHC class-I molecules should be discarded.
The precise mechanm responsible for the apparent disappearance of EBNA 1-specific
activity following the acute phase of EBV inection remai unown, however this
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observation is not unque to EBV. Dug acute inectious mononucleosis, as with many primary
virs infections, the host imune respons must be regulated so as to minimze bystander
damage caused by over-exuberant responses. The practical implications of this concept mean
that variables influencing precursor frequency of memory cells must be well regulated. In order
to understand the factors inuencing the generation of imunologic memory cells, one must
consider certain aspects of the primary response, particularly the fate of the large num 
acutely activated lymphocytes. Under certai circutances clonal stimulation can lead to
tolerance, or conversely, to imunologic memory. In an elegant set of experients complete
antigen-specific CTL exhaustion was demonstrated by showing that when LCMV-specific TCR
trangenic T cells are transferred to LCMV -infected mice, the donor T cells undergo intense
proliferation followed by complete eliination of the donor T cells, leaving the mice
fuctionally tolerant without clearance of the virus (Moskophidis et al., 1993) (Moskophidis et
al. , 1994). Importantly, complete eliation of T cells only occured when cells were exposed to
high doses of virs. Lower doses of virs produced a more intense CD8+ proliferative response,
resulting in rapid virs clearance. Here, the authors suggest that virus may have persisted as a
result of such complete induction/exhaustion of specific antiviral CD8+ CTL that the virs was
not eliminated, and further that partially induced (protective) imunty and complete CTL
exhaustion (peripheral tolerance) represent quantitatively different points m the imunity
scale. Similar examples of imunty induced extrathymic tolerance via matue T cell
elimination have also be described (Webb et aI., 1990). Accordingly, we observed the
disappearance of EBNA1-specific CTL activity following acute EBV infection, which may
reflect either the induction of anergy or the peripheral deletion of EBNA1-specific CTL.
The cell surface concentration of antigen presented by APCs can also directly inuence
the outcome of TCR encounter with antigen, as was recently demonstrated in a trangenic mou
model (Ferber et aI., 1994). In this case, expression of miute amounts of :MC antigen m
hepatocytes induced tolerance by partial downeguation of TCR m self-rective CD8+ cells.
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Importantly, subsequent contact of tolerant T cells with high doses of MHC resulted in complete
TCR downreguation, suggestig that tolerant T cell are susceptible to further tolerogenic
signals, includig high doses of antigen/MHC complexes. Thus, if EBNA1-specific CTL are
present durg the primary imune response, and partially tolerized following contact with
B7-deficient type-I EBV-transformed-B cells in vivo, then the above mou model data would
suggest that subseent restiulation with high doses of BLCL-derived antigen in vitro may
drive the partially tolerant T cells further into a state of complete EBNA1-specific tolerance.
Another example of specific T-cell tolerance preceeded by a primary respons was
recently described by the Benacerraf lab (Vidard et aI., 1994), where they detected an early
primary T-cell respons in mice tolerized with Ova, prior to the establishment of Ova T-cell
tolerance. The authors of this work suggest that in vivo unesponsiveness can result from the
same experimental procedures us to grw T-cell lies in vitro, whereby, uness the cells are
allowed to rest after each stimulation, over-stimulation leads to unesponsiveness. They
further suggest that when a primary response preceeds secondar unesponsiveness, anergy
canot be invoked to explain the tolerance, as strictly speakig, anergy is defined as the
recogntion of antigen by cells lackig costimulatory molecules. Accordingly, the correct term
for tolerance described here is refractoriness, which describes the state of activated T cells that
have abandoned some or all of their fuctional activities. The fact that EBV persists for life 
type-I tranformed B cells in the peripheral blood of all healthy EBV-seropositive
individuals, suggests it may serve as a "constant source of EBNA-1 over stiulation , leading to
EBNA-1 unresponsiveness. In our opinion, the persistent presentation of EBNA-1 by quiescent B
cells, lackig the B7 (CD80) molecule, is unlikely to result in overstiulation of CTL. However
the impressive T-lymphocytosis present during acute 1M suggests that overstiulation would be
more liely to occur durig primary EBV infection as opposed to convalescence.
Simar to the discrepancy between primar vs memory CTL responses to EBV described
in this dissertation, a group from Louisiana has reported preliminary evidence describing a
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HSV -1 epitope-specific CTL population present at high frequency durg primary infection
which is absent from the memory response (Nugent and Jenngs, 1994).
rtance of identif EBNA- TL anti for accine ment. Latent EBV
inection represents an important model to study vaccines for human cancers as vaccine
development for virus-associated tuors is strategically simpler than attemptig to identify
protective tuor antigens in tuors of unown etiology.
The development of successfu vaccines for human vir infections is based up 
understanding of the effector cell and imune mechanms required to provide the host with 
protective respons to acute infection and which promote memory responss to provide
protection durg persistent viral infections. Additionally, there is now increasing interest in
the use of CTLs to destroy tuor cell in vivo. In ths context, the identification of imunogenc
EBV antigens offers the potential for designg vaccine based imunotherapy against EBV
associated malignancies. The significance of identifying EBV CTL epitopes is underscored by
the description of EBV peptide epitopes which sensitize Burkitt's lymphoma cells to lysis by
EBV-specific CTL (Khana et aI. , 1993). However, if CT therapy is to be fully exploited in
the treatment of the diverse array of EBV associated malignancies, then we must first strive 
understand why a given individual CTL response is unable to destroy tuor cell. For example,
is there a deficiency of relevant CTLs, or has the virs modifed the tuor cells in such a way
that relevant antigens now deliver inibitory signals to inactivate potentially protective
CTLs.
The primary benefit of an EBV vaccine for Western societies would be to prevent the
symptoms of acute inectious mononucleosis. Ths very realistic goal doe not requie that the
vaccine induce sterile imunity, but rather produce a population of memory cells which would
limit virs replication and spread durg primary inection. An equally important, though
currently less achievable goal of an EBV vaccine, would be to prevent the establishment of
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latent EBV infection, since the majority of EBV associated malgnancies develop several years
after primary infection. The contiued addition of newly recogned EBV-associated tuors
including gastric carcinoma and adult T cell leukemia lymphoma this year, suggest the list 
not complete. Accordingly, patterns of EBV gene expression in association with diseased tissue
and specific T cell responses to EBV antigens in these patients wil be needed.
Ou analysis of the imunodomit T cell response durg primary EBV infection
suggests that an effective EBV vaccine necessarily include at minum, all thee proteins in the
EBNA-3 family, and also the lytic cycle protein gp350. Ou work has demonstrated that
greater than 90% of patients with acute 1M have CTL which lyse target cells expressing on or
more of the EBNA3 protein, suggestig that such a vaccine would be expected to protect the
majority of individuals. Whle only 20% of acute 1M patient CTL lyse targets expressing gp350,
we feel it should be included in any potential EBV vaccine, based in part on some compellg in-
vivo evidence generated by other groups. Imunation of marosets with mA affinity-
colum purified gp350 doe not protect against EBV in spite of high virus-neutralizing titers
(Epstein et aI., 1986), suggestig that in addition to neutralizing antibody, other imune
mediators, such as CTL, are requied to prevent the development of EBV -associated I '
I.,;
lymphomas. In order to overcome some of the observed variations in imunty induced by
various gp350 antigen preparations, the gp350 gene was inserted into a vaccinia virs vector 
allow for the homogeneous expression and post-translational processing of this glycoprotein.
" ,,
Curiously, the gp350 vaccinia constrct did not induce EBV-neutralizing antibody but did
protect cottontop marmosets agaist a lymphomagenic dose of tranformg EBV (Morgan et al.
1988). Ths unexpected finding clearly suggested the need to exame the cell mediated imune
response against this major EBV glycoprotein. Thus, it would be prudent to more completely
define the primary CT response to gp350 in acute 1M patients. The potential benefits of
including EBNA1 in an EBV vaccine remain uncertai, and may require removal of the Gly-Ala
repeat, but wil surely require more in vivo studies.
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Convincig evidence that mior CT reactivities, in addition to the imunodomiant
CTL response, may play an important role in the imune protection againt virses was recently
provided by Oldstone et al (Lewicki et aI., 1995). When the viral genomic seuence encodg
the imunodomit CTL epitopes of LCMV is mutated, the CT response is shifted toward
novel virs epitopes not previously recognzed. The authors have suggested that CT epitopes
typically form a hierarchy, in which responses to "weak" epitopes are suppressed in the
presence of "stronger" epitopes. Thus, mutation of the domiant epitopes may be of limited
advantage to a virs, since the host can then mout a protective response directed against the
weaker T cell epitopes.
The rational design of an EBV vaccine must also incorporate new evidence that EBV
protein other than latent genes may provide signficant CT epitopes. Cytotoxic T
lymphocytes specific for the immediate-early transactivator ZTA (BZLF1) have recently bee
described (Bogedai et aI., 1995). This fiding is particularly important as CTL directed I"M
against this protein have the potential to eliminate EBV-latently infected cells at the earliest
stage of switch to lytic cycle replication. Oldstone et aI. have suggested just such an early gene-
based vaccine approach to prevent persistent viral infection (Oldstone et aI., 1993). Evidence
, ,
suggests that EBV transformed B cells in vivo, which phenotyically represent type-1 latency,
. .
can undergo ZTA-mediated switch from latency to virs replicatio , in the absence of other
II, 
' "
latent gene expression (Rowe et aI., 1992). Additionally, ZTA has be detected in small
. ,
num of tuor cell in EBV-associated Hodgki' s disease, EBV-associated non-Hodgki'
lymphomas in AIDS patients, and posttransplant lymphoproliferati disease (Pallesen et
aI., 1991). Accordingly, ZTA-specific CTL activity should be sought in a broader base of
patients and the ZTA protien should be carefully considered for inclusion in any EBV vaccine.
The significance of B7 costimulation in tuor imunty is undersored by the
demonstration that nonunogenc tuors beome imunogenc following transfection
mediated expression of the B7 gene (Chen et aI., 1992) (Townd and Allson, 1993). In fact
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one grup has suggested that contiued TCR stimulation by foreign antigens presented m or
released from tuors in the absence of adequate costiulation, by molecules such as B7, will
suppress tuor imunty (Helltrom et aI., 1993). Thus, this phenomenon may account for the
abscence of reported EBNA1-specific memory CTL and may also explain why LM1+ /LM+
NPC tuor cells can grw in imunocompetet hosts. This concept is potentially important,
since EBV expresses an IL-10 like molecue which has be demonstrated to prevent B7 up-
regulation m IFN-y-activated human monoces (Wilems et aI. 1994), and mure
macrophages (Ding et aI., 1993). Importantly, the majority of human tuors do not express B7,
and mice which have rejected B7-transfected tuors acquire the capabilty to mediate rejection
against wild type tuors lackig B7. Moreover, the newly acquired tumor-specific respons is
mediated by CD8+ CTLs (Harding and Allson, 1993). Thus, B7-mediated CD28 costimulation
provides an attactive approach to enhance tuor imunity. Unfortuately, transfer of B7 into
nonunogenc lymphomas does not always induce an effective T cell respons (Chen et aI.
1994). This is not completely unexpected, as naive T cells respond best to costimulatory
molecules when expressed on the same cell as the TCR ligand (Liu and Janeway, 1992), and only
cells which express costiulatory molecules can effectively activate naive T cells. Ths would
suggests that when T cell encounter antigen on B7 negative cells, they are likely to be rendered
anergic, even if B7+ cells are also present. Evidence that T cell tolerance to EBNA1 could be
maintained in vivo, in the presence of B7+ BLCLs, comes from the demonstration that T cell
tolerance to myelin basic protein is maintained in the presece of costiulation provided by
transfectants which expresss high levels of B7 (LaSalle et aI., 1992). Ths phenomenon is
likely very important in maitaining tolerance to other self-tissues, as it allows active
costimulatory cells to coexist with costimulator-negative cells expressing self-antigens not
found in the thymus, where strongly self-reactive T lymphocytes are eliminated (Nossal,
1994). If th concept is correct, then on would predict that CD8+ EBNA1-specific CTL would
be rendered anergic by the in-vivo pool of B7- EBV -infected B cells present during convalescence
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(Miyashita et aI., 1995), and maintain tolerance to the phenotypically activated, EBV-
transformed lymphoblasts expressing high levels of B7. These findings have potential
therapeutic implications for B7- EBV-associated tuors and may provide an approach to
achieving sterile immunity against EBV (Roitt, 1994).
As recently suggested by Thorley-Lawson et aI. , in order to constrct a relevant model
for EBV latency in vivo, it is necessar to know whether EBV-infected cell are
lymphoblastoid or resting. In fact, EBV -infected cells in the peripheral blood are
predomiantly ().95%) CD19+ /CD23- /CD80- (B7-). Accordingly, when TCR engagement is
accompaned by a costimulatory signal, a T cell wil prolierate and differentiate, whereas the
absence of costimulation usually results in anergy or cell death. Thus, encounter with antigen
can lead quite distict outcomes, proliferation and differentiation vs inactivation or death
depending upon the natue of costiulatory signals.
clas I restri ion elem nts. The recogntion of viral peptides by CD8+ CT is
restricted through :MC class-I molecues m inected cells. Additionally, a given peptide
tyically associates with certain MHC molecules in accordance with amino acid sequence of the
peptide and the properties of the :MC peptide binding site. In this regard, many EBV
peptide/HLA class-I molecule pairs have be identified, which allow comparon with our
data. Of the nie patients who lysed EBNA2 expressing targets, 7 (78%) carry :MC class-
alleles previously demonstrated to be restriction elements for EBNA2 (Masucci et aI., 1993)
(Lee, 1994). Other alleles present in high frequency of EBNA2 specific CTL include A1 (44%),
and B40 (33%). Similarly, 18/22 patients (82%) recogng EBNA3A share previously
identified class-I restriction elements. Interestingly, two of the other 4 patients carried the
All allele, and all 4 patients carrying the All allele recognized EBNA3A. Importantly, All is
particularly rare among the general U.S. population (3%). With regard to EBNA- , only 6/20
(30%) 1M patients carry :MC class-I alleles previously described as restriction elements for
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EBNA-3B (All and B8). However, all patients carrying the All allele recogned target cells
expressing EBNA-3B. Our data suggests that other possible restriction elements include A2, A3
and B40 which were present in 13/14 (93%) of the All-/B8- patients who 
recogned EBNA-3B.
Interestingly, subsequent to ou findings, A2 has be described as a restriction element for
EBNA- , carried by 6 of ou patients, brigig the percent of patients with known restriction
elements to 12/20 (60%). Of the remaiing 8 patients, seven (88%) carry either A3 or B40
alleles. In patients who recogned EBNA-3C, 27/29 (93%) carried MHC alleles which have
been reported to serve as restriction elements for EBNA-3C. Amazingly, 11 of 13 patients (85%)
with the A2 allele recognize EBNA-3C, and 8/10 (80%) of HLA-B7 patients recogne EBNA-
3C, suggestig a preference for EBNA-3C epitopes by the A2 and B7 allelels. EBNA-
restriction elements have not be described, although ou data did show a higher than
expected prevalence of the B7, B13 and B39 alleles. Four of five (80%) patients recogning
LM1 carry previously defined restriction elements A24 and B40, and significantly, 
60% also
carry the A28 allele. In fact, virtually 100% of patients recogng LM1 carried either the
A28 or B40 alleles, or both. Thee of five (60%) of patients carry restriction elements described
for LMP-2 (A2) while no other alleles were obviously domiant. Class-I restriction elements for
gp350 have not been described, however, of the 7 patients in ou study who recogned 
gp350, 5
were HLA-typed, 3 of which (60%) carried the A2 allele. Similar to gp350, 11 class-
restriction elements for EBNA1 have been described.
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Summ of Previousl Defined MIC Class-I Restrction Elements for EBV E ito
EBNA1 EBNA2 EBNA3A EBNA3B EBNA3C EBNALP LMP1
HLA
+++
All
+++
A24
++++++
B18
B27
B35
B39
B40
B44
B51
B55 :lll
- : No CTL response at clonal or polyclonallevel in any donor.
+ : Weak CTL response in some donors.
++ : Strong CTL respons in polyclonal culture and rare clones in some donors.
+++ : Strong CTL response at polyclonal and clonal level in all donors tested.
Prom: (Masucci et aI., 1993) (Masucci and Ember!?, 1994) (Lee, 1994) (deCampos-Lima et aI., 1996) I';
I, 
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Phenotype of effect r cell . The hallmark of imunologic memory 
is the abilty of
lymphocytes to respond more quickly, specifically, 
and with greater magntude up seond
exposure to a given antigen. Accordingly, the goal of vaccination is to prime the imune system
to make anamestic responses against inectious pathogens. Unlike memory B cells which
undergo somatic hypermutation, memory T cells do not participate in "affinity maturation
" of
their TCRs (Vitetta et aI., 1991). Thus, other less specific means of distinguishing memory from
naive T cells have evolved, based primarily upo the differential expression of cell surface
molecules involved in T cell adhesion and activation. CD45 is one well studied surface molecule
used to distiguh memory and naive T cell in human. The CD45RA molecule on naive T 
cells
(200-220 kDa) undergoes alternative RNA splicing to produce the lower molecular weight form
(CD45RO) present m memory T cells (Akbar et aI., 1993). Ths distiction is supported by the
fidig that human CD8+ /CD45RO+ memory CTL have less strgent requiements for in vitro
activation than naive CD8+ /CD45RA + T cell (DJong et aI., 1991). To complicate the simple
scheme of CD45RA and CD45RO markig naive and memory T cells respectively, reversal 
CD45R isoform switching has been demonstrated in CD8+ T cell (Fuji et aI. , 1992). Thus, with
the possible exception that CD8+ /CD45RA- T cells are primed, there are 11 other generally
accepted phenotypic cell surface markers that distinguish memory from virgi T cells. In fact,
most markers associated with memory are activation markers (Akbar et aI., 1991), or adhesion
molecules (Cerottoni and McDonald, 1989) (McFarland et al., 1992). The significance of altered
adhesion molecue expression on memory T cells can be appreciated by understandig that this
process increases the affiity of T cells for antigen presentig cells. By analogy with memory B
cells, which increase antigen bindig affinity through somatic mutation of their receptors,
memory T cell may alter adhesion molecules to accomplish the same goal of higher affinity.
In this context, it is important to point out that some authors have suggested that memory T cell
responss in-vivo requie periodic restimulation with the original primg antigen for
maintenance, and thus may actually represent sub-optially stiulated effector cells (Gray
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and Matzinger, 1991). However, other groups have argued that re-xposure to virus or antigen
is not required for the maitenance of memory CD8+ T cells (Ahed, 1992) (Mullbacher, 1994).
integrins such as Mac-1 (CDllb) and LFA-1 are extremely versatile adhesion
molecules, which both bind ICAM-1 and can be rapidly modulated by the cells expressing them.
Importantly, some very convicig data suggests that CDllb represents a marker for CD8+
cytotoxic T cell activation and memory durg virs infection (McFarland et aI., 1992). The
authors have shown that CDllb is present in high levels (- 50% of CD8+ cells) m activated
LCMV-specific CTL durig acute infection, and that depletion of CDllb+ T cells results in the
inabilty to mediate in vitro secondary LCMV -specific responses. Futhermore, virtually all of
the virs-specific killing was mediated by the CD8+ /CDllb+ cell poulation. Ou results
support these findings and show that while CD8+ /CDllb+ T cell comprise only 5% of healthy
donor peripheral blood lymphocytes, levels of CD8+ /CDllb+ T cells in peripheral circulation
rise by 8-12 fold (40-60%) during the peak of the EBV-specific CTL response. In fact, 50-85% of
CD8+ T cells coexpress CDllb durg primary inection with EBV. In contrast to the LCMV
model, where expression of CDllb by CD8+ splenocytes declined to near naive levels by day 19-
20 p.i., the percentage of CD8+/CDllb+ T cells in the peripheral blood of acute 1M patients
remained markedly elevated at 6 weeks p.i., and had only declied to near naive levels by 6
month. The longevity of CDllb expression by CD8 imune lymphocytes also differed from the
T cell activation marker HLA-DR, which peaked durg the acute phase of primary EBV
inection and was reduced by 50% at 6 weeks p.i. In ou hands, CDllb is quickly lost durg in
vitro culture (4-5 days), and thus, as has already be suggested, CDllb may be the single best
in-vivo marker to identi memory CTL. The following model depicts a scheme for identifying
memory and naive T cells bearing various cell surface markers.
I'II'
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Pevelopment of T cell memory
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Model of T cell memo based upon work of Mueller, Jenkns and Schwarz. Antigen
specific T cells expand prior to entering the state of anergy, which occurs about one
week post antigen stimulation. The reason certain signals induce anergy rather than an
effector response and memory generation is unclear, but the triggering of T cells in the
absence of costimulator signals is believed to contribute substantially to th
development of anergy.
Mueller L. Jenkins, M.K. Schwartz, R.H. (1989) Clonal expansion versus function 
inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen
receptor occupancy. Anu. Rev. Imunol. 7:445-480.
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The fuction of human CDllb (Mo-1) remains unown, however, it is interestig tha t
the adhesiveness of mure CDllb (Mac-1) can be increased by activation of neutrophis with
formyl-peptide, and expression can be increased 10 fold by specific chemoattractants.
Changes in Mac-1 adhesiveness are thought to be mediated by conformational changes induced
durg cellular activation, suggested by changes in mA reactivity with Mac-1 following
activation (Diamond and Springer, 1993). Similar affinity measurements of the cell surface
integrin LFA-1 have recently demonstrated that cellular activation increases the affinity of a
subpopulation of LFA-1 molecules for ICAM-1 by approxiately 200 fold (Lollo et al., 1994).
The importance of integrin/ adhesion molecue expression for CT fuction is
highlighted by work demonstratig that in vivo cytotoxicity of CD8+ T clones correlates most
closely with their levels of adhesion molecule expression (Rodrigues et al., 1992). In fact, anti-
malarial protective and nonprotective CTL clones do not differ in their fine epitope specificity
or pattern of lymphokie production, but rather in their levels of CD44 and VLA-4 expression.
Not surprisingly, the clones also differ in their adhesive properties, and while cross-linkig of
CD44 can induce LFA-1-mediated aggregation of protective clones, the nonprotective clones fail
to aggregate.
Thus, it would not be uneasonable to propose that CDllb may fuction as an adhesion
molecue to strengten cell-cell interactions, and it may be informative to determine the
relative contribution of CDllb to CD8 CTL/target cell avidity, possibly through the us anti-
CDllb mAb. Accordingly, one can only speculate on the possible effects of CDllb loss durg in-
vitro CTL cultue, and any potential signficance to target cell lysis. However, ou cuent
understading of CDllb suggests that anti-CDllb depletion studies would likely conf the
important role of CD8+/CDllb+ CTL in the long-term imune surveilance against EBV.
In o growth of EBNA- spec CTL. It is our opinon that many investigators have
prematurely come to the incorrect conclusion that the EBNA1 protein contain 11 CT epitopes.
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This conclusion is based primarily up data generated with CT restimulated in-vitro using
the autologous BLCL. Current understanding of antigen recogntion by cytotoxic T cells entails 
multimolecular interaction involving the TCR, antigen, :MC molecule, CD8, B7, CD28 and an
ever growig list of adhesion and activation molecules, all bathed in a plethora of
lymphokies. We know that antigen recogntion by TCR does not always result in T cell
activation. In ths sense, it is antigen context (ie. costiulation) which regulates the threshold
for discrimating self vs foreign antigens. Thus, given that EBV has evolved to establish a
dynamc equilbrium consistig of multiple phenotypic form of latency, each of which
differentially affects B cell phenotye, should we not expect multiple outcomes from antigen
recogntion? Simarly, should we expect in vitro stimulated CTL, exposed only to BLCL cells
expressing high levels of activation and adhesion molecules, to recogn an antigen, which in
vivo, is expressed in quiescent B cell lackig all adhesion molecules and all but a few 
MHC
class I molecules? While stimulation of EBV-specific CTL with BLCLs has the potential 
provide valuable inormation m the imune recogntion of phenotypically similar EBV-
positive imunoblastic lymphomas, one should not expect this to accurately represent T cell
recognition of type-I EBV-transformed B cells.
Shortly following our origial description of EBNA1-specific CTL present durg acute
1M (Beaulieu and Sullvan, 1994), a second group described a CD4+ CTL clone which recogned
the EBNA1 antigen (Khana et aI., 1994). The authors were seekig to specifically identify
EBNA1 epitopes, and discovered a CD4+ CTL clone which recogned targets coated (0.1 Jlg/ml)
with a class-II restricted (HLA DR1) peptide from EBNAl. The clone was however unable to
lyse EBV infected BLCLs and Vac-EBNA1 infected B cells. Precor frquency analysis
demonstrated the presence of significant num of memory T cells specific for this EBNA1
epitope. In our analysis of 32 convalescent 1M patients, we identified only one EBNA1-specific
memory CTL response, which we were unable to reproduce due to a lack of additional blood
samples.
11" "
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We were alo unuccessfu in our attempts to selectively stimulate and expand EBNA1-
specific CT from the peripheral blood of EBV imun donors using aldehyde fixed APCs.
While stimulation of acute 1M patient (Levro) PBMC with Vac-EBNA1 initially increased
EBNA1-specific lysis by 12.5%, subsequent stiulation favored a Vaccinia-specific response.
Curiously, this vaccina-specific CTL response was observed in several vaccinia naive patients.
Cold-target competition assays confed the vaccinia specificity, and FACS analysis of the
effector cells in one patient demonstrated a predomiance of y'O T cells. Our data do not allow us
to determe the phenotype of cells responsible for the EBNA-1-specific activity initially
present in ths culture, and thus one might consider implicatig the y'O+ T cell.
In this regard, y'O+ T cells are often detected at sites of viral infection and are believed
to participate in host defense (Born et aI., 1991). In contrast to a. + T cells, which are highly
specific effector cells with enormous diversity for antigen recogntion, y'O+ T cells represent
effector cells with lited diversity for antigen recognition. Many y'O+ T cells recogne targets
expressing heat shock proteins, which includes a broad array of cells, includig virs infected
cells. However, target cell recogntion by y'O+ T cell is usually not restricted by classical :MC
antigens (Sciamas et aI., 1994), and anti-class-I mAb failed to block the y'O-mediated lysis.
One possible explanation for our results comes from the fiding that various
costimulatory molecules have different sensitivities to aldehyde fixation (Jenk and
\:.
Schwartz, 1987). While B7.2 costiulation is significantly eliminated following fixation, B7
is apparently relatively insensitive (Freeman et aI., 1991) (Freeman et aI. 1993).
Additionally, ICAM- costiulation is eliminated by paraformaldehyde fixation.
Accordingly, the costiulatory capacity of native APCs is significantly greater than that of
chemically fixed APCs and should be accounted for in the interpretation of results generated
using fied APCs (Moreno and Lipsky, 1986). Importantly, Harding and Allson have recently
shown that anti-CD28 mA can provide the necessar costimulatory signal to CD8+ T cells,
when the costiulator capacity of stiulator cells is destroyed by aldehyde fixation (Harding
;'1' 1' ..
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and Allson, 1993). Th indicates that while fixation destroys the costiulatory capacity of
APC, it does not affect the integrity of the antigen-specific signal (Harding et aI., 1992). Thus,
perhaps the addition of anti-CD28 mA to ou EBNA1-expressing aldehyde-fixed APCs may
have altered the outcome in our attempt to restimulate EBNA1-specific CTL in-vitro.
That target cell phenotype inuences CTL recogition was nicely demonstrated by
measurg the differentiation dependent sensitivity of human B-cell-derived lines to MHC-
restricted CTLs (Torsteinsdottir et al., 1986). The sensitivity of in-vitro EBV-infected Burkitt
lymphoma lies showed a direct correlation with cell surface phenotype. EBV inected B 
lines which acquired BLCL-like characteristics became sensitive to CTL, while BL which
retained their origial BL phenotype remaied insensitive to CT lysis. This work set a
precedent for establishig a lik between BL cell phenotype and the accompanyig pattern of
EBV latent gene expression (Rowe et aI., 1987), and also applies to normal B cells (Rowe et aI.
1992). Importantly, ths same grup also described experiments in which early passage EBV +
BL lies were not lysed by MHC-matched EBV-specific CTL. The authors concluded that the
finding could not be explaied by altered expression of HLA class I antigens, but in several cases
did correlate with altered latent gene expression. However, reduced latent gene expression
could not explai all cases of BL imune escape, as several BL lines which expressed all latent
genes remained insensitive to EBV-specific CTL, likely due to reduced adhesion molecule
expression.
The relative contribution of low adhesion molecule expression to imune evasion by BL
cells was evaluated in a peptide sensitization assay involving a phenotypically diverse grup
of BL cell lines (Khana et aI., 1993). Despite reduced levels of the adhesion molecues LFA-
LFA-3, and/or ICAM-1, peptide-sensitized BL cells were recognized and lysed by EBV-specific
CTL. Ths data suggests that when suffcient antigenic peptide/MHC complexes exist, the
reduced expression of adhesion molecules alone wil not account for the lack of BL cell lysis by
EBV-specific memory CTL. Furthermore, mA blockig experiments designed to evaluate the
II .
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individual contribution of various adhesion molecues in CTL recogntion suggested that 
EBV-
specific memory CTL recogne BLCL and Burkitt's lympho
cells differently. While EBV-
specifc CTL recogntion of BLCLs was dependent on LFA-3/CD2 interaction, CTL recogntio
peptide-sensitized BL cells was absolutely dependent m LFA-
1jICAM-2 interaction, with
little if any contribution from the LFA-3/CD2 pathway. Importantly, all of 
the BL cell lines
evaluated in this study consistently expressed high levels of cell surface ICAM-
2. Thus,
downregulation of LFA-1, LFA-3 or ICAM-1 m BL cell does not appear to provide an absolute
barrier to tuor cell lysis by virs-specific CTL, though it may prevent 
recogntion of EBV
transformed B cells in-vivo with a latency tye -1 phenotype.
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Table 1. Summary of Patient Information:
Donor Date of Infectin Sta e of MHC Class-
Name Birth EBV Strain Infection
Alar -: 1965 Convalescent A26 A31 B35,B38
Alba 04/26/7 5 type- I Acute 1M A28,B8,B40
Arach 10/16/60 Acute 1M A3,A24,B7,B35
Aumr 03/08/74 Acute 1M A30,B27,B40
Belch 11/14/73 type- Acute 1M A34 B51,B53
Belk 07/17/70 type- I Acute 1M A1, B35,B49
Blabo 09/28/74 Acute 1M A3 ,A32,B 14 B40
Blabr -: 1965 Convalescent A28,B27,B40
Borth 03/03/7 5 type- I Acute 1M , B18, B39
Busjo 12/28/71 Acute 1M A3, B40
Clia 02/28/7 5 type- I Transitional , B13, B18
Conia 08/23/74 type- I Acute 1M
Cort 02/10/73 Acute 1M
Croma -: 1965 Convalescent A3,A24 B7,B62
Delsa -: 1965 Convalescent A11,A34 B44 B62
Dowda 09/02/75 type- Acute 1M A24,A28 BI4 B39
Friie
----------
type- I Acute 1M A24 B44 B55
Gowad 11/25/75 type- I Transitional B40 B62
Hale 08/09/69 Acute 1M A28, B41 , B40
Hesru -: 1965 Convalescent All B55
Kaa 10/14/74 type- I Transitional A2,A29,B39,B62
Kowre 03/01/71 type- I Transitional A2,A3,B7,B44
Lana -: 1965 Acute 1M Al,A25 B8,B18
Levpa 02/28/72 type- I Acute 1M All ,A30,B52
Levro 02/12/73 type- I Acute 1M Al,A24,B7,B38
Mooch 03/02/73 Acute 1M A3,B8,B14
Maro 06/08/70 Acute 1M A3,AI9, B40
Mar 08/29/71 ype- I Acute 1M A2,B7,B45
Maz 12/13/73 ype- I Acute 1M A23, A24 , B49
Mckm 11/24/71 ype- I Acute 1M , B8, B14
Nicdo 12/20/72 ype- I Acute 1M A28, BI4
Porwi 02/08/7 5 ype- I Transitional , B27 , B40
Ptaba -: 1965 ype- I Convalescent A26 B 13,B38
Ronch 07/12/75 ype- I Transitional A3, B13
Saran 03/17/75 :ype- I Acute 1M A24 A28,B44,B51
Shech 07/15/74 type- I Acute 1M A2,A24,B7,B44
Stuie 09/16/70 type- I Transitional , B7, B55
Suljo - -: 1965 type- I Convalescent A29,A32 B40 B44
Tavio 04/20/7 5 type- I Transitional A28, B53
Trajo 07/31/74 Acute 1M All , A33, B35
Wilph 11/28/70 type- I Acute 1M A2,A32 B27,B44
Yake 07/13/72 Transitional A30 B13,B44
* n. d. = not determed.
I" !
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Table 2. Established Cell Lines and Corres ondin MHC Class-I Ha es.
Cell Line
ALIAR-BLCL
BAKSH-BLCL
BEABR-BLCL
BLABR-BLCL
BREFR-BLCL
BYREL-BLCL
BYRKE-BLCL
CRODI-BLCL
CROMA-BLCL
DELSA-BLCL
HESRU-BLCL
LAZKA-BLCL
PIKCH-BLCL
PTABA-BLCL
SULJO-BLCL
HUNCA-BLCL
TOMBL-BLCL
B95-
Cell Line/Ori Class-I Ha
EBV transformed B cell A26, A31, B35, B38, C4
EBV transformed B cell , A30, B8, Cw7
EBV transformed B cell A2, A9, B17, B27, Cw6
EBV transformed B cell A1, A28, B27, B60, C1, C3
EBV transformed B cell , A3, B7
EBV transformed B cell , A3, B7, B8, Cw7
EBV transformed B cell All, A26, Bw57, Cw6
EBV transformed B cell A3, A9, B49, Bw62
EBV transformed B cell A3, A9, B7, B62, Cw3
EBV transformed B cell All, AM, B44, B62, C7
EBV transformed B cell , All, B8, B55, C3, C7
EBV transformed B cell A3, AM, B7, B62, C7
EBV transformed B cell A25, B38, B53, Cw4
EBV transformed B cell A2, A26, B13, B38, C6
EBV transformed B cell A29, A32, B4, Bw60
EBV transformed B cell A2, A28, B27, B53, C1, C7
EBV transformed B cell A1, A2, B49, Bw52
Marmoset B cell, A TCC #: CRL 1612
(EBV type-1 producer)
Jijoye Burkitt lymphoma (Hu) A TCC #: CCL 87
Namalwa Burkitt lymphoma (Hu) A TCC #: CRL 1432
K562 Human CML lie A TCC #: CCL 243
EBNA (-), Class-I (-)
ll!! "
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Table 2. cont'
ell Line ll Line/O I Ha
CV- Kidney, fibroblast like ATCC #: CCL 70
(African green monkey)
MT- T -lymphoma, HTL V -1 producer A TCC #: TIB 162
ALIAR-MT2 HTL V1 tranformed T cell A26, A31, B35, B38, C4
BEABR-MT2 HTL V1 tranformed T cell A2, A9, B17, B27, C6
CROMA-MT2 HTL V1 tranformed T cell A3, A9, B7, B62, Cw3
HESRU-MT2 HTL V1 tranformed T cell A1, All, B8, B55, C3, C7
SULJO-MT2 HTL V1 tranformed T cell A29, A32, B4, Bw60
TOMBL-Fib Primar human fibroblast lie A1, A2, B49, Bw52
SULJO-Fib Primary human fibroblast lie A29, A32, B4, Bw60
DELSA-Fib Primary human fibroblast lie All , A34, B4, B62, C7
BLABR-Fib Primar human fibroblast lie A1, A28, B27, B60, C1, C3
HUNCA-Fib Primar human fibroblast lie A2, A28, B27, B53, C1, C7
BEABR-Fib Primar human fibroblast lie , A9, B17, B27, Cw6
PIKCH-Fib Primary human fibroblast lie A25, B38, B53, Cw4
HLA-typing was performed by the HLA tying laboratory at the University of Massachusetts
Medical Center.
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Table 3. Specifications of recombinant vaccinia virus constructs.
Vaccinia Constrct Open Reading Frame Size (kDa) Titer of Virus Stock
V ac- TK- none
---
3 x 108 pfu/ml
Vac-EBNA1 BKRF1 60-85 kDa 2 x 109 pfu/ml
Vac-EBNA2A BYRF1 - 90 kDa 9 x 108 pfu/ml
Vac-EBNA3A BLRF3/BERF1 - 145 kDa 1 x 109 pfu/ ml
Vac-EBNA3B BERF2a/2b - 165 kDa 2 x 109 pfu/ ml
Vac-EBNA3C BERF3 / 4 - 155 kDa 8 x l08pfu/ml
Vac-EBNALP BamHI-W1/W2 20-30 kDa 1 x 109 pfu/ml
BamHI-Y1/Y2
V ac- LMP1 BNLF1 63 kDa 5 x 108 pfu/ml
Vac-LMP2A U5- TR- 54 kDa 3-9 x 108 pfu/ml
Vac-gp350 BLLF1 350/220 kDa 1 x 109 pfu/ml
rl '
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Table 4. Monoclonal antibodies and corresponding antigen specificities.
Cluster 
Antibodv Differentiation Reactivitv of mAb
Leu-4 CD3 Human T cell; TCR
Leu- CD4 Human, Helper T cells
OKTl CD5 Pan T cell marker
Leu2a CD8 Cytotoxic T Cells
Leu-15, Mo-1 CDllb Human CR3; activated/memory CTL
Leu-llb CD16 FcyRIII; NK cells
Leu- CD19 Pan B cell marker
Leu- CD20 Pan B cell marker
Leu- CD23 Activated B cells
Leu- CD45RA Naive T cells
Leu-45RO CD45RO Memory T cell
Leu- CD56 NK cell, CTL subsets
Leu- CD57 T Cell / NK cell subsets
BBM. non microglobuli
W6/32 non microglobuli
BB7. non microglobul
HLA- non HLA class II molecules
72A1 none EBV envelope gp350
S12 non EBV LMP-
TCR non (X/ + T cell
TCR y/ non + T cells
' .
11il. "
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Table 5. Activation Marker Expression on CD8+ T Cells from 1M Patients.
Acute 1M Patient % CD8+/DR+ Cells
GRIBR 44.
BUSRO 37.
GUZTH 72.
KA YSE 40.
CONMA 27.
CLAJO 41.7%
SCHSA 45.
NUFMA 43.
BECTE 69.
MINER 50.
GAFCH 20.
EXLZA 49.
MUSP A 39.4%
HESJA 28.
HEVJE 36. Mean = 43.2% + / -13.
Healthv Controls % CD8+/DR+ Cells
DELSA
PTABA 10.
BEABR 10.
GREKI Mean = 8.9% + / - 2.3%
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Table 6. Summary of Primary vs Secondary EBV -Specific CTL Responses.
Patient Primar Res onse Memor Res onse Class-
Alar EBNA 2A A26,A31,B35,B38
Alba EBNA 3A, 3C, LP EBNA I, 3A, 3C, A28,B8,B40
Arach EBNA 3B, 3C A3,A24 B7,B35Aur LMP I, EBNA 3C EBNA 2A A30,B27,B40
Belch EBNA 3A, 3B EBNA 3B A34,B51 B53
Belk EBNA 2A, 3C EBNA 3A, 3B AI,A3,B35,B49
Blabo EBNAI, 3B,LMPI,gp350 EBNA 3B, 3A, 3C A3,A32 B 14,B40
Blabr LMP I AI,A28,B27,B40
Borth EBNA I EBNA LP A3, B18, B39
Busio EBNA 3B, 3C EBNA 3C, 2A, 3A AI,A3,B7,B40
Clia EBNA 3C A2,BI3,BI8
Conia gp350
Cort EBNA I , 2B, 3C, gp350
Croma EBNA 3A A3,A24,B7,B62
Delsa EBNA 3A, 3B AII A34,B44 B62
Dowda EBNA I, 3A, LP A24 A28,B 14 B39
Friie EBNA 3C, LMP 2A EBNA 3A, 3B, 3C A24,B44 B55
Gowad EBNA 2A, 3A, 3B LMP2A EBNA 3A, 3B, 3C, LMP2A A2, B40,B62
Hale EBNA 3B A28, B41, B40
Hesru EBNA 3A, 3B AI,AII,B8,B55
Kala EBNA 2A, 3C A2,A29,B39,B62
Kowre EBNA LP A2,A3,B7,B44
Lana EBNA I, 2A, 3B AI,A25,B8,BI8
LeYDa EBNA 3B EBNA 3A, 3B, 3C AII,A30,B52
Levro EBNA 2A, 3A, 3B , 3C, LP EBNA 3C Al ,A24,B7 ,B38
Mahch EBNA 3C EBNA 3C AI,A3,B8,BI4
Maro EBNA 3A, 3C EBNA 3A A3,A32 B8,B40
Mar EBNA 3A, gp350 EBNA 3A, 3C A2,B7,B45
Maz EBNA 3C, LMP 2A LMP 2A A23,A24 B49
Mckm EBNA 3A, LP EBNA 3A , B8, BI4
Nicdo EBNA 3A EBNA 3A, 3C AI,A28,B8,BI4
Porwi EBNA 3A, 3C EBNA 3B , 3C , LMP2A A2, B27, B40
Ptaba EBNA 3B , 3C A2,A26,B 13,B38
Ronch EBNA 3A, 3C, gp350 EBNA 3C, LP A3,B7,BI3
Saran EBNA 3C, LMP I EBNA 3C A24 A28 B44,B51
Shech EBNA 3C EBNA 3C A2,A24 B7,B44
Stuie EBNA 3A EBNA2,3A, 3C,LMP2A A3, B7, B55
Sulio EBNA 3B, 3C A29,A32,B40,B44
Tavio EBNA 3A, I, LMPI EBNA 3A, 3C A3,A28,B7,B53
Traio EBNA I, 3B,3 C, gp350 EBNA 3A, 3B All, A33, B35
Wilph EBNA 3C EBNA 3C, 3B A2,A32 B27 B44
Yake EBNA3C,LP,LMP2A gp350 A30,B 13,B44
Prmar Responses equal composite of several assays. * n.d. = not determned
149
J:ble 7. Acute IM patient CTL responses specific for EBNA-
Patients with significant* CTL resgonses directed against EBNA-
Tar ets (gAllba Blabo Borth Corti Dowda Lanna T a v Trajo
Blasts
V ac- TK 13.
31.3
EBNA- 24. 14. 24. 24. 13.
16. 24. 44.
EBNA- 13. 1.3 20. 10.
10. 11.2 32.
EBNA- 32. 24. 16.4
31.1 30.
EBNA- 17. 12. 17. 6.4
38.
EBNA- 31.4 16. 20. 11.9
20.4 36.
EBNA- 21.2 18. 13.
20.5 49.
LMP- 37. 16. 21.1 10.
34.3 37.4
LMP- 12. 13.
21.2 35.
1W350 13. 47. 16.5
20. 15. 47.
Values represent % specific lysis of Vac-infected targets mius background 
lysis of B blasts.
(g 
Ony patient with EBNA-1-specific memory CTL response -;: no EBNA1 primary 
response.
* Criteria used to determine si ificant tar et cell l sis:
- Spontaneous release of 51Cr from target cells .c 25%.
- Lysis considered significant only if exceeded lysis of Vac-
TK infected targets lysis by;: 10%.
,.,
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Table 8. Acute 1M patient CTL responses specific for EBV -g:350:
Patients with si nificant* CTL responses directed a ainst p350
Tar ets Blabo Con Corti Marth Ronch Trajo Yakme
Blasts
V ac- TK 25. 31.3
EBNA- 14. 24. 34. 44.
EBNA- 20. 42.4 32. 1.0
EBNA- 24. 33. 30.
EBNA- 17. 27. 38.
EBNA- 20.3 56. 25. 36.4
24.
EBNA- 52. 49.
19.
LMP- 37. 21.1 36. 37.
LMP- 13. 43. 35.
35.5
gp350 47. 18. 20. 49. 12. 47.
15.
Values represent % specifc lysis of Vac-inected targets minus background lysis of B blasts.
eria o d rmine s ant t cell l is:
- Spontaneous release of 51Cr from target cells -c 25%.
- Lysis considered signicant only if exceeded lysis of Vac-TK inected targets lysis by)- 10%.
' '11 
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B Cells Saliva
CI 
CI 
'''
.i-
EBV Type 1
PCR Product
10 Lane
EBV Type 2
PCR Product
10 Lane
Figue 1. EBV strain typing by DNA-PCR amplification of cells and saliva
from acute infectious mononucleosis patients.
Lanes 1-4 contain PCR-amplified product from AIM patient B cells. Lanes
8 contain PCR-amplified product from AIM patient saliva. Lane 9
contains PCR-amplified product from the EBV tye-1 infected line;
Namalwa. Lane 10 contains PCR-amplied product from the EBV tye-
infected line: Jijoye. Blot (a) was hybridized with the EBV tye-1 specifc
probe and blot (b) was hybridized with the EBV tye-2 specifc probe.
Fig. 2a.
Separation of T - and B-Iymphocyte
subsets via SRBC-rosette selection.
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Anti -CD3- Fite
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Fig 2b. T- and B-lymphocyte enrichment via AET-SRBC rosette selection.
Cell Population
Rosette positive cells, approx. 90% T cells, used to establish CTL (effector).
Rosette negative cells, approx. 80% B cells, used to generate B-blast (targets).
a. EBV (-) T Cell Line (CEM).
c. Vac-EBNA 1 infected fibroblasts.
e. Vac-EBNA3a infected fibroblasts.
g. Vac-EBNA3c infected fibroblasts.
.. 
b. B-Lymphoblastoid Cell Line (BLCL)
:l-t .
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. .
to 
,'" -
;J- -
d. Vac-EBNA2a infected fibroblasts.
f. Vac-EBNA3b infected fibroblasts.
h. Vac-EBNALP infected fibroblasts.
a. Vac-TK infected human fibroblasts.
c. Vac-LMP1 + fibroblasts (5hrs).
e. Vac-LMP1 + fibroblasts (10hrs).
g. Vac-TK infected fibroblasts.
b. B Iymphoblastoid cell line.
d. Vac-LMP1 + fibroblasts (8hrs).
f. Vac-LMP1 + fibroblasts (12hrs).
h. Vac-gp350 infected fibroblasts.
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Patient: BUSRO
. 0
liMg'
Anti-HLA-DR-Fitc
Patient: GUZTH
'''. '' :
Anti-HLA-DR-Fitc
Activation marker ex ression on CD8+ T cells in acute 1M atients.
Peripheral blood mononuclear cells were isolated from acute 1M patients (Busro, Kayse
and Guzth), stained with fluorochome conjugated antibodies specifc for CD8, HLA-DR,
CDllb and subjected FACS analysis. Peripheral blood from acute 1M patients contain large
numbers of triple positive cells (quadrant 2) which are absent from blood samples derived
from healthy control donors. The CD8+/HLA-DR+/CDllb+ cells represent activated,
virus-specific, cytotoxic-T-cells which mediate lysis of EBV-inected B cells.
Healthy Control
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Patient :GRIBR Day 1
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8. Kinetics of HLA-DR & CDllb ex ression on CD8+ T-cells durin AIM
Peripheral blood samples were obtained from acute 1M patients on sequential days in order
to follow changes in cell surface marker expression. PBMC were stained with fluorochrome
conjugated mAb specifc for C08, HLA-OR and C011b prior to FACS analysis. Representative
results shown here demonstrate a large population of CD8+/HLA-DR+/CD11b+ cells
(quadrant 2) present early in the course of inection (day 1), which subsequently lose HLA-
expression over a period of several weeks (50% reduction/week), but which retain high levels
of C011b expression for many months. These CD8+/HL-OR- /CD11b+ cells are thought to
represent long lived memory CTL which provide life long EBV imunity (also see fig 11).
Healthy Control
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9. Kinetics of HLA-DR ex ression on CD8+ T-cells durin acute 1M.
PBMC from acute 1M patients were stained with fluorochrome conjugated mAb specifc
for CD8, HLA-DR and CD57 prior to FACS analysis. Blood samples drawn at the time of
intial patient evaluation (day 1) contain predominantly CD8+/HLA-DR+/CD57- cells
(quadrant 1). As the acute phase of illness resolves, the percentage of CD8+/HLA-DR+
cells (activated CTL) is reduced (day 8), while the number of CD8+/HLA-DR- /CD11b+
(memory CTL) rises (see figures 8 + 11).
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Acute 1M Patients
( mean, n=3 )
100
CD8+/DR-/Mol-
...
Ii CD8+/DR+/Mol-
CD8+/DR-/Mol +
CD8+/DR+/Mol+
Healthy Control AIM Blood #l AIM Blood #2 AIM Blood #3
day 1 day 6 day 12
% CDS+/DR+ .. (2.9%) (52.1%) (35.4%) (20.2%)
Cells
10. Kinetics of ALA-DR and Mol CDllb ression on CDS+ CTL durin acute 1M.
PBMC from acute 1M patients (n=3) were staied with fluorochome conjugated
mAb specifc for CD8, HLA-DR and CDllb (Mo-1) prior to FACS analysis. High levels
of triple positive cell present on day one declie with resolution of the acute phase of
inection. The long lived CD8+/HLA-DR-/CDllb+ population likely represent
memory CTL and are maitaied at high levels in the peripheral blood for many
month following infection.
161
HLA-DR+
Phase of Illness
1m Symptomatic acute 1M patients (n=6)
Convalescence at 6 wks (n=6)
. EBV sero (+) healthy controls (n=4)
Mo1+
100
% Cells Stained
11. Kietics of HLA-DR vs CD11b Mo- on CDS+ T-cells followin acute 1M.
Facs analysis was utilized to measure levels of HLA-DR and Cdllb on CD8+ T
cells following EBV infection. At 6 weeks post-inection, HLA-DR expression
was signficantly reduced, while CDllb expression remained maximally
elevated. At 6 months post-infection, HLA-DR expression returned to baseline
levels, while CDllb levels remained at twice the level of healthy controls.
-0 K562-neo
-r K562-
BYRBLCL
." 
SULJD-BLC
Efecor COOS = SULJO PBMC
1:1 3:1 12:1 50:125:16:1
Effector: Target Ratio
Fig. 12a. Non-specific lysis of NK-sensitive targets
(K562) mediated by untiulated, whole PBMC
from EBV-seropositive donor SULJO.
Auto-BLCL
Aulo-MT2 m
Effedor: Taret = 5:1 
Allo-BLCL
14 Day In-Vitr Cultue
BtCL Stimulation X 2
NK Depleted; CD16 + C
% Specc Lysis
Fig. 12c. Bulk cultures of BLCL-stiulated
PBMCs, depleted of NK cell, primarily
lyse HLA-matched, EBV-inected targets.
Auto-BLCL
Aulo-MT2 m
Allo-BLCL
Allo-Mf2 m
K52
HSB-2
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Effedor:Tarel = 1:1 
18 Day In-Vitro Culture
BtCt Stimulation X 2
Not NK-Cell Depleted
% Specc Lysis
Fig. 12b. Bul cultues of BLCL-stiulated
PBMCs, not NK depleted, mediate lysis of
NK-sensitive (K562) & EBV infected targets.
BYREL-LCL (Auto)
HESRU-LCL (AlIo
CROMA-LCL (Allo)
BLABR-LCL (AlIo
K562 IN Target)
Shared HLA ClassI
AI, A3, B7, B8
AI, B8
':T=":1 
AJ, B7
14 Day In-Vilro Culture
B-LCL Stiulation X 2
NK Dtpleled: CD16 + C'
None
None
100
% Specc Lysis
Fig. 12d. EBV -specific CTL canot be
cultured from the peripheral blood
of EBV-seronegative individuals.
SULJo-BLCL
SULJO B Blasts
SULJOVac-TK-
Vac-BBNAI
Vac-BBNA2
Vac-BBNA3A
Vac-BBNA3B
Vac-BBNA3C
Vac-BBNALP
Vac-LM
Vac-LMP
Effecto.. Target = 25 ,I 
Spec LY"is
Fig. 13a. EBV-specifc memory CTL lyse
blasts expressing individual EBV genes
(EBNAs 3b+3c).
PrABA-BLCL
KS2
PrABA B Blasts
PrABA Vac-TK-
Vac-BBNAI
Vac-BBNA2
Vac-BBNA3A
Vac-BBNA3B
Vac-BBNA3C
Vac-BBNALP
Vac-LM
Vac-LMP
Effect.. Taret = 25: 
Spec LY"is
Fig. 13c. In-vitro restiulated EBV-specific
memory CTL lyse B-blasts expressing
individual EBV latent genes (EBNA 3b+3c).
BLABR-LCL (Auto)
HUCA-LCL (A28,B27)
AUAR-LCL (Allo
KS2
BLABR Vac-TK-
Vac-BBNAI
Vac-BBNA2
Vac-BBNA3A
Vac-BBNA3B
Vac-EBNA3C
Vac-LM
Vac-LM
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Bffecto.. Taret = 5 ,I 
% Specc LY"is
Fig. 13b. EBV-specific memory CTL lyse
fibroblasts expressing individual EBV
genes (LMP-1).
HBSRU-LCL (Auto)
BYRBL-LCL (Alo)
BLABR-LCL (Allo)
K562 INK Taret)
HBRU B Blasts
HBSRU Vac-TK-
Vac-EBNAI
Vac-BBNA2
Vac-BBNA3A
Vac-BBNA3B
Vac-BBNA3C
Vac-BBNALP
Vac-LM
Vac-LM2A
Vac-350
Effect.. Taret = 25,1 
% Specc LY"is
Fig. 13d. In-vitro restiulated EBV-specific
memory CTL lyse B-blasts expressing
individual EBV latent genes (EBNA 3a+3b).
AliarBLCL
AliarMT
Beab..BLCL
E:T=100:1
SRBC-Rontt (+) en
RapJe: HLA-Unlyped
Beabl'MT2
Suljo-BLCL
Suljo-MT
K562
Spec Lysis
Fig. 14a. In-vivo activated CTL from acute 1M
patients preferentialy lyse EBV -inected
target cell.
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Acute IM Patient Turia
Shared HLA Class
A26, A31, 835, B38
AliarBLCL
Beab..BLCL
Crma-BLCL
H..ru-BLCL
Suljo-BLCL
K562
No match
No match
E:T=5:1 
No match
No match
Class-I Negative
Spec Lysis
Fig. 14b. SRBC-rosette(+) T cell from acute
1M patients lyse both HLA-matched and
HLA-unatched target cell.
Acute IM Patient TUQ3 crs
nlle IM Patient Turia
Shared HLA C ass AliarB Blasts
A26, A31, 835, B38 AliarVac-TK-
AliarBLCL Vac-EBNA 1
No match Vac-EBNA 2A
Beabr-BLCL Vac-EBNA 2B
No match Vac-EBNA 3A
Croma-BLCL
E:T=10:1 Vac-EBNA 3B
Hesru-BLCL
No match Vac-EBNA 3C
Vac-EBNA LP
Suljo-BLCL No match Vac-
Vac-LM2A
K52 Class-I Negative Vac-350
K562
Spec Lysis
Fig. 14c. SRBC-rosette-selected NK-depleted
CTL from acute 1M patients preferentially
lyse HLA-matched target cells.
E:T=10:1
% Specc Lysis
Fig. 14d. The primar imune response to
EBV includes virs-specific CTL which lyse
allogeneic HLA-matched targets expressing
individual EBV genes.
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Fig. 15a Lanna-B Blasts
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Fig. 15c LevroB Blasts
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Fig. 15e
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Fig. 15b
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Fig 15d
E:T=20:1 
% Specc Lysis
Fig. 15f
E:T=lO:l 
% Specifc Lysis
. R ntative c posite o rima spec c CTL responses in 1M atients.
In-vivo activated CD8+ effector-cells were prepared as described previously. Target cells consisted
of autologous B-blasts infected with recombinant vaccina vir constrcts. Criteria for signficant
lysis includes spontaneous release of 51Cr oe 25%, and specifc lysis 10%above Vac-TK (control).
Results: 90% of patient' CTL lyse targets expressing one of the EBNA3 proteins, with 60% recogning
EBNA-3C alone. Seven of 35 patient' CTL lysed targets expressing EBNA-l. A detailed sumary is
included in table 5.
Levro-B Blasts
Levro Vac-
Vac -EBNA 1
Vac-EBNA 2A
Vac-EBNA 3A
Vac-EBNA 3B
Vac-EBNA 3C
Vac-EBNA LP
Vac-LMPI
Vac-LMP2A
Vac-gp350
Levro BLCL
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II E:T = 40:1, Ros(+)/NKH
. + BBM.l (anti Class-
% Specific Lysis
Fig. 16a. Target cell lysis by in-vivo pried, EBV-specific crL is blocked by
mAb directed against HLA class-I molecules.
RM-B Blasts
RM-Vac-
Vac-EBNA 1
Vac-EBNA 2A
Vac-EBNA 3A
Vac-EBNA 3B
Vac-EBNA 3C
Vac-EBNA LP
Vac-LMPI
Vac-LMP2A
Vac-g350
K562
E:T-I0:1
. + anti-COB mAb
% Specific Lysis
Fig. 16b. Taret cell lysis by in-vivo pried, EBV-specific crL is partally
bloced by mAb directed agaist COB.
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CD3+/CDl6-
CD3+/CD16+
CD3-/CD16+
CD3-/CDl6-
CDS+/CD4-
CDS+/CD4+
CD8-/CD4+
CDS-/CD4-
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CD3+/CD57+
CD3-/CD57+
CD3-/CD57-
CD56+/CD16-
CD56+/CD16+
CD56-/CD16+
CD56-/CD16-
100
0/0 Cells Stained
Fig. 17. Surface marker phenotype of SRBC-rosette (+), NK-depleted
PBMCs from acute 1M patients.
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Vac-EBNAJA Vac-EBNA 3A
Vac-EBNAJB
Vac-EBNA 3B
Vac-EBNAJC
Vac-EBNALP
Vac-EBNA 3C
Vac-EBNA LP
Vac-LM
Vac-LMP2
Vac-LM
Vac-3SO Vac-LM2A
Mcka-BLCL Mar-BLCL
% SpeC Lysis
Fig. 18a. In vitro expanded memory CTL
from acute 1M patient "Mckma" lyse targets
expressing single EBV genes.
% Specc Lysis
Fig. 18b. In vitro expanded memory CTL
from acute 1M patient "Marth" lyse targets
expressing single EBV genes.
BlabOoB Bias.. E:T=10:1 E:T=ZS:1Frije-B Bias"
Blabo-Vac-TK Frije-Vac-TK
Vac-EBNA 1 Vac-EBNA 1
Vac-EBNA2 Vac-EBNA 2A
Vac-EBNAJA Vac-EBNA 3A
Vac-EBNAJB Vac-EBNA 3B
Vac-EBNAJC Vac-EBNA3C
Vac-EBNALP Vac-EBNA LP
Vac-LMP Vac-LM
Vac-LM2A Vac-LM2A
Vac-3SO Vac-g3SO
BlaboBLCL Frije-BLCL
% Specic Lysis
Fig. 18c. In vitro expanded memory CTL
from acute 1M patient "Blabo" lyse targets
expressing single EBV genes.
% Specc Lysis
Fig. 18d. In vitro expanded memory CTL
from acute 1M patient "Frije" lyse targets
expressing single EBV genes.
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Marro-B Blasts E:T=10:1 Marro-B Blasts E:T=10:1
Marro-Vae- TK MarVae- 
Va.-EBNA 1 Va.-EBNA 1
Va.-EBNA2A Va.-EBNA2
Va.-EBNA3A Va.-EBNAJA
Va.-EBNA 3B
Va.-EBNAJB
Va.-EBNAJC
Va.-EBNA3C
V a.-EBNALP
Va.-EBNA LP Vac-LM
Vac- Vac-LM2A
V a.-LM2A Vac-3SO
Vac-350 MarBLCL
K52 K52
% Specc Lysis% Specc Lysis
Fig. 19a. Primary CTL response to EBV
by acute 1M patient "Marro
Fig. 19b. Memory CTL response to EBV
by acute 1M patient "Marro
Tavjo-Vac-TK
E:T=10:1
Tavjo B-blasts
E:T=10:1
Va.-EBNA 1 Tavjo-Vac-TK
Va.-EBNA 1
Va.-EBNA2A
Va.-EBNA 2A
Va.-EBNA3A Va.-EBNA 3A
Va.-EBNA 3B Va.-EBNA 3B
Va.-EBNA 3C Va.-EBNA 3C
Va.-EBNA LP Va.-EBNA LP
Vac-LM
Vac-
ac-LM
Va.-LM2A Vac-SO
Vac-3SO Tavjo-BLCL
% Specifc Lysis Spec Lysis
Fig. 19c. Prima CTL response to EBV
by acute 1M patient "Tavjo
Fig. 19d. Memo CTL response to EBV
by acute 1M patient "Tavjo
Alba-B Blasts
Allba-Vac-
Vac-EBNA 1
Vac-EBNA 2A
Vac-EBNA 3A
Vac-EBNA3B
Vac-EBNA 3C
Vac-EBNA LP
Vac-LMP1
Vac-LMP2A
Vac-g350
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E: T = 10 : 1 
% Specic Lysis
Fig. 20a. Priar CTL response to EBV by acute 1M patient "Allba
Alba-B Blasts
Alba-Vac-
Vac-EBNA 1
Vac-EBNA 2A
Vac-EBNA 3A
Vac-EBNA 3B
Vac-EBNA 3C
Vac-EBNA LP
Vac-LMP1
Vac-LMP2A
Vac-g350
Alba-BLCL
E:T=10:1
% Specific Lysis
Fig. 20b. Memory CTL response to EBV by Acute 1M Patient "Allba
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EBNA 1
EBNA 2A
EBNA 3A
EBNA 3B
..-
EBNA 3C
EBNA LP
LMP1
LMP2A
gp350
.. Priar Responses n=35
Memory Responses n=32
/0 Patients Recognizing Specified EBV Antigen
Fig. 21. Primary vs Memory CTL Responses to Epstein-Barr virus.
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Hesru-B Blasts I- 
E:T = 25:1 
Hesru-Blast TK
Hesru-Blast El
Hesru-
Hesru-LCL TK
Hesru-LCL El
K562 40 
% Specific Lysis
100
Fig 22a. Target cell lysis by PBMC stiulated with Vac-EBNAI infected B blasts.
Suljo B Blasts
E:T = 25:1 
Suljo Blast TK-
Suljo Blast El
Suljo-B LCL
Suljo LCUfK-
Suljo LCL/El
K562
% Specific Lysis
Fig 22b. Target cell lysis by PBMC stiulated with Vac-EBNAI infected BLCLs.
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Vac TK-
Vac EBNA 1 50.
01"
01"
Vac EBNA3C
II E:T=2S:1, B Blasts
E:T=2S:1, BLCLs
% Specific Lysis
Fig 23. Target cell lysis by acute 1M patient "Levro" PBMC stimulated with
Vac-EBNA1/B cell blasts.
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Hot"Vac-TK/ Blast
.. 
"Hof' Vac- EVB Blast
Cold Competitor:Target=10:1
Competitor = B Blast+Vac-
Hot TK/ Blast + Cold compo
-0 HotEVB .""+ Cold 
""p.
1:1 5:1
Effector: Target Ratio
Fig 24a. Cold target competition of PBMC stiulated with Vac-EBNAlI Blasts.
RL B blastfK+C
I- 
E:T=I:11
RL B blastIac-
C = Cold Competitors
Competitor:Taret=10:1
RL B blastIac-
RL B blastJl +C
B blastJ1+BBM.
B blastJ1+RHLCL
B blastJ1+MCLCL
B blastJ1+AALCL
+W632/BBM.l (anti Class-
HLA-Al matched BLCL
HLA-A24,B7 matched BLCL
HLA-B38 matched BLCL
% Specic Lysis
Fig 24b. Cold target competition of PBMC stimulated with Vac-EBNAlI Blasts.
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. Fig 26. Surface marker phenotype of Vac-EBNAl stimulated bulk CTL culture.
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